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1CHAPTER 1 
Introduction
Introduction
Esophageal cancer is worldwide the eight most common type of cancer and the sixth 
leading cause of cancer related mortality1. The incidence of esophageal cancer in the 
Netherlands is rapidly rising with 789 patients diagnosed in 1990 to 2360 patients 
diagnosed in 2015 (Figure 1)2. 
 
Figure 1. Incidence of esophageal cancer in the Netherlands (www.cijfersoverkanker.nl). 
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More than 90 percent of esophageal cancers are either squamous cell carcinomas 
or adenocarcinomas. The majority or the adenocarcinomas develop in the distal 
esophagus, whereas the squamous cell carcinomas most often develop in the 
middle and lower third3. In the development of squamous cell carcinoma of the 
esophagus, alcohol consumption and smoking are the most important risk factors. 
For adenocarcinoma of the esophagus, obesity, gastro-esophageal reflux disease 
(GERD) and Barrett’s esophagus are the most important risk factors3-5. Esophageal 
cancer is mainly a disease of the elderly with most patients aged between 60 and 85 
years at time of diagnosis (Figure 2)4. In the Netherlands approximately 30% of all 
diagnosed patients is 75 years or older2. 
The preferred treatment in non-metastatic resectable esophageal cancer in the 
Netherlands is a multidisciplinary approach with neoadjuvant chemoradiation 
followed by esophagectomy6. Esophageal cancer is unfortunately an aggressive 
disease with an early lymphatic and hematogenous dissemination. At diagnosis 
approximately 50% of the patients present with metastatic disease7. The overall 
5-year survival of esophageal cancer is still poor ranging from 15% to 25% depending 
on stage and treatment5.
Further research on esophageal cancer is important since it is an aggressive disease 
with a rapidly rising incidence, in which treatment requires a multidisciplinary 
approach in a challenging patient group with many elderly. This thesis will provide 
insight in important treatment decisions in part 1 and will provide data on influence 
of  neoadjuvant treatment in esophageal cancer in part 2.  
Part 1. Treatment decisions in patients with esophageal cancer
The first successful resection of an esophageal tumor was described in 1877. A 
malignant stricture below the pharynx was treated with a local resection and a 
feeding esophagostomy was provided. Between 1877 and 1912 early esophageal 
surgical procedures were described, without any attempt to restore continuity. 
Between 1913 and 1938 the first attempts to restore continuity with a presternal tube 
of skin, stomach, jejenum or a rubber tube were performed. Ultimately, in 1938 the 
first successful transpleural esophageal resection with lymph node dissection and 
gastric tube reconstruction was described8. The modern era of esophageal surgery 
started after the second world war with more advanced anesthetic possibilities, 
anastomotic techniques, infection control and postoperative management8. In order 
to decrease the high postoperative morbidity and mortality after transthoracic 
esophagectomy, Orriger introduced the transhiatal esophagectomy without the need 
for a thoracotomy in 19789.  Nowadays, after further development and improvement 
of surgical techniques the esophagectomy has evolved to a complete minimally 
invasive transthoracic or transhiatal approach10.
Throughout the years the outcome of esophageal cancer has further improved due 
to several factors, such as  concentration of care, neoadjuvant treatment modalities, 
alternative treatment strategies, improved diagnostics and multidisciplinary decision 
making. 
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Figure 2. Age and incidence of esophageal cancer by histological subtype  
(SEER Stat Database: Incidence: SEER 9 Regs Public Use, November2004 submission, released 
April 2005).
In order to further improve perioperative results, concentration of surgery has been 
proposed based on the results of studies by van Lanschot et al and Birkmeijer et al. 
showing a relation between hospital volume and postoperative mortality11-13. In the 
Netherlands concentration of care has evolved due to the introduction of minimum 
annual volume numbers and has been shown to improve outcome after esophageal 
surgery11;14;15. This concentration of care potentially leads to an improvement of 
surgical experience and perioperative care which is of crucial importance. The 
continuous refinements in the pre, intra- and postoperative management improve 
outcomes in esophageal cancer surgery. This has been shown in a high volume 
centre in which over more than two thousand transhiatal esophagectomies were 
performed. Postoperative mortality decreased from 4% to 1%, anastomotic leakage 
rate decreased from 14% to 9% and discharge within ten days increased from 52% 
to 78%16.
In order to improve survival in patients with resectable esophageal cancer, 
perioperative strategies containing radiotherapy and/or chemotherapy were 
introduced. Perioperative radiotherapy and chemotherapy could improve local 
or systemic disease control by downstaging, eradicating micrometastatic disease 
and decrease further dissemination17. The first randomised controlled trials with 
perioperative radiotherapy, chemotherapy or chemoradiation were published 
in the nineties of the previous century18. Two important randomised controlled 
trials i.e. the CROSS19 and MAGIC trial20, revealed an impressive survival benefit of 
combining surgery with preoperative chemoradiation or perioperative chemotherapy 
respectively in patients with resectable esophageal or gastro-esophageal junction 
(GEJ) tumors. These results led to an increase in use of multimodality treatment, 
primarily neoadjuvant chemoradiation,  in the Netherlands. Between 2000 and 2012 
the use of multimodality treatment increased from 20% to 90% in esophageal cancer 
and from 6% to 85% in GEJ cancer21. 
Even though postoperative mortality decreased over time, esophageal cancer surgery 
remains high risk surgery with a relative high postoperative morbidity, especially in 
patients with multiple co-morbidities and a higher age22-25. Higher age is an important 
factor in 30-day postoperative mortality with a postoperative mortality of 10% in 
patients older than 75 years compared to postoperative mortality of 5% in patients 
younger than 65 years26. Elderly and vulnerable patients unfit for surgery are 
therefore often treated with alternative potentially curative modalities like definitive 
chemoradiation5;27-30. This different treatment strategy has an acceptable survival  and 
is often well tolerated28;29. 
Hence, treatment of esophageal cancer has evolved to a complex patient tailored 
decisional process. In order to determine the best personalised approach for patients 
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with esophageal cancer, all patients in the Netherlands need to be  discussed at 
multidisciplinary team (MDT) meetings. These MDT meetings have shown their 
importance for rectal and breast cancer since it improves surgical outcomes through 
better patient management31;32. In esophageal cancer treatment it has shown to 
improve staging accuracy and often alterations in the initial treatment are made in 
almost one third of the cases33;34. 
Aim and outline of part 1. 
In the current literature most studies have focussed on treatment results of patients 
who have actually received a potentially curative treatment in individual centres and 
not on the whole group of patients diagnosed with esophageal cancer, including 
those that have not received curative treatment. Several factors influence the decision 
to propose potentially curative treatment. Therefore, it is important to determine 
which factors influenced overall survival and whether these factors play a role in the 
decision to propose a potentially curative treatment. This decisional process will be 
investigated in chapter one.  Furthermore, a large proportion of the patients with 
esophageal cancer are elderly patients. Unfortunately, most treatment strategies and 
guidelines are based on clinical trials in which elderly patients are often excluded. 
Therefore, it is of significant importance to investigate with real-world, population-
based data the effect of different treatment options on survival in this specific group 
of patients. Treatment choices in this specific group will be addressed in chapter two. 
During local MDT meetings in the hospital of diagnosis in the Netherlands it is 
most often decided whether or not a patient is referred to an expert centre for 
further treatment.  Hence, the hospital of diagnosis plays an important role in the 
probability of receiving potentially curative treatment. Two nationwide studies in 
gastric or pancreatic cancer have revealed the influence of hospital of diagnosis on 
the probability of undergoing curative treatment for gastric or pancreatic cancer35;36. 
The influence of hospital of diagnosis on the probability to receive curative treatment 
in esophageal cancer on a regional and nationwide scale will be studied in chapter 
three and four.
Part 2. The influence of neoadjuvant treatment on morbidity and oncological 
outcome in esophageal surgery
GEJ tumors are classified according to the Siewert classification37 which had its 
epicentre within 5cm of the anatomic  GEJ. The anatomic GEJ is defined as the 
proximal end of the gastric folds. Patients with resectable GEJ tumors are either 
treated via an esophagectomy followed by a gastric pull-up or by a gastrectomy with 
Roux-en-Y reconstruction. The literature does not provide conclusive evidence on 
the optimal surgical treatment strategy. Furthermore,  GEJ tumors are both included 
in the two cornerstone randomised controlled trials (CROSS19 and MAGIC20) which 
revealed impressive survival benefit of neoajuvant chemoradiation and perioperative 
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chemotherapy.  Again, the literature does not provide conclusive evidence on the 
optimal perioperative treatment strategy.
Since the introduction of neoadjuvant chemoradiation in esophageal cancer, the 
optimal timing of surgery after neoadjuvant treatment is unclear en needs to be 
elucidated. In clinical trials, the timing of surgery has been chosen empirically to be 
within 2 to 8 weeks after completion of neoadjuvant chemoradiation38;39. However, 
many factors such as toxicity of neoadjuvant chemoradiation, comorbidity, poor 
physical status and also logistical problems may postpone surgery beyond this 
timeframe. Postponing surgery might be beneficial since it could result in a better 
patient condition by the time of surgery and probably more tumor regression and 
higher complete response rates as shown in rectal cancer40. However it also raises 
the theoretic fears of primary or metastatic tumor growth and an increase in surgical 
complexity due to more radiation induced tissue damage and fibrosis.
Nowadays, esophageal surgery in the Netherlands has an acceptable low postoperative 
mortality, however still high rates of postoperative morbidity are described, 
especially pulmonary and anastomotic complications such as leakage and stenosis. 
Several factors, such as the presence of multiple co-morbidities, nutritional status, 
anastomotic location, anastomotic technique, and atherosclerotic vascular condition, 
are hypothesized to influence anastomotic leakage and stenosis41-43. Neoadjuvant 
chemoradiation might also play a role in developing anastomotic complications, 
however the literature shows conflicting results. Two meta-analyses revealed no 
difference in mortality and morbidity between patients receiving neoadjuvant 
chemoradiation and surgery and patients receiving surgery alone44;45. Furthermore, 
two randomized trials comparing neoadjuvant chemoradiation and surgery with 
surgery alone did not show a difference in morbidity and anastomotic complications 
between both groups19;46. In contrast, another study showed that the mean dose to 
the gastric fundus was a predictor for anastomotic leakage47. In addition, a recent 
study revealed that neoadjuvant chemoradiation had no influence on the incidence of 
postoperative complications, but only affected the severity of complications48.
Aim and outline of part 2. 
There is no conclusive evidence which perioperative regime (chemotherapy or 
chemoradiation) and which surgical resection (esophagectomy or gastrectomy) 
should be used in treatment of GEJ tumors since there are no specific trials performed 
in GEJ tumors and the two cornerstone perioperative trials (MAGIC and CROSS) both 
included GEJ tumors. Therefore, a study in a population- based setting that evaluates 
patterns of care in treatment strategies for GEJ tumors is of interest and could 
possibly elucidate part of this dilemma. Thus Chapter Five evaluates patterns of care 
in treatment strategies for GEJ tumors in a population-based setting.
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In order to evaluate the influence of the time period between neoadjuvant 
chemoradiation and surgery on the postoperative morbidity, pathological 
response, and long-term survival, in Chapter Six a study was performed 
on the Catharina Hospital Eindhoven cohort to evaluate the influence of 
the time period between neoadjuvant chemoradiation and surgery on the 
postoperative morbidity, pathological response, and long-term survival. 
Since neoadjuvant chemoradiation is now standard of care and there several 
theoretical and practical concerns remain regarding a related possible 
increase in morbidity, we performed a study whether or not radiation 
dose to the fundus of the stomach influences postoperative anastomotic 
complications is needed. In chapter seven and eight the influence 
of radiation dose to the gastric fundus on postoperative anastomotic 
complications have been investigated in the Catharina Hospital Eindhoven 
and Amsterdam Academic Medical Center cohort.
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2Abstract
Background: Preferred treatment  for resectable esophageal cancer is surgery with or 
without neoadjuvant treatment. However, esophageal surgery has high morbidity and 
in vulnerable patients with co-morbidity other treatment modalities can be proposed. 
We examined determinants in decision making for surgery and factors affecting 
survival in patients with resectable esophageal cancer in southern Netherlands. 
Methods: All patients with resectable (T1-3, N0-1, M0-1A) esophageal cancer (n=849) 
diagnosed between 2003-2010 were selected from the population-based data of the 
Eindhoven Cancer Registry. Logistic regression analysis and multivariable Cox survival 
analysis were conducted to examine determinants of surgery and survival. 
Results: Forty-five percent of the patients underwent surgery. In multivariable 
survival analysis only surgery, chemoradiation alone and tumor stage influenced 
Overall Survival (OS). Patients aged ≥70 years, a low socioeconomic status (SES), one 
or more co-morbidities, cT1-tumors, cN1-tumors, a squamous-cell carcinoma, and 
those with a proximal tumor were significantly less often offered surgical resection. 
 Older patients and patients with cT1 tumors were less likely to receive chemoradiation 
alone. Patients with clinically positive lymph nodes or a proximal tumor were more 
likely to receive chemoradiation alone.
Conclusions: Treatment modalities including surgery and chemoradiation alone 
as well as stage of disease were independent predictors of a better OS in patients 
with potentially resectable esophageal cancer. Therefore, the decision to perform 
potentially curative treatment is of crucial importance to improve OS for patients with 
potentially resectable esophageal cancer. Although age and SES had no significant 
influence on overall survival, a higher age and low SES negatively influenced the 
probability to propose potentially curative treatment. 
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2Introduction
Esophageal cancer is worldwide the eight most diagnosed type of cancer and it is 
the sixth leading cause of cancer deaths1.The incidence of esophageal cancer in 
the Netherlands, especially adenocarcinoma, is rapidly rising from 1731 in 2000 to 
2499 in 20102. Esophageal cancer is an aggressive disease with early lymphatic and 
hematogenous dissemination, with a 5-year overall survival rate ranging between 15% 
and 51% depending on tumor stage and treatment3-5. At diagnosis, 50%-63% of the 
patients have in-situ or resectable esophageal cancer and are eligible for potentially 
curative endoscopic mucosal resection (EMR) or surgical treatment6;7. According to the 
Dutch and the United Kingdom national guidelines, the preferred treatment regimen 
for resectable esophageal cancer (T1-3, N0-3, M0-1A) is neoadjuvant chemoradiation 
followed by radical transhiatal or transthoracic surgery. For squamous-cell carcinoma, 
chemoradiation alone is also a curative option8. The choice for the type of surgery is 
based on tumor stage, tumor location, lymph node involvement, and the condition of 
the patient. Transthoracic esophagectomy generally results in a higher lymph node 
yield and a trend to a higher 5-year overall survival, but also in a higher mortality 
and morbidity rate4;9;10. Surgical treatment of esophageal cancer has a high rate of 
post-operative complications, especially in patients with multiple co-morbidities 
and a higher age9;11;12. Hence, elderly and vulnerable patients might not be eligible 
for potentially curative surgical treatment5. Patients with an irresectable tumor, 
or patients who are too vulnerable for surgery are often proposed for definitive 
chemoradiation or palliative options only13-16.
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Due to regionalisation and centralisation in the Netherlands, surgical and EMR 
treatment is mainly performed in regional referral centres in which  patients are 
discussed in a multidisciplinary team (MDT) and managed accordingly17. However, 
patients who are not referred to a regional referral centre are discussed in an MDT of 
the  local hospital of diagnosis in which less experience in the possibilities of surgical 
and endoscopic treatment for esophageal cancer is available. A recent study by our 
group showed that hospital of diagnosis plays a significant role on the probability to 
receive potentially curative treatment18. Several factors may play a role in the decision 
whether patients are eligible candidates for surgery, like tumor characteristics, age 
and co-morbidity. The Eindhoven Cancer Registry (ECR) has a prospective registration 
of co-morbidity, which provides a unique possibility to examine the role of this factor 
in relation to others. Furthermore, most studies focus on results of patients who 
received potentially curative treatment in individual centres and not on the whole 
group of patients diagnosed with esophageal cancer, including those that have not 
received curative treatment. Therefore, the aim of this population-based study is 
to determine which factors influenced overall survival and whether these factors 
play a role in the decision to propose potentially curative treatment in patients with 
resectable esophageal cancer. 
Materials and methods
Population-based data from the ECR, which is maintained by the Comprehensive 
Cancer Centre South, were used. The ECR collects data for all patients with newly 
diagnosed cancer in a large part of the southern Netherlands, which comprises 
about 2.3 million inhabitants. This population-based registry includes ten community 
hospitals, six pathology departments, and two radiotherapy institutions. 
Information on age, sex, socioeconomic status (SES), co-morbidity, histology, 
tumor stage (classified by the International Union Against Cancer (UICC) TNM 6)19, 
tumor location (according to International Classification of Diseases for Oncology 
(ICD-O-3))20, and treatment is routinely extracted from the medical records by 
specially trained administrators of the cancer registry. Tumor location was classified 
as proximal (above tracheal bifurcation, C15.0, C15.1, C15.2 and C15.3), mid (between 
tracheal bifurcation and gastro-esophageal junction, C15.4), distal (gastro-esophageal 
junction, C15.5) and overlapping or not otherwise specified (C15.8, C15.9). 
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Clinical tumor stage was determined by at least endoscopy, CT scanning of the 
chest and abdomen and ultrasound of the supraclavicular nodes. Since PET CT or 
Endoscopic Ultrasound (EUS) were not mandatory according to the guidelines, they 
were only performed when indicated. Definitive tumor stage was determined as the 
pathologic (post-operative) stage or if not available as the clinical tumor stage. 
Information on medical history and co-morbidity was based on a modified list of the 
Charlson co-morbidity index21. We excluded hypertension as co-morbidity, since it is 
generally regarded as a minor co-morbidity. Individual SES, based on fiscal data on 
the value of the home and household income, is provided at an aggregated level for 
each postal code22. 
Surgery with a potentially curative intent was defined as an esophagectomy,  multi-
organ surgery or surgery not otherwise specified. Definitive chemoradiation was 
defined as the combination of radiotherapy and chemotherapy as the primary 
treatment with a curative intent. Hormone therapy, immunotherapy, local tumor 
surgery, palliative therapies in general, and palliative therapy of metastases were 
defined as “other” therapy. Treatment with no curative intent included radiotherapy 
alone, chemotherapy alone, and other therapy.
Study population
Between 2003 and 2010, 1672 patients with esophageal cancer (C15) were diagnosed 
in the ECR region. We excluded 533 patients with metastatic disease (M1 or M1B) and 
143 patients with tumors extended into surrounding organs (T4), since these patients 
were not all eligible for curative surgery. Furthermore, patients with an unknown or 
missing M-status where excluded (n=145). So, we included 851 patients with potential 
resectable and curable esophageal cancer according to their stage (T1-3, N0-1, M0-
1A). Within this group we excluded two patients with unknown therapy, resulting in a 
definitive study population of 849 patients (Figure 1). 
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Statistical analyses
Univariable and multivariable Cox proportional hazard regression analyses were 
performed to determine the prognostic significance of age, gender, co-morbidity, 
SES, tumor location, tumor differentiation, tumor stage, curative intent surgery, and 
chemoradiation on overall survival. Survival time was defined as time from diagnosis 
to death or until January 1st, 2010 for the patients who were still alive. Results were 
reported as hazard ratios (HR) and 95% CI. Unadjusted estimates of survival rates 
were made using the Kaplan-Meier method, and compared using the log-rank 
statistic. Univariable and multivariable logistic regression analyses were conducted to 
evaluate the influence of age, gender, SES, co-morbidity, clinical tumor stage, tumor 
differentiation, and tumor location on undergoing surgery. Results were reported as 
odds ratios (OR) with 95% confidence intervals (95% CI). All analyses were performed 
using Statistical Package for Social Sciences version 19.0 (SPSS Inc., Chicago, IL, USA). 
All reported p-values below 0.05 were considered statistically significant. 
1672 patients with
esophageal cancer
Exlusion of T4 
tumors (n=143)
Exlusion of 
metastatic disease 
(n=533)
Exclusion of 
unknown/missing 
M-status (n=145)
Exclusion of unknown 
treatment (n=2)
Study population 
T1-3, N0-1, M0-1A
 (n=849)
Figure 1. Flowchart study population.
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Results 
Type of treatment
From the patients with resectable esophageal cancer, 86% received any kind of 
treatment, thus 14% did not receive any type of treatment at all. Almost half of the 
patients (45%) underwent surgery (or surgery combined with other (neo)adjuvant 
treatment), and 15% underwent definitive chemoradiation alone. A combination 
treatment with (neo-adjuvant) chemoradiation and surgery was given to 17% of the 
patients. Throughout the years  (2003 -2010) there was an increase from 12%  to 34% 
in patients receiving this trimodality treatment.  Treatment with no curative intent 
was administered to 26% of the patients and consisted of radiotherapy alone (20%), 
chemotherapy alone (2%), and other therapy (4%). 
Predictors of overall survival
Patients who underwent surgery had a better 3 year overall survival compared to those 
who received chemoradiation alone or no curative intent/ no treatment (47% vs. 27% 
vs. 11%, p<0.001) (Figure 2). In the  univariable analysis, advanced age (≥70 years), co-
morbidity, being institutionalised, squamous-cell carcinomas, or high tumor stages 
were all associated with a worse overall survival; whereas surgery, chemoradiation 
alone, good tumor differentiation, and stage I were associated with better survival 
(Table 1). However, in the multivariable Cox regression survival analysis only surgery, 
chemoradiation alone, and tumor stage I were significant predictors of a better 
survival, whereas tumor stage III and IV were significant predictors for worse survival. 
2
Part I  |  Chapter 2  |  27
Number at risk 0 1 2 3 4 5
Surgery 382 252 154 95 66 39
Chemoradiation alone 127 67 24 12 8 4
No curative intent/ no treatment 340 106 36 16 13 7
Figure 2. Overall survival of patients with esophageal cancer treated with different types of 
treatment.
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Univariable  
overall survival 
Multivariable  
overall survival
HRa 95% CI p-value HRa 95% CI p-value
Age (yrs)
     <70
     ≥70
  
484
365
1.0
1.6 1.4-1.9 <0.001
1.0
1.0 0.9-1.3 0.686
Gender
     Male
     Female
633
216    
1.0
1.1 0.9-1.3 0.406
1.0
0.9 0.7-1.1 0.467
Co-morbidity
    None 
    1
    2 or more
    Unknown
   
271
227
259
92 
1.0
1.4
1.6
0.8
1.1-1.7
1.3-1.9
0.5-1.1
0.004
<0.001
0.107
1.0
1.2
1.0
0.8
0.9-1.5
0.8-1.3
0.6-1.2
0.241
0.800
0.345
Type of treatment
   Surgery
    Chemoradiation alone
    No curative intent/ no treatment
382
127
340
0.3
0.5
1.0
0.3-0.4
0.4-0.6
<0.001
<0.001
0.3
0.4
1.0
0.2-0.4
0.3-0.5
<0.001
<0.001
Socioeconomic status
    Low
    Mediate
    High
    Institutionalised 
    Unknown
  
204
329
255
38
23 
1.3
1.0
0.8
2.0
0.8
1.0-1.5
0.7-1.1
1.3-2.9
0.5-1.6
0.065
0.177
0.001
0.552
1.1
1.0
0.8
1.3
0.9
0.9-1.4
0.7-1.1
0.8-2.0
0.5-1.8
0.440
0.194
0.239
0.809
Tumor location
    Proximal 
    Mid 
    Distal 
     Overlapping/NOSb 
 
52
105
655
37   
1.2
1.2
1.0
1.4
0.9-1.7
1.0-1.6
0.9-2.1
0.222
0.108
0.103
0.8
1.1
1.0
1.1
0.5-1.1
0.8-1.5
0.7-1.7
0.171
0.523
0.725
Histology
     Squamous-cell carcinoma    
Adenocarcinoma
    Other
 
271
537
41   
1.3
1.0
1.5
1.1-1.5
1.0-2.1
0.011
0.051
1.2
1.0
1.1
0.9-1.5
0.7-1.7
0.159
0.778
Tumor differentiation 
    Good
    Moderate 
    Poor
    Anaplastic 
    Unknown
 
28
219
325
8
269   
0.6
0.8
1.0
1.5
1.0
0.3-1.0
0.7-1.0
0.7-3.1
0.8-1.2
0.046
0.072
0.333
0.879
0.6
0.8
1.0
0.8
0.7
0.3-1.1
0.6-1.0
0.3-1.8
0.6-0.9
0.129
0.069
0.525
0.005
Tumor stage
    I
    II
    III
    IV
    Unknown
110
214
172
81
272
0.5
1.0
1.7
3.1
2.5
0.3-0.7
1.3-2.2
2.3-4.2 
2.0-3.2
<0.001
<0.001
<0.001
<0.001
0.4
1.0
1.7
2.5
1.5
0.2-0.6
1.3-2.2
1.8-3.4 
1.2-2.0
<0.001
<0.001
<0.001
0.002
Number of  
patients 
(n=849)
Table 1. Univariable and multivariable overall survival analyses for patients with esophageal 
cancer in the ECR region in the period 2003-2010 (n=849).
a  A higher risk of dying is denoted by a hazard ratio (HR) value >1 and a lower risk of dying by a HR value <1.
b Not otherwise specified.
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Table 2. Predictors of surgery in patients diagnosed with resectable esophageal cancer in the 
ECR region in the period 2003-2010 (n=849).
a  Not otherwise specified.
Univariable  
analysis
Multivariable  
analysis
OR 95% CI p-value OR 95% CI p-value
Age (yrs)
     <70 
     ≥70 
484
365
1.0
0.2 0.2-0.3 <0.001
1.0
0.3 0.2-0.4 <0.001
Gender
     Male
     Female
633
216
1.0
0.6 0.4-0.8 0.001
1.0
1.1 0.7-1.6 0.728
Socioeconomic status
     Low
     Intermediate
     High
     Institutionalised
     Unknown
204
329
255
38
23
0.5
1.0
1.1
0.3
1.4
0.4-0.8
0.8-1.6
0.2-0.7
0.6-3.2
0.001
0.453
0.005
0.466
0.5
1.0
1.1
0.5
1.5
0.3-0.8
0.7-1.6
0.2-1.3
0.6-3.8
0.004
0.620
0.169
0.413
Co-morbidity
     None 
     1
     2 or more
     Unknown
271
227
259
92
1.0
0.6
0.3
0.5
0.4-0.8
0.2-0.4
0.3-0.8
0.001
<0.001
0.003
1.0
0.6
0.3
0.5
0.4-1.0
0.2-0.5
0.3-0.8
0.038
<0.001
0.009
Clinical T stage
    T1
    T2
    T3
    TX/missing
47
102
313
387
0.6
1.2
1.0
0.3
0.3-1.0
0.8-1.9
0.2-0.5
0.062
0.416
<0.001
0.5
1.4
1.0
0.4
0.2-0.9
0.8-2.5
0.2-0.5
0.026
0.188
<0.001
Clinical N Stage
   N0
   N1
   NX/missing
375
349
125
1.0
0.8
0.4
0.6-1.1
0.3-0.6
0.125
<0.001
1.0
0.4
0.6
0.3-0.6
0.4-1.0
<0.001
0.063
Histology
     Squamous-cell carcinoma   
    Adenocarcinoma
    Other
271
537
41
0.5
1.0
0.3
0.4-0.7
0.1-0.6
<0.001
0.001
0.7
1.0
0.3
0.4-0.98
0.1-0.7
0.040
0.005
Tumor location
    Proximal 
    Mid 
    Distal 
     Overlapping/ NOSa  
52
105
655
37
0.1
0.5
1.0
0.5
0.0-0.2
0.3-0.8
0.3-1.1
<0.001
0.003
0.078
0.1
0.6
1.0
0.7
0.0-0.2
0.4-1.1
0.3-1.6
<0.001
0.111
0.390
Number of  
patients 
(n=849)
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Predictive factors for surgery
In the univariable analysis age, gender, SES, co-morbidity, cT-stage, cN-stage, histology, 
and tumor location all had a significant influence on the probability to receive surgery 
(Table 2). In the multivariable analysis older patients (≥70 years), patients with low 
SES and patients with co-morbidities were less likely to receive surgery. Furthermore, 
patients with cT1 tumors, patients with clinically positive lymph nodes, patient with 
proximal tumors and patients with squamous-cell carcinomas or other carcinomas 
were also significantly less likely to receive surgery (Table 2). 
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Univariable  
analysis
Multivariable  
analysis
OR 95% CI p-value OR 95% CI p-value
Age (yrs)
     <70 
     ≥70 
484
365
1.0
0.8 0.6-1.2 0.277
1.0
0.6 0.4-0.9 0.028
Gender
     Male
     Female
633
216
1.0
1.4 0.9-2.2 0.091
1.0
1.1 0.7-1.9 0.676
Socioeconomic status
     Low
     Intermediate
     High
     Institutionalised
     Unknown
204
329
255
38
23
1.2
1.0
1.1
0.3
1.7
0.7-1.9
0.7-1.7
0.1-1.4
0.6-4.7
0.457
0.733
0.139
0.335
1.1
1.0
1.3
0.5
2.0
0.6-1.9
0.8-2.3
0.1-2.4
0.6-7.1
0.862
0.299
0.376
0.278
Co-morbidity
     None 
     1
     2 or more
     Unknown
271
227
259
92
1.0
1.4
1.0
1.0
0.8-2.2
0.6-1.6
0.5-2.0
0.220
0.865
0.979
1.0
1.3
0.8
1.0
0.7-2.3
0.4-1.4
0.5-2.3
0.445
0.421
0.948
Clinical T stage
    T1
    T2
    T3
    TX/missing
47
102
313
387
0.2
0.8
1.0
0.3
0.1-0.8
0.5-1.5
0.2-0.5
0.019
0.558
<0.001
0.2
0.9
1.0
0.2
0.1-0.7
0.5-1.8
0.1-0.3
0.014
0.784
<0.001
Clinical N Stage
   N0
   N1
   NX/missing
375
349
125
1.0
2.9
13.8
1.0-8.4
5.5-34.3
0.049
<0.001
1.0
3.1
28.7
1.1-9.2
11.0-75.0
0.039
<0.001
Histology
     Squamous-cell carcinoma   
    Adenocarcinoma
    Other
271
537
41
2.7
1.0
2.5
1.8-3.9
1.1-5.4
<0.001
0.025
1.9
1.0
1.4
1.1-3.2
0.5-3.5
0.023
0.504
Tumor location
    Proximal 
    Mid 
    Distal 
     Overlapping/ NOSa  
52
105
655
37
4.9
1.8
1.0
1.1
2.7-8.9
1.1-3.1
0.4-3.0
<0.001
0.031
0.815
2.3
0.9
1.0
0.9
1.1-5.0
0.5-1.9
0.3-2.8
0.033
0.868
0.893
Table 3. Predictors of chemoradiation alone in patients diagnosed with resectable esophageal 
cancer in the ECR region in the period 2003-2010 (n=849).
Number of  
patients 
(n=849)
a  Not otherwise specified.
Predictive factors for chemoradiation alone.
In ther univariable analysis cT-stage, cN-stage, histology and tumor location all had 
a significant influence on the probability to receive chemoradiation alone. In the 
multivariable analysis older patients and patients with cT1 tumors were less likely 
to receive chemoradiation alone. Patients with clinically positive lymph nodes or a 
proximal tumor were more likely to receive chemoradiation alone (Table 3). 
Discussion
In our population-based study of patients with potentially resectable esophageal 
cancer the curative resection rate was 45%, which is relatively high. Other studies 
found overall resection rates of 34% to 41%5;23. However, these studies had a slightly 
different study population which also included patients with T4 tumors. We found that 
14% of the study population did not receive any kind of treatment, which might be 
caused by the patient choice for no treatment. Furthermore, we showed that surgery 
was an independent predictor for a better survival when compared with no curative 
intent treatment/ no treatment (HR 0.3; 95% CI 0.2-0.4). This is in concordance with 
other studies with comparable hazard ratios favouring surgery5;23. Recent analysis of 
population based SEER data confirmed that surgery is an independent predictor for a 
better 5- and 10-year overall survival when compared with no surgery7. 
Trimodality treatment containing neo-adjuvant chemoradiation followed by surgery 
has recently become standard treatment in the Netherlands8. In our study only 
144 patients (17%) were offered this therapy regimen, which is probably due to the 
fact that our study has started in 2003 and randomized trials studying neoadjuvant 
chemoradiation like the CROSS trial were still ongoing24. Guidelines in that period 
did not advice neoadjuvant chemoradiation as standard treatment, however 
we observed an increase in use of this trimodality treatment from 12% to 34%. 
Definitive chemoradiation might also be an option for patients with advanced age 
and/or multiple co-morbidities or locally advanced tumors14-16;25;26. Chemoradiation 
alone was a significant predictor for a better survival in our multivariable survival 
analysis with a hazard ratio of 0.4 (95% CI 0.3-0.5) when compared with  no curative 
intent/no treatment at all. A recent study showed no survival difference between 
chemoradiation alone and chemoradiation combined with surgery (hazard ratio of 
1.01 (95%CI 0.90–1.13)23. These results suggest the need for further research on the 
role of definitive chemoradiation vs. neoadjuvant chemoradiation followed by surgery 
in patients with esophageal cancer. 
We observed that patients aged ≥70 yrs were significantly less likely to undergo 
surgery, which is in line with other observations5. A recent Dutch study showed that 
age ≥70 yrs was a risk factor for surgical complications and post-operative mortality27. 
Others have shown similar results with a significantly increased risk for in-hospital 
mortality for patients aged ≥ 70 yrs11. In our multivariable analysis older patients 
(≥70 yrs) were less likely to receive chemoradiation alone. In a study conducted in 
the United States in which they analysed toxicity after chemoradiation in the elderly 
(>75yrs), only fifty percent of the patients completed the planned chemoradiation 
and 71% of the patients experienced adverse events during treatment that required 
hospitalization, emergency department visit, and/or treatment break28. 
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We did not observe an independent effect of advanced age on overall survival. 
This in contrast to other studies, in which age was a significant predictor for worse 
overall and disease-specific survival in a large study from the Netherlands and the 
United Kingdom11;27.This difference might be explained by the inclusion of all patients 
diagnosed with resectable (T1-3, N0-1, M0-1A) esophageal cancer in our study. This is 
in contrast with the other studies in which they included only patients who underwent 
surgery and thus a potential selection bias could play a role11;27. Furthermore, co-
morbidity appears to play an important role in decision making, since multiple co-
morbidities are a significant predictor to be detained from potentially curative surgery 
in our study, which is in concordance with others in which the Romano-Charlson 
score of 1 or more was an independent predictor for not receiving surgery5. An 
Australian study showed that the number of co-morbidities predicted post-operative 
morbidity like pneumonia, respiratory failure, and overall pulmonary morbidity29. 
Respiratory co-morbidity has been shown to be an independent predictor for non-
surgical complications and post-operative mortality but not for disease-specific 
5-year survival27.  Co-morbidity has also been shown to be an independent predictor 
for survival in colon, rectal, breast, and prostate cancer21. 
We showed that low SES was a significant predictor for not receiving surgery compared 
with intermediate SES. Others have also associated low SES with a smaller chance to 
be referred for surgery5. Another Dutch population-based study also showed that 
resections are more often performed in patients with a higher SES30. Since many 
other factors may be associated with SES, it would be tentative to conclude that 
SES is an important independent determinant in decision-making.  Furthermore, a 
study from the south-east London Cancer Network showed no difference between 
the highest and lowest income quintiles for the chance to be proposed for surgery31. 
In addition, once operated upon, SES did not influence overall survival in this study, 
which is comparable with others32. 
Histological type of tumor was in our study an independent predictor for surgery 
and chemoradiation alone. Patients with squamous-cell and other carcinomas 
were less often associated with referral for surgery compared to patients with an 
adenocarcinoma, which is in concordance with others33. This might be due to the 
fact that most distal tumors are adenocarcinomas and proximal tumors are more 
often squamous-cell carcinomas. In our study proximal tumors are indeed less likely 
to be treated surgically, but more likely to be treated with chemoradiation alone. 
Considering these results, it is remarkable that histological type of tumor and tumor 
location were no independent predictors for survival in our study. On the other hand, 
these results are in concordance with a study in which no significant difference on 
disease specific survival between adenocarcinoma and squamous-cell carcinoma 
was observed27. However, distal tumors were shown to have a tendency to a better 
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overall survival23. As expected, clinical T and N stage were independent predictors for 
receiving surgery or definitive chemoradiation in our study. Furthermore, patients 
with a cT1 tumor were less likely to receive surgery or definitive chemoradiation in 
our study, which  is probably caused by the upcoming use of Endoscopic Mucosal 
Resection (EMR).  Tumor and lymph node stage, when known preoperatively, are 
thus relevant factors for decision making whether or not a patient could be proposed 
for surgery or definitive chemoradiation. Furthermore, this seems  reasonable since 
tumor stage is an independent predictor for disease-specific survival, disease-free 
survival, and overall survival34.  
This study included patients with potentially resectable and curable esophageal 
cancer. We excluded patients with distant metastasis (M1B-M1) as well as 
patients with unknown or missing M-status. Excluding patients with unknown or 
missing M-status might give some selection bias, however we aimed to assure 
that we included only patients with a potentially resectable and curable tumor. 
All T4 tumors were excluded, since in the ECR it was not possible to determine T4 
tumors which might be eventually resectable with or without neo-adjuvant treatment. 
In the ECR, clinical T-stage was determined by the results from endoscopy, CT scan, 
and EUS. Since EUS was not performed in all patients there are many missing clinical T 
stage values (n=387). However, for determining resectability of an esophageal tumor 
EUS has been shown not to be necessarily needed35. 
The question remains whether other factors might play a role in the decision to 
propose patients for curative treatment, since that decision is a multifactorial process 
in which patient characteristics and doctors preferences may both play a role. 
Unfortunately data on factors like nutritional status and tolerance of neoadjuvant 
treatment which might play a role in decision making are not available for this analysis. 
Furthermore, all patients are discussed within local multidisciplinary team meetings 
however, not in all MDT’s participate regional experts knowing all possibilities of 
esophageal cancer treatment. Multidisciplinary meetings within expert centres have 
shown to be important for decision making in esophageal cancer. In a recent study, in 
35% of patients with esophageal cancer, the initially proposed plan was altered after 
the multidisciplinary meeting36. 
In conclusion, treatment modalities including surgery and chemoradiation alone as 
well as stage of disease were independent predictors of a better overall survival in 
patients with potentially resectable esophageal cancer. Therefore, the decision to 
perform potentially curative treatment is of crucial importance to improve overall 
survival for patients with potentially resectable esophageal cancer. Although age 
and socioeconomic status had no significant influence on overall survival, a higher 
age and low socioeconomic status negatively influenced the probability to propose 
potentially curative treatment. 
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3Abstract
Introduction: The aim of our study was to describe treatment patterns and the impact 
on overall survival among elderly patients (75 years and older) with potentially curable 
esophageal cancer.
Methods: Between 2003 and 2013, 13244 patients from the nationwide population-
based Netherlands Cancer registry were diagnosed with potentially curable 
esophageal cancer (cT2-3,X, any cN, cM0,X) of which 34% were elderly patients 
(n=4501). 
Results: Surgical treatment with or without neoadjuvant treatment remained 
stable among elderly patients (around the 16% between 2003-2013). However, 
among  younger patients surgical treatment increased from 60.2% to 67.0%. The 
use of definitive chemoradiation (dCRT) increased in elderly patients from 1.9% 
to 19.5% and in  younger patients from 5.2% to 17.2%. Due to the increase in 
dCRT, treatment with curative intent doubled in the elderly from 17% to 37.1%. 
Multivariable Cox regression revealed that elderly patients with an adenocarcinoma 
receiving surgery alone or dCRT had a significantly worse overall survival compared 
to those receiving surgery with neoadjuvant chemo(radio)therapy (nCRT/CT) (HR: 1.7 
95%CI 1.4-2.0 and HR=1.9 95%CI 1.5-2.3). However, among elderly with squamous cell 
carcinoma overall survival was comparable between dCRT, surgery alone and surgery 
with nCRT/CT.
Conclusion: Survival was comparable among elderly patients with squamous cell 
carcinoma who underwent surgery with nCRT/CT, surgery alone or received dCRT, 
while elderly patients with an adenocarcinoma who underwent surgery with nCRT/CT 
had a better overall survival, when compared with surgery alone or dCRT. Therefore, 
dCRT can be considered as a reasonable alternative for surgery among potentially 
curable elderly patients with esophageal squamous cell carcinoma. However in elderly 
patients with esophageal adenocarcinoma surgery with nCRT/CT is still preferable 
regarding overall survival.
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3Introduction
The incidence of esophageal cancer, especially adenocarcinoma, has increased 
dramatically over the past four decades in the Western world and is still rising but 
at a slower rate than previously1,2. Esophageal cancer is mainly a disease of the 
elderly as a significant number of patients is aged between 60 and 85 year at time of 
diagnosis3,4. In the Netherlands approximately 30% of all newly diagnosed patients 
with esophageal cancer is 75 years or older5.  
 
According to the Dutch clinical practice guidelines, the preferred treatment for 
patients with potentially curable  esophageal cancer is neoadjuvant chemoradiation 
followed by a subsequent esophagectomy. Early esophageal cancer (T1a) can 
be treated with Endoscopic Mucosal Resection (EMR)6. Frail patients unfit for 
surgery, such as some elderly patients, can be treated alternatively with a curative 
intention using definitive chemoradiation (dCRT)7,8. Furthermore, histological 
subtype plays a role in treatment of patients with potentially curable esophageal 
cancer. For example, patients with squamous cell carcinoma seem to have a 
better response to dCRT compared to patients with an adenocarcinoma9,9-11. 
Surgical treatment of esophageal cancer is complex with a high post-operative 
complication rate, especially in elderly patients with multiple co-morbidities, which 
might be an argument to withhold some patients from surgical treatment12,13. A 
previous study has shown an increase in 30-day postoperative mortality from 4.9% in 
patients younger than 65 years to 10.3% in patients older than 75 years14.
 
However, most treatment strategies and guidelines are based on clinical trials in which 
elderly patients are excluded. Therefore, it is of significant importance to investigate 
the effect of different treatment options on survival in this specific group of patients. 
The aim of our study was to describe treatment patterns and the impact on overall 
survival in elderly patients (75 years and older) with potentially curable esophageal 
cancer (adenocarcinoma or squamous cell carcinoma) in the Netherlands.  
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Patients and Methods
Data collection
Nationwide population-based data from the Netherlands Cancer Registry (NCR) were 
used. The NCR is based on notification of all newly diagnosed malignancies in the 
Netherlands by the national automated pathological archive (PALGA). Additional 
sources are the national registry of hospital discharge, radiotherapy institutions 
and diagnosis therapy combinations (specific codes for reimbursement purposes). 
Specially trained data managers of the NCR routinely extracted information on 
diagnosis, tumor stage and treatment from the medical records. Information on vital 
status was obtained through an annual linkage with the Municipal Administrative 
Database, in which all deceased and emigrated persons in the Netherlands were 
registered.  Institutional Review Board approval was obtained from the NCR. 
 
Patients
Between January 2003 and December 2013, 25.638 patients were diagnosed with an 
adenocarcinoma or squamous cell carcinoma of the esophagus or gastro-esophageal 
junction in the Netherlands. The topography and morphology of the tumors were 
coded according to the International Classification of Diseases for Oncology (ICD-O-3)15. 
Subsite distribution was divided as: proximal (C15.0, C15.3), mid (C15.4), distal (C15.5), 
overlapping or not otherwise specified (C15.8, C15.9) and gastro-esophageal junction 
(GEJ) (C16.0). Patients diagnosed from 2003 to 2009 were staged according to TNM-6, 
whereas patients diagnosed from 2010-2013 were staged according to TNM-7 16,17. 
Patients with potentially curable esophageal tumors were eligible for this study (Figure 
1). Patients were considered potentially curable in this study if they had no clinically 
distant metastasis (cM1b for TNM-6 and cM1 for TNM 7) (n=8009) and no tumors 
infiltrating surrounding organs (cT4 according to TNM-6 and cT4A and cT4B according 
to TNM-7) (n=1368). We excluded patients with tumors infiltrating surrounding 
organs since it was uncertain whether or not these patients were eligible for curative 
treatment. For the analyses, patients with a cM1A tumor according to TNM-6 were 
categorized as having cN+ as most patients with a cM1A tumor had a distal tumor 
with coeliac lymph nodes which can be considered as having cN+ according to TNM-7. 
Furthermore, patients with unknown clinical distant metastases (cMX) were included. 
It should be noted that as of 2010 coding regulations to register a cM0 or cM1 status 
into the NCR were less strict than before 2010, and therefore as of 2010 relatively 
more patients were registered with a cM0 rather than a cMX into the NCR. To account 
for this, we decided to include all patients with cMX. Patients with an in-situ or a cT1 
tumor (n=1002) were also excluded since these tumors are treated predominantly 
with an Endoscopic Mucosal Resection (EMR) rather than surgical treatment. In 
addition, patients with missing/unknown treatment (n=92) and patients receiving 
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25638 patients with 
esophageal cancer
 (2003-2013)
Exclusion histology 
other than ADE/SCC 
(n=1573)
Exclusion of cT4 
tumours (n=1368)*
Exclusion of EMR 
alone (n=350)
Exclusion of 
metastatic disease 
(n=8009)
Exclusion of cT1 
tumours (n=1002)**
Exclusion of unknown
 treatment (n=92)
Potentially curable patients
 
cT2, 3, X, any cN, cM0, X 
(n=13244)
Potentially curable elderly patients 
cT2, 3, X, any cN, cM0, X (n=4501)
EMR alone (n=350) were excluded. This resulted in 13.244 patients with a potentially 
curable esophageal carcinoma (cT2, 3, X, any cN, cM0, X). Of these patients 4501 (34%) 
were elderly patients being 75 years and older (Figure 1).
Figure 1. Flowchart of the study population.
*cT4 according to TNM-6 and cT4a and cT4b according to TNM-7.  
**cT1 according to TNM-6 and cT1a and cT1b according to TNM-7. 
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Treatment
Surgery with potentially curative intent was defined as an transhiatal esophagectomy 
or transthoracic esophagectomy. Definitive chemoradiation (dCRT) was defined as 
the combination of radiotherapy and chemotherapy as primary treatment without 
surgery.  Curative treatment was defined as dCRT, surgery alone or surgery with 
neoadjuvant chemoradiotherapy or chemotherapy (nCRT/CT). All other treatments 
were defined as “other” therapy.
Statistical analysis
Differences in patient and tumor characteristics between elderly patients with an 
adenocarcinoma and squamous cell carcinoma were described and compared 
using the Pearson’s Chi-square test for nominal data. For differences in continuous 
variables, the independent T-test was used. Survival time was defined as time 
from diagnosis to death or until February 1st 2016 for patients who were still alive. 
Survival curves per treatment option were obtained using the Kaplan-Meier method 
for elderly patients according to histology. Differences in overall survival according 
to treatment were assessed by using log-rank tests. Multivariable Cox regression 
analyses were performed to evaluate independent prognostic factors for overall 
survival. All statistical analyses were performed using Statistical Package for Social 
Sciences version 22.0 (IBM Corporation, Armonk, NY, USA) and P-values less than 0.05 
were considered statistically significant.
Results
Patient characteristics
Of the potentially curable elderly patients of 75 years and older diagnosed with an 
esophageal carcinoma, 75.6% (n=3402) was diagnosed with an adenocarcinoma and 
24.4% (n=1099) with a squamous cell carcinoma. There were no significant differences 
in age, cT- stage, cN-stage and cM-stage between both histology groups. However, 
patients with an adenocarcinoma had more often a distally located tumor and a poor 
tumor differentiation. Furthermore, elderly patients with an adenocarcinoma more 
often received surgical treatment (21.3%) than dCRT (7.7%), whereas patients with a 
squamous cell carcinoma more often received dCRT (13.1%) than surgery (10.4%) (Table 1). 
Of all elderly patients diagnosed with potentially curable esophageal carcinoma, 6.9% 
received surgery with nCRT/CT, 11.8% received surgery alone, 18.6% received surgery, 
9.0% received dCRT and 72.4% received other/no treatment. 
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Table 1. Patient characteristics of the elderly patient (≥75 years) diagnosed with potentially 
curable esophageal cancer in the period 2003-2013 (n=4501).
a Gastro-esophageal junction 
b Not otherwise specified 
c Among this group of patients 77.3% received nCRT and 22.7% received CT. Two patients received CRT postoperatively. 
Adenocarcinoma Squamous  
cell carcinoma 
Total N= 4501 3402 (75.6%) 1099 (24.4%) P-value
Mean age 81.6 (SD 4.9) 81.3 (SD 5.0) 0.051
Gender:
  Male
  Female
2374 (69.8%)
1028 (30.2%)
514 (46.8%)
585 (53.2%) <0.001
cT-stage:
  2
  3
  Unknown/missing
582 (17.1%)
863 (25.4%)
1957 (57.5%)
171 (15.6%)
308 (28.0%)
620 (56.4%) 0.163
cN-stage
  N0
  N+
  Unknown/missing
1167 (34.3%)
1173 (34.5%)
1062 (31.2%)
388 (35.3%)
395 (35.9%)
316 (28.8%) 0.302
cM-stage
  M0
  Unknown/missing
2790 (82.0%)
612 (18.0%)
921 (83.8%)
178 (16.2%) 0.174
Tumor location:
  Proximal
  Mid
  Distal
  GEJa
  Overlapping/NOSb
38 (1.1%)
208 (6.1%)
1983 (58.3%)
1040 (30.6%)
133 (3.9%)
164 (14.9%)
398 (36.2%)
454 (41.3%)
7 (0.6%)
76 (6.9%) <0.001
Differentiation:
  Well
  Moderate
  Poor
  Unknown
67 (2.0%)
677 (19.9%)
1147 (33.7%)
1511 (44.4%)
31 (2.8%)
296 (26.9%)
254 (23.1%)
518 (47.1%) <0.001
Type of treatment
   Surgery with nCRT/CTc
  Surgery alone
   Definitive chemoradiation
  Other/no treatment
250 (7.3%)
475 (14.0%)
261 (7.7%)
2416 (71.0%)
59 (5.4%)
55 (5.0%)
144 (13.1%)
841 (76.5%) <0.001
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Trends in treatment
From 2003 until 2013, the use of surgery with nCRT/CT among the elderly (≥75 
years) and the younger patients (<75 years) increased over time from 0.5% to 13.5% 
and from 14.4% to 63.3% respectively. In line with these findings, the proportion 
of patients with underwent surgery alone decreased among both the elderly and 
the younger patients from respectively 14.5% to 4.2% and from 45.8% to 3.7%. 
The use of surgical treatment (surgery with nCRT/CT or surgery alone) among 
all elderly patients (≥75 years) remained relatively stable over time from 15.0% in 
2003 to 17.7% in 2013, whereas among the younger patients (≥75 years) the use 
of surgical treatment increased over time from 60.2% in 2003 to 67.0% in 2013. 
Furthermore, there was an increase in administration of dCRT in elderly patients 
from 1.9% to 19.5% as well as in the younger patients from 5.2% to 17.2% (Figure 2a). 
The increase in dCRT was most prominent among elderly patients with a squamous 
cell carcinoma in which treatment with dCRT increased from 3.5% to 30.7%, while 
among younger patients with squamous cell carcinoma an increase from 9.5% to 
29.3% was observed (Figure 2b). In patients with an adenocarcinoma, the increase in 
use of dCRT was comparable in the elderly patients compared to the increase among 
younger patients (Figure 2c). Mainly due to the increase in dCRT, the administration 
of treatment with  curative intent (surgery or dCRT) doubled over time in all elderly 
patient from 17% to 37.1%. The increase of treatment with a curative intent quadrupled 
over time in the elderly patient with squamous cell carcinoma from 10.5% to 41.2%. 
However, the increase in the use of treatment with curative intent was less prominent 
in the younger patients (Figure 2). 
Figure 2. Trends in treatment of patients with esophageal carcinoma according to age and 
histology. 
Figure 2a. Trends in treatment of all patients with esophageal carcinoma.
3
Part I  |  Chapter 3  |  47
Figure 2b. Trends in treatment of patients with a squamous cell carcinoma.
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Figure 2c. Trends in treatment of patients with an adenocarcinoma.
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Survival
Overall, elderly patients with a potentially curable adenocarcinoma had a 
comparable 1- and 3-year overall survival rate compared to elderly patients with 
a potentially curable squamous cell carcinoma with 1-year overall survival rates 
of  40.8% vs. 36.5% and  3-year survival rates of 12.0% vs. 14.1%, respectively (log 
rank p=0.621). Furthermore, the 1- year overall survival in elderly patients with 
an adenocarcinoma treated with surgery and nCRT/CT was 79.6% which was 
comparable to the overall survival of patients treated with surgery alone (64.8%) 
or dCRT (72.4%) whereas 3-year overall survival was significantly better for patients 
who underwent surgery with nCRT/CT (51.2%) compared to patients receiving 
surgery alone (29.5%) or dCRT (11.6%) (p<0.001) (Figure 3a). Among  elderly patients 
with a squamous cell carcinoma, patients receiving surgery with nCRT/CT had a 
better 3-year overall survival (50.2%) compared to surgery alone (40.0%) and dCRT 
(36.8%) however this difference was not statistically significant (p=0.267) (Figure 3b). 
Multivariable Cox regression analyses showed that patients with male gender, 
a poor tumor differentiation, an overlapping tumor/not otherwise specified 
tumor location, cT3 tumors, regional lymph nodes metastasis and a squamous 
cell histology had a significantly worse overall survival. Regarding the treatment 
strategy, the multivariable Cox regression analysis which included both histologies 
showed that elderly patients who received surgery alone (Hazard ratio [HR]: 
1.6, 95% confidence interval [CI] 1.3-1.9), dCRT (HR: 1.7, 95% CI 1.4-2.0) or 
other/no treatment (HR:4.1, 95% CI 3.5-4.8) had a significantly worse overall 
survival compared to patients who underwent surgery with nCRT/CT (Table 2). 
Comparable results were found for elderly patients with an adenocarcinoma. 
Among elderly patients with an adenocarcinoma, patients receiving surgery alone 
(HR: 1.7, 95% CI 1.4-2.0), dCRT (HR: 1.9, 95% CI 1.5-2.3) or other/no treatment (HR: 
4.3, 95% CI 3.6-5.1) had a significantly worse overall survival compared to patients 
receiving surgery with nCRT/CT. However, among elderly patients with a squamous 
cell carcinoma overall survival was comparable for patients who underwent surgery 
alone (HR: 1.3, 95% CI 0.8-2.1), dCRT (HR: 1.4, 95% CI 0.9-2.0) or surgery with nCRT/CT 
(Table 2). 
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Figure 3a. Kaplan-Meier survival analysis among elderly patients with an 
adenocarcinoma (n=3402).
3
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Figure 3b. Kaplan-Meier survival analysis among elderly patients with a squamous 
cell carcinoma (n=1099).
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Multivariable analysis* All elderly patients
(N=4501)
Adenocarcinoma 
(N=3402)
Squamous cell  
carcinoma (N=1099)
HR 95%CI p-value HR 95%CI p-value HR 95%CI p-value
Gender
    Male
    Female 
1.0
0.9 0.8-1.0 0.001
1.0
0.9 0.8-1.0 0.015
1.0
0.8 0.7-0.9 0.003
Period of diagnosis
  2003-2006
  2007-2010
  2011-2013
0.9
0.9
1.0
0.9-1.0
0.9-1.0
0.084
0.085
0.9
1.0
1.0
0.8-1.0
0.9-1.0
0.058
0.304
1.0
0.9
1.0
0.8-1.1
0.7-1.0
0.581
0.097
Tumor differentiation
  Well
  Moderate
  Poor
   Unknown/missing
0.8
0.9
1.0
0.8
0.6-1.0
0.8-0.9
0.8-0.9
0.031
<0.001
<0.001
0.6
0.8
1.0
0.8
0.5-0.8
0.7-0.9
0.7-0.8
0.001
<0.001
<0.001
1.7
1.1
1.0
1.0
1.1-2.5
0.9-1.3
0.8-1.2
0.009
0.269
0.922
Tumor location
  Proximal 
  Mid 
  Distal 
  GEJa
   Overlapping/ NOSb  
0.8
0.9
1.0
1.0
1.3
0.7-0.9
0.8-1.0
0.9-1.1
1.1-1.5
0.008
0.041
0.828
0.001
1.0
1.0
1.0
1.0
1.2
0.7-1.4
0.8-1.1
0.9-1.1
1.0-1.4
0.954
0.721
0.997
0.042
0.7
0.9
1.0
1.9
1.4
0.6-0.9
0.7-1.0
0.9-4.0
1.1-1.8
0.002
0.030
0.104
0.008
Clinical T-stage
  cT2
  cT3
  cTunknown
0.9
1.0
1.2
0.8-1.0
1.1-1.3
0.019
<0.001
0.9
1.0
1.2
0.8-1.0
1.1-1.3
0.019
0.002
0.9
1.0
1.4
0.7-1.1
1.2-1.7
0.411
<0.001
Clinical N-stage
  cN0
  cN+
  cNunknown
1.0
1.2
1.6
1.1-1.3
1.4-1.7
<0.001
<0.001
1.0
1.2
1.5
1.1-1.3
1.4-1.7
<0.001
<0.001
1.0
1.2
1.8
1.0-1.4
1.5-2.1
0.057
<0.001
Type of treatment
   Surgery with nCRT/CT
  Surgery alone
   Def. Chemoradiation
   Other/no treatment
1.0
1.6
1.7
4.1
1.3-1.9
1.4-2.0
3.5-4.8
<0.001
<0.001
<0.001
1.0
1.7
1.9
4.3
1.4-2.0
1.5-2.3
3.6-5.1
<0.001
<0.001
<0.001
1.0
1.3
1.4
3.8
0.8-2.1
0.9-2.0
2.7-5.4
0.222
0.123
<0.001
Histology
  Squamous cell
  Adenocarcinoma
1.1
1.0
1.0-1.2 0.037
Table 2. Multivariable Cox survival analysis for all elderly patients and according to histology
a Gastro-esophageal junction 
b Not otherwise specified 
* Adjusted for all variables listed in table 2. 
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Discussion
This large nationwide population-based study among elderly patients with potentially 
curable esophageal cancer who were 75 years or older revealed an increase in 
treatment with a curative intent, with a consistent use of surgical treatment and a 
significant increase in the use of dCRT among all elderly patients in the period 2003-
2013. The increase in administration of dCRT was most prominent in elderly patients 
with a squamous cell carcinoma.  Furthermore, multivariable analysis showed no 
difference in overall survival for elderly patients with a squamous cell carcinoma who 
received surgery with nCRT/CT or surgery alone or dCRT. However, elderly patients 
with an adenocarcinoma who underwent surgery with nCRT/CT had a significantly 
better overall survival compared to patients who underwent surgery alone or dCRT.  
Despite the increase in the use of treatment with curative intent among potentially 
curable elderly patients, explained by the increase in dCRT, there is still a large 
proportion of patients that were not treated with curative intent (72.4%).This study 
demonstrates that the elderly patients with potentially curable tumors received less 
often surgical treatment compared to younger patients (17.7% vs. 67.0%), whereas 
the use of dCRT was slightly higher in the elderly patients compared to the younger 
patients (19.5% vs. 17.2%). These findings may be explained by the fact that an older age 
is a risk factor for post-operative morbidity and mortality after esophagectomy12,18-20. 
Although, other studies have shown that age alone should not be regarded as a 
predictor for worse overall survival after esophagectomy, in daily practice it appears 
that advanced age is a significant factor in decision making whether or not patients 
are proposed for surgery12,13. 
Our study revealed a relatively stable use of surgical treatment and a significant 
increase in use of dCRT among all elderly patients during the study period especially 
after 2010.  This striking increase in administration of dCRT is higher compared to 
another study in the Netherlands in an earlier period (1989-2008) in which they 
reported an increase from 0.19% to 2.20%21. The increase in use of dCRT is probably 
caused by the increasing awareness that dCRT has a favorable survival, especially 
among patients with squamous cell carcinoma, and is often well tolerated, even in 
patients with considerable co-morbidity7,8. Although toxicity after chemoradiation 
is occuring frequently, with 75% of the patients experiencing toxicity of grade 3 or 
greater, especially in the elderly patients, it is often manageable22,23.  
This study showed that elderly patients with an adenocarcinoma received more often 
surgical treatment compared to patients with a squamous cell carcinoma which 
received more often dCRT especially after 2010. These result are in line with result 
from a large population based study in the United States9. The observed difference in 
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treatment could be explained by the fact that most studies show a better response to 
dCRT of squamous cell carcinomas when compared to adenocarcinoma, with a better 
overall survival and disease free survival in good responders10. On the other hand, 
a study from the United Kingdom on dCRT revealed a comparable overall survival 
and disease free survival between both histological subtypes. However patients 
with squamous cell carcinoma had significantly more advanced stages of disease24. 
Furthermore, a significant difference in relapse pattern has been described, with 
adenocarcinomas being more likely to relapse in distant sites and squamous cell 
carcinoma more likely to recur locally8,24.
The multivariable Cox survival analysis revealed that elderly patients with an 
adenocarcinoma who received  surgery with nCRT/CT have a better overall survival 
compared to the patients receiving surgery alone or dCRT. However, among elderly 
patient with squamous cell carcinomas there was no significant difference in overall 
survival between patients who underwent surgery with nCRT/CT, surgery alone or 
patients who received dCRT. Currently, there are only three randomised control trials 
which have directly compared dCRT with surgical treatment in patients with squamous 
cell carcinoma. These trials have shown comparable survival rates in patients treated 
with definitive chemoradiation or chemoradiation followed by surgery11,25,26. However, 
in two of the three trials elderly patients were excluded and in the third trial results were 
not reported for elderly patients as a separate group. Furthermore, a recent Cochrane 
review states that there is only low quality evidence in the literature which showed that 
chemoradiation appears to be equivalent to surgery in squamous cell carcinoma who 
are responsive to chemoradiation, however in adenocarcinoma there is uncertainty 
whether or not patients receiving definitive chemoradiation benefit compared to 
surgery27. Our results provide more arguments for the equivalence of definitive 
chemoradiation to surgery in squamous cell carcinoma and confirm their statement 
on adenocarcinoma. The results of our study advocate for further research in which 
the use of dCRT and surgery are compared for disease free survival and quality of life. 
Univariable and multivariable survival analysis also revealed a similar overall survival 
for patients with esophageal squamous cell carcinoma who underwent surgery with 
or without nCRT/CT. Although there seems to be immortal time bias, the Kaplan-
Meier curves for these treatment groups were parallel, assuming overall survival 
is comparable (Figure 3b). Immortal time bias exists of patients receiving nCRT/CT 
which takes more time to receive than surgery alone. However, no landmark analysis 
was performed as this would result in exclusion of many patients in the ‘other/no 
treatment’ group. Multivariable analysis confirmed the non-significant difference in 
overall survival between squamous cell carcinoma patients with and without nCRT/CT. 
These results are in contrast with results from the CROSS trial28,29, which showed an 
improved survival for patients who received surgery with nCRT compared to patients 
who received surgery alone. Moreover, the difference in overall survival was higher 
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for squamous cell carcinoma compared to adenocarcinoma. However, most elderly 
patients did not meet the eligibility criteria from the CROSS trial. Therefore, further 
research should investigate the difference in outcomes between surgery with or 
without nCRT/CT among elderly patients with esophageal squamous cell carcinoma.
A limitation of this study is that the NCR did not register nationwide information 
on co-morbidity or performance status during the study period. This might have 
influenced the survival analyses since co-morbidity and performance status plays an 
important role in the clinical decision making, especially among the elderly patients 
and has a significant influence on overall survival.  However,  the survival benefit 
for dCRT might even be more than observed, because especially unfit patients with 
multiple co-morbidities and an a priori unfavorable prognosis receive dCRT. Thus, 
the lack of co-morbidity data might even lead to an underestimation of the potential 
favorable impact of dCRT on overall survival. This study has also several strengths, 
such as its observational nature resulting in a representative nationwide population 
and therefore enabling the demonstration of current patterns of care and its impact 
on overall survival among elderly patients with esophageal cancer in daily clinical 
practice. 
In conclusion, this large nationwide population-based study revealed that there was 
a consistent use of surgical treatment and a major increase in use of dCRT among 
all elderly patients with potentially curable esophageal cancer in the period 2003 
to 2013. The increase in dCRT was most prominent among patients with squamous 
cell carcinoma. Survival was comparable among elderly patients with squamous cell 
carcinoma who underwent surgery with nCRT/CT, surgery alone or received dCRT, 
while elderly patients with an adenocarcinoma who underwent surgery with nCRT/CT 
had a better overall survival, when compared with surgery alone or dCRT. Therefore, 
dCRT can be considered as a reasonable alternative for surgery among potentially 
curable elderly patients with esophageal squamous cell carcinoma. However in elderly 
patients with esophageal adenocarcinoma surgery with nCRT/CT is still preferable 
regarding overall survival. 
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4Abstract
Background: Surgical treatment of esophageal cancer in the Netherland is performed 
in high volume centres. However, the decision to refer patients for curative surgery 
is made in the referring hospital of diagnosis. The objective of this study was to 
determine the influence of hospital of diagnosis on the probability of receiving a 
curative treatment and survival.
Material and method: All patients with resectable esophageal cancer (cT1-3, cN0-1, 
cM0-1A) diagnosed between 2003-2010 (n=849) were selected from the population 
based Eindhoven Cancer Registry, an area with ten non-academic hospitals. 
Multivariable logistic regression analysis was conducted to examine the independent 
influence of hospital of diagnosis on the probability to receive curative treatment. 
Furthermore, the effect of hospital of diagnosis on overall survival was examined 
using multivariable Cox regression analysis. 
Results: 849 patients were included in the study. A difference in the proportion 
of patients referred for surgery was observed ranging from 33% to 67% (p=0.002) 
between the hospitals of diagnosis. Multivariable logistic regression analysis 
confirmed the effect of hospital of diagnosis on the chance to undergo curative 
treatment (OR 0.1, 95% CI 0.1-0.4). Multivariable Cox regression analysis showed that 
hospital of diagnosis also had an effect on overall survival up to a hazard ratio of 2.2 
(95% CI 1.3-3.7).
Conclusion: There is a strong relation between  hospital of diagnosis and the chance 
of referring patients with esophageal cancer for a curative treatment as well as overall 
survival. Patients diagnosed with esophageal cancer should be discussed within a 
regional multidisciplinary expert panel.
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4Introduction
The incidence of esophageal cancer in the Dutch population has increased over the 
past three decades1. The European Standard Population adjusted incidence rate 
(ESR) for esophageal adenocarcinoma in males tripled from 3.2 per 100,000 in 1989 
to 9.9 per 100.000 in 2008. In females the ESR increased from 0.7 to 1.7 per 100,000. 
For males no change in the incidence for esophageal squamous-cell carcinoma was 
observed, while females showed a slight increase2. 
According to the Dutch clinical practice guidelines, neoadjuvant chemoradiation 
followed by surgery is the preferred treatment for patients with locally advanced 
esophageal cancer. Endoscopic mucosal resection (EMR) is indicated for early cancer 
(T1a- lesions)3. Definitive chemoradiation or palliative treatment is indicated for 
patients with non-metastasized T4b tumors or for patients who are frail4-7. Due to a 
process of centralisation, treatment of esophageal cancer in the Netherlands is now 
largely performed in regional centres of referral. Within these centers of excellence, 
patients are discussed at multidisciplinary team (MDT) meetings and managed 
according to the national guidelines and latest evidence. Concentration of care for 
esophageal cancer patients is associated with improved peri-operative mortality and 
overall survival in surgically treated and non-surgically treated patients8-11.
Most patients with esophageal cancer are diagnosed in non-referral centres. In a non-
referral hospital, patients might not be discussed in a MDT proficient in all aspects 
of diagnosis and treatment of esophageal cancer. These hospitals thus play a crucial 
role in deciding whether or not a patient is referred to an expert centre for further 
treatment. MDT meetings for rectal and breast cancer improve surgical outcomes 
through better patient management12;13. MDT meetings for esophageal cancer 
improve staging accuracy and often to alter the initial treatment plan14;15. 
The aim of this study is to assess the relationship between hospital of diagnosis and 
referral for a curative treatment. Secondly, the referral pattern and its influence on 
overall survival in patients with resectable esophageal cancer was explored. 
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Methods
Population-based data from the Eindhoven Cancer Registry (ECR), which is maintained 
by the Comprehensive Cancer Centre South, were used. All patients diagnosed with 
a histological diagnosis of esophageal cancer between 2003 and 2010 were selected 
for this study (ICD-0-3: 8010, 8012, 8020, 8021, 8032, 8033, 8041, 8046, 8070-8072, 
8076, 8078, 8083, 8140, 8144, 8145, 8210, 8211, 8246, 8260, 8480, 8481, 8490, 8560, 
8570, 8574). 
The ECR collects data on all patients with newly diagnosed cancer in the south of 
the Netherlands. This region comprises approximately 2.4 million inhabitants. This 
population-based registry includes ten hospitals, six pathology departments, and two 
radiotherapy institutions. Since 1999 esophageal cancer surgery has been centralized 
in two centres.  
Information on hospital of first diagnosis, age, gender, socioeconomic status (SES), 
co-morbidity, histology, tumor stage (classified by the International Union Against 
Cancer (UICC) TNM 616), tumor location (according to International Classification of 
Diseases for Oncology (ICD-O-3))17, and treatment is routinely extracted from the 
medical records by specially trained administrators of the cancer registry. Tumor 
location was classified as proximal (above tracheal bifurcation, C15.0, C15.1, C15.2, 
and C15.3), mid (between tracheal bifurcation and gastro-esophageal junction, C15.4), 
distal (gastro-esophageal junction, C15.5), and overlapping or not otherwise specified 
(C15.8, C15.9).
Clinical tumor (cT) and lymph node (cN) stage was determined by at least endoscopy, 
computed tomography (CT) scanning of the chest and abdomen and ultrasound of 
the neck. Positron emission tomography (PET)-CT or Endoscopic ultrasound (EUS) 
were performed when indicated. Tumor stage recorded by the ECR was defined by 
pathologic examination of the resection specimen or, if not available, clinical tumor 
stage. 
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Information on medical history and co-morbidity was summarized on a modified list 
of the Charlson co-morbidity index18. Hypertension was not scored as co-morbidity 
given its high prevalence and minor impact on patients’ health status. Individual SES, 
based on fiscal data on value of the home and household income, is provided at an 
aggregated level for each postal code19.  Surgery with curative intent was classified 
according to the cancer registry as total esophagectomy, partial esophagectomy, multi-
organ surgery or surgery not otherwise specified. Radiotherapy and chemotherapy 
were classified as yes or no. Local tumor surgery, palliative therapies in general, and 
palliative therapy of metastases were defined as ‘other therapy’. Treatment with 
curative intent was defined as surgery or definitive chemoradiation. Treatment with no 
curative intent included radiotherapy alone, chemotherapy alone, and other therapy. 
Hospital of diagnosis was classified as the hospital where the clinical or pathological 
diagnosis of esophageal cancer was made. Hospitals of diagnosis outside the ECR 
region were defined as “non regional” hospitals. 
Statistical analysis
Differences in patient and tumor characteristics between hospitals of diagnosis were 
compared using chi-square tests. Univariable and multivariable logistic regression 
analyses were conducted to evaluate the influence of hospital of diagnosis, age, 
gender, SES, co-morbidity, tumor stage, tumor differentiation, and tumor location 
on surgery and treatment with curative intent (surgery or definitive chemoradiation). 
Results were reported as odds ratios (OR) and 95% confidence intervals (95% CI). 
Univariable and multivariable Cox regression analyses were performed to determine 
the prognostic impact of hospital of diagnosis, age, gender, co-morbidity, SES, tumor 
location, tumor differentiation, tumor stage, surgery and definitive chemoradiation 
on overall survival. Survival time was defined as time from diagnosis to death or until 
January 1st, 2010 for the patients who were still alive. Survival results were reported 
as hazard ratios (HR) and 95% CI. In all analyses we used the hospital with the highest 
percentage of patients receiving esophageal surgery with curative intent as our 
reference. All analyses were performed using Statistical Package for Social Sciences 
version 19.0 (SPSS Inc., Chicago, IL, USA). All reported p-values below 0.05 were 
considered statistically significant. 
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Results
Patients
Between 2003 and 2010, 1672 patients with esophageal cancer (C15) were diagnosed 
in the ECR region. We excluded 533 patients with metastatic disease (UICC-TNM 6 
M1b-M1) and 143 patients with tumors infiltrating surrounding organs (T4) since these 
patients are not always eligible for curative intent resection. Furthermore, patients 
with an unknown or missing M-status where excluded (n=145) and  two patients with 
unknown therapy, resulting in a study population of 849 patients with resectable and 
curable esophageal cancer (T1-3, N0-1, M0-1a).
Treatment
No significant differences were observed in gender, age, co-morbidity, T-stage, 
histology and tumor location of the patients from the hospitals of diagnosis in 
the ECR region (Table 1). However, SES and N-stage were significantly different 
between the hospitals of diagnosis. There was a difference in the proportion 
of patients that underwent surgery, ranging from 33% to 67% (p=0.002). 
Furthermore, the proportion of patients that underwent definitive chemoradiation 
ranged from 8% to 25% between the hospitals of diagnosis (p=0.039) (Figure 1). 
17% of all patients received chemoradiation with surgery.  
Figure 1. Proportions (%) of patients with esophageal cancer receiving treatment with curative 
intent in 10 hospitals of diagnosis in the ECR region in the period 2003-2010 (N=849)
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a Groups with <5 patients were not included in the Chi-square test.
b Does not add up to total due to unknown/missing values n= 92 
c Excluding hypertension
d Not otherwise specified
*11= patients diagnosed in extra-regional hospitals
Hospital of diagnosis
1 2 3 4 5 6 7 8 9 10 11* p-value
88 60 81 118 99 50 62 79 81 72 59
Gender
   Male
   Female
633
216
62
26
45
15
65
16
84
34
72
27
39
11
47
15
63
16
61
20
54
18
41
18 0.865
Age (yrs)
   <70
   ≥70
484
365
42
46
42
18
52
29
68
50
58
41
31
19
35
27
46
33
42
39
32
40
36
23 0.114
Socioeconomic statusa
  Low 
  Intermediate 
  High 
  Institutionalised 
  Unknown
204
329
255
38
23
18
37
29
3
1
13
21
21
2
3
28
28
17
3
5
19
48
40
8
3
22
41
30
4
2
9
22
14
2
3
25
21
12
2
2
28
23
21
5
2
15
35
27
2
2
16
28
21
7
0
11
25
23
0
0 0.032
Co-morbidityb, c
  None 
  1 
  2 or more
271
227
259
37
21
24
25
17
15
26
27
23
36
31
47
27
32
33
24
13
11
17
20
21
28
21
28
25
25
26
24
18
29
2
2
2 0.541
T-stagea
  T1 
  T2 
  T3 
  TX/missing
47
102
313
387
6
12
36
34
10
7
26
16
1
10
24
46
3
12
37
66
4
9
39
47
4
4
23
19
1
6
29
26
5
8
30
36
0
14
24
43
3
14
24
31
10
6
21
22 0.173
N-Stage
  N0
  N1
  NX/missing
375
349
125
36
38
14
31
24
5
27
41
13
44
50
24
38
44
17
27
17
6
24
30
8
28
37
14
47
26
8
36
28
8
37
14
8 0.022
Histologya
    Squamous-cell carcinoma  
  Adenocarcinoma 
  Other
271
537
41
31
52
5
19
38
3
22
55
4
38
75
5
39
53
7
21
27
2
17
45
0
17
54
8
26
53
2
27
42
3
14
43
2 0.178
Tumor locationa
  Proximal 
  Mid 
  Distal 
  Overlapping/NOSd
52
105
655
37
6
16
63
3
1
6
49
4
6
10
61
4
10
16
85
7
9
18
68
4
2
6
40
2
2
7
51
2
4
6
68
1
5
7
65
4
3
6
58
5
4
7
47
1 0.324
Surgery
    Yes
    No
382
467
36
52
40
20
36
45
58
60
35
64
31
19
26
36
26
53
34
47
34
38
26
33 0.002
Definitive chemoradiation
    Yes
    No
127
722
22
66
11
49
10
71
9
109
14
85
7
43
12
50
10
69
17
64
6
66
9
50 0.039
Number 
of 
patients
Table 1. Characteristics of patients diagnosed with resectable esophageal cancer in the ECR 
region in the period 2003-2010 (n=849).
Predictive factors for surgery
In unadjusted analyses, hospital of diagnosis, age, gender, SES, co-morbidity, cT-
stage, cN-stage, histology, and tumor location all had a significant influence on the 
probability to receive surgery (or surgery combined with peri-operative strategies) 
(Table 2). After adjustment for all variables listed in table 2, the multivariable analyses 
showed that in four hospitals patients were significantly less likely to receive surgery 
compared to the reference hospital with the highest percentage of patients receiving 
surgery. This hospital was a referral hospital for surgical treatment. Older patients 
(≥70 years), patients with low SES and patients with two or more co-morbidities were 
less likely to receive surgery. Furthermore, patients with a cT1 tumor, positive lymph 
node status, a proximal tumor and those with a squamous cell carcinoma or other 
cancers were significantly less likely to receive surgery (Table 2).  
Predictive factors for curative treatments 
In the univariable analyses, hospital of diagnosis, age, gender, SES, co-morbidity, clinical 
T-stage, clinical N-stage, histology, and tumor location all had a significant influence 
on predicting curative intent treatment which was defined as surgery or definitive 
chemoradiation with a curative intent (Table 3). In the multivariable analysis, patients 
diagnosed in 8 hospitals were less likely to receive a curative treatment compared to 
the reference hospital in the ECR region. Older patients (≥70 years), patients with two 
or more co-morbidities, patients with cT1 tumors and patients with positive lymph 
node status were less likely to receive curative intent treatment (Table 3). 
Predictors of overall survival
In the unadjusted Cox regression survival analysis, hospital of diagnosis, age, co-
morbidity, SES, surgery, histology, tumor differentiation, and tumor stage all had a 
significant influence on overall survival (Table 4). After multivariable analysis patients 
diagnosed in 3 hospitals were associated with a worse overall survival compared to 
the reference hospital. Tumor stages III and IV were significant predictors for worse 
overall survival, while stage I, moderate tumor differentiation and receiving surgery 
or definitive chemoradiation were significant predictors for better overall survival. 
While age ≥70 and two or more co-morbidities, were significant determinants for 
receiving curative intent treatment, they were not significant predictors for overall 
survival (Table 4).
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Univariable analysis Multivariable analysis
OR 95% CI OR 95% CI
Hospital of diagnosis
     1
     2
     3
     4
     5
     6
     7
     8
     9
     10
     11a
88
60
81
118
99
50
62
79
81
72
59
0.4
1.0
0.4
0.5
0.3
0.8
0.4
0.2
0.4
0.5
0.4
0.2-0.7
0.2-0.8
0.3-0.9
0.1-0.5
0.4-1.8
0.2-0.8
0.1-0.5
0.2-0.7
0.2-0.9
0.2-0.8
0.4
1.0
0.6
0.8
0.4
0.9
0.5
0.3
0.4
0.7
0.4
0.2-1.0
0.2-1.3
0.4-1.8
0.2-0.8
0.3-2.2
0.2-1.1
0.1-0.7
0.2-0.9
0.3-1.6
0.1-1.1
Age (yrs)
     <70 
     ≥70
484
365
1.0
0.2 0.2-0.3
1.0
0.3 0.2-0.4
Gender
     Male
     Female
633
216
1.0
0.6 0.4-0.8
1.0
1.0 0.7-1.6
Socioeconomic status
     Low
     Intermediate
     High
     Institutionalised
     Unknown
204
329
255
38
23
0.5
1.0
1.1
0.3
1.4
0.4-0.8
0.8-1.6
0.2-0.7
0.6-3.2
0.6
1.0
1.1
0.5
1.4
0.4-0.9
0.7-1.6
0.2-1.2
0.5-3.7
Co-morbidity
     None 
     1
     2 or more
     Unknown   
271
227
259
92
1.0
0.6
0.3
0.5
0.4-0.8
0.2-0.4
0.3-0.8
1.0
0.7
0.3
0.6
0.5-1.0
0.2-0.5
0.3-1.2
Clinical T stage
    T1
    T2
    T3
    T X/missing
47
102
313
387
0.6
1.2
1.0
0.3
0.3-1.0
0.8-1.9
0.2-0.5
0.4
1.5
1.0
0.3
0.2-0.8
0.8-2.6
0.2-0.5
Clinical N stage
   N0
   N1
   NX/missing
375
349
125
1.0
0.8
0.4
0.6-1.1
0.3-0.6
1.0
0.4
0.6
0.3-0.6
0.4-1.1
Histology
     Squamous-cell carcinoma   
    Adenocarcinoma
    Other
271
537
41
0.5
1.0
0.3
0.4-0.7
0.1-0.6
0.6
1.0
0.3
0.4-0.9
0.1-0.7
Tumor location
    Proximal 
    Mid 
    Distal 
     Overlapping/ not other specified  
52
105
655
37
0.1
0.5
1.0
0.5
0.0-0.2
0.3-0.8
0.3-1.1
0.1
0.6
1.0
0.6
0.0-0.2
0.4-1.1
0.3-1.4
Number of  
patients (n=849)
Table 2. Univariable and multivariable logistic regression analysis for determining predictors 
of surgery in patients diagnosed with resectable esophageal cancer in the ECR region in the 
period 2003-2010 (n=849).
a Diagnosis in extra-regional hospitals.
Table 3. Univariable and multivariable logistic regression analysis for determining predictors 
of curative intent treatment (surgery or chemoradiation) in patients diagnosed with resectable 
esophageal cancer in the ECR region in the period 2003-2010 (n=849).
a Diagnosis in extra-regional hospitals.
Univariable analysis Multivariable analysis
OR 95% CI OR 95% CI
Hospital of diagnosis
     1
     2
     3
     4
     5
     6
     7
     8
     9
     10
     11a
88
60
81
118
99
50
62
79
81
72
59
0.3
1.0
0.2
0.2
0.2
0.6
0.3
0.1
0.3
0.2
0.3
0.1-0.8
0.1-0.5
0.1-0.5
0.1-0.4
0.2-1.5
0.1-0.7
0.1-0.3
0.1-0.7
0.1-0.5
0.1-0.6
0.4
1.0
0.3
0.3
0.2
0.6
0.3
0.1
0.3
0.3
0.3
0.2-1.1
0.1-0.7
0.1-0.8
0.1-0.5
0.2-1.8
0.1-0.8
0.1-0.4
0.1-0.9
0.1-0.7
0.1-1.0
Age (yrs)
     <70 
     ≥70
484
365
1.0
0.2 0.2-0.3
1.0
0.3 0.2-0.4
Gender
     Male
     Female
633
216
1.0
0.7 0.5-1.0
1.0
1.1 0.7-1.7
Socioeconomic status
     Low
     Intermediate
     High
     Institutionalised
     Unknown
204
329
255
38
23
0.6
1.0
1.2
0.2
2.1
0.4-0.8
0.9-1.7
0.1-0.5
0.8-5.9
0.7
1.0
1.3
0.4
2.6
0.4-1.1
0.8-1.9
0.2-1.1
0.8-8.2
Co-morbidity
     None 
     1
     2 or more
     Unknown   
271
227
259
92
1.0
0.6
0.3
0.4
0.4-0.9
0.2-0.4
0.3-0.7
1.0
0.9
0.4
0.5
0.5-1.4
0.3-0.6
0.2-1.2
Clinical T stage
    T1
    T2
    T3
    T X/missing
47
102
313
387
0.2
1.1
1.0
0.2
0.1-0.5
0.6-2.0
0.1-0.2
0.2
1.3
1.0
0.2
0.1-0.4
0.7-2.5
0.1-0.3
Clinical N stage
   N0
   N1
   NX-missing
375
349
125
1.0
1.1
0.3
0.8-1.5
0.2-0-5
1.0
0.5
0.5
0.4-0.8
0.3-0.9
Histology
    Squamous-cell carcinoma   
    Adenocarcinoma
    Other
271
537
41
0.8
1.0
0.5
0.6-1.1
0.3-1.0
0.9
1.0
0.5
0.6-1.4
0.2-1.2
Tumor location
    Proximal 
    Mid 
    Distal 
     Overlapping/ not other specified 
52
105
655
37
0.6
0.7
1.0
0.6
0.3-1.0
0.5-1.1
0.3-1.1
0.5
0.7
1.0
0.6
0.3-1.1
0.4-1.3
0.3-1.4
Number of  
patients (n=849)
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Univariable overall survival Multivariable overall survival
HRb 95%CI HRb 95% CI
Hospital of diagnosis
     1
     2
     3
     4
     5
     6
     7
     8
     9
     10
     11a
88
60
81
118
99
50
62
79
81
72
59
2.1
1.0
3.0
2.7
2.8
1.7
3.1
3.3
2.4
3.1
1.6
1.3-3.5
1.8-4.9
1.7-4.4
1.7-4.6
0.9-3.0
1.8-5.2
2.0-5.5
1.4-4.1
1.8-5.1
0.9-2.9
1.5
1.0
1.8
1.5
1.4
1.4
1.9
1.6
1.5
2.2
1.6
0.9-2.5
1.1-3.1
0.9-2.5
0.8-2.3
0.8-2.6
1.1-3.2
1.0-2.8
0.9-2.6
1.3-3.7
0.8-3.2
Age (yrs)
     <70
     ≥70
 
484
365
1.0
1.6 1.4-1.9
1.0
1.0 0.8-1.3
Gender
     Male
     Female
633
216    
1.0
1.1 0.9-1.3
1.0
0.9 0.8-1.2
Socioeconomic status
    Low
    Intermediate
    High
    Institutionalised 
    Unknown
   
204
329
255
38
23 
1.3
1.0
0.8
2.0
0.8
1.0-1.5
0.7-1.1
1.3-2.9
0.5-1.6
1.1
1.0
0.9
1.3
0.9
0.8-1.3
0.7-1.1
0.9-2.0
0.5-1.8
Co-morbidity
    None 
    1
    2 or more
    Unknown
   
271
227
259
92 
1.0
1.4
1.6
0.8
1.1-1.7
1.3-1.9
0.5-1.1
1.0
1.2
1.0
0.8
0.9-1.5
0.8-1.3
0.5-1.3
Surgery
     Yes 
     No
   
382
467
0.4
1.0
0.3-0.5 0.3
1.0
0.2-0.4
Definitive Chemoradiation
    Yes
    No
127
722
0.9
1.0
0.7-1.1 0.4
1.0
0.3-0.5
Tumor location
    Proximal 
    Mid 
    Distal 
     Overlapping/ not other specified  
 
52
105
655
37   
1.2
1.2
1.0
1.4
0.9-1.7
1.0-1.6
0.9-2.1
0.8
1.1
1.0
1.2
0.5-1.1
0.8-1.5
0.7-1.8
Histology
    Squamous-cell carcinoma   
    Adenocarcinoma
    Other
 
271
537
41   
1.3
1.0
1.5
1.1-1.5
1.0-2.1
1.2
1.0
1.1
0.9-1.5
0.7-1.7
Tumor differentiation
    Good
    Moderate 
    Poor
    Anaplastic 
    Unknown
 
28
219
325
8
269   
0.6
0.8
1.0
1.5
1.0
0.3-1.0
0.7-1.0
0.7-3.1
0.8-1.2
0.6
0.8
1.0
0.7
0.7
0.3-1.1
0.6-1.0
0.3-1.6
0.6-0.9
Tumor stage
    I
    II
    III
    IV
    Unknown
110
214
172
81
272
0.5
1.0
1.7
3.1
2.5
0.3-0.7
1.3-2.2
2.3-4.2 
2.0-3.2
0.4
1.0
1.6
2.5
1.5
0.2-0.6
1.2-2.1
1.7-3.4
1.1-1.9
Table 4. Univariable and multivariable Cox proportional hazards regression  analyses of overall 
survival for patients with esophageal cancer in the ECR region in the period 2003-2010 (n=849).
Number of  
patients (n=849)
a Diagnosis in extra-regional hospitals.
b A higher risk of dying is denoted by a hazard ratio (HR) value >1 and a lower risk of dying by a HR value <1.
Discussion
This population-based study showed a large variation between the hospitals in the 
proportion of esophageal cancer patients that underwent surgery in a center of 
referral. Furthermore, a large variation between the referring hospitals was observed 
in patients that underwent definitive chemoradiation. Patients diagnosed in the 
majority of hospitals were less likely to receive treatment with a curative intent 
(surgery or definitive chemoradiation) compared to being diagnosed in the reference 
centre with the highest probability to receive this treatment. Since all patients are 
first discussed in a local non-expert MDT before referral, we hypothesize that these 
differences might be explained by the fact that a local MDT is less proficient in 
defining the best treatment options for esophageal cancer patients. The finding that 
patients from three referring hospitals in the ECR region had a significantly worse 
overall survival supports this.  
Hospital volume and centralization
Hospital volume is related to mortality and survival in patients after esophagectomy9;11. 
In the Netherlands, hospitals with a medium (11-20/year) or high (≥21/year) volume 
of esophagectomies had a significant lower 6-month mortality and a better 3-years 
survival compared to hospitals with very low (1-5/year) volume. Regionalisation and 
centralisation to increase the hospital volume of esophageal surgery might thus 
decrease postoperative mortality and increase long-term survival. Centralisation of 
esophageal cancer surgery in the ECR region has been established since 1999, when 
it was decided that esophageal surgery should be performed in dedicated referral 
hospitals. As a consequence, 3-year overall survival rates for patients with esophageal 
or gastric cardia cancer who received surgical treatment significantly improved from 
32% in the period before centralisation to 45% in the period of centralisation in the 
ECR region8.  These results are likely not only due to better surgery, but also to better 
staging, patient selection and decision making due to increased expertise of the health 
care professionals in the referral hospitals. It has been suggested that increasing 
volume has not only a beneficial effect on the outcome after surgery but also on 
the expertise of other specialties involved in esophageal treatment, since not only 
surgeon volume, but also hospital volume is important. For example, the sensitivity to 
identify lymph node metastases by CT scan or ultrasound was significantly higher in 
a high volume regional centre when compared with low volume centres20;21. Another 
study has shown that experience in endoluminal ultrasound (EUS) is important. High 
volume EUS centres (performing more than 50 EUS per endoscopist) had better 
results in staging compared with low volume centres22. 
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Predictors for treatment
Factors that influenced the probability to receive curative treatment were hospital 
of diagnosis age, SES, co-morbidity, clinical T-stage, clinical N-stage, histology, and 
tumor location. Elderly patients and patients with multiple co-morbidities were less 
likely to receive surgery, results that are in concordance with others23;24. Low SES was 
a significant predictor for not receiving surgery. Previous Dutch studies also showed 
that patients with a higher SES were more likely to receive surgery25;26. Patients with 
squamous-cell carcinoma were less likely to receive surgery, which is in concordance 
with a recent study from the United States27. Patients with proximal tumors received 
surgery less often. A possible explanantion is that most proximal tumors are primarily 
treated with definitive chemoradiation, as advocated by the Dutch guidelines3. In our 
study cT-stage and cN-stage influenced receiving surgery, which is supported by a 
study that showed an influence of cT-stage and cN-stage on disease-free, disease-
specific, and overall survival28.  Patients with cT1 tumors were less likely to undergo 
surgical treatment. This is probably caused by the systematic introduction of the EMR 
in the ECR region during the study period. Age, gender, SES, co-morbidity, clinical 
T-stage, clinical N-stage, histology, and tumor location all influenced the probability to 
receive curative treatment. However, since most of these factors were not significantly 
different between the hospitals of diagnosis and hospital of diagnosis was the most 
powerful independent predictor to receive curative treatment, other factors might 
influence the decision whether or not to refer  patients for curative treatment.
In our study only 144 patients (17%) were offered chemoradiation and surgery 
according to the Dutch guidelines, which is probably due to the fact that our study 
has started in 2003 and randomized trials studying neoadjuvant chemoradiation like 
the CROSS trial were still ongoing29. 
In the ECR region, the referring hospital’s MDT includes physicians with a vast 
experience in oncological decision making. However, the palliative and curative 
treatment options  for esophageal cancer patients has become more complex and 
new developments diffuse rapidly. This might explain the differences in the proportion 
of patients receiving curative treatment between hospitals.
Multidisciplinary team meetings
Specialised MDT meetings have shown to improve outcome in other solid tumors like 
rectal and breast cancer. The implementation of expert based MDT meetings in rectal 
cancer has resulted in a major improvement of surgical outcome with a reduction in 
positive resection margins (CRM+) from 26% to only 1%.12  MDT meetings in breast 
cancer have shown to lead to  changes in recommendations for surgical management 
in 52% of the cases13. In esophageal cancer, a recent study has shown that in 35% 
of the cases the initially proposed management plan by the referring hospital was 
altered after the MDT meeting even within a referral centre15.  Furthermore, due to the 
interaction between disciplines, MDT meetings have been shown to improve staging 
accuracy of esophageal cancer, which ensures correct management decisions14. 
These studies support the concept of regional tumor board meetings to increase the 
probability of receiving a curative treatment. This could be organised by referring all 
patients with esophageal cancer to an expert centre for further staging and decision 
making or to organize a regional diagnosis based expert MDT meeting in every hospital 
by means of expert consultation or video conferencing. Since hospital of diagnosis 
also influenced the probability of survival, implementation of these processes might 
improve survival of patients with esophageal cancer. After multivariable analysis the 
differences in survival between the hospitals are decreasing, probably by correction 
for treatment. For patients with esophageal cancer who are not eligible for surgery 
due to co-morbidities or irresectable/inoperable tumors, definitive chemoradiation is 
a well tolerated option with encouraging survival rates5;6. Furthermore, two important 
clinical trials in patients with squamous cell carcinoma showed that good responders on 
chemoradiation alone versus chemoradiation with surgery have comparable survival 
rates30;31. Thus, definitive chemoradiation is a reasonable alternative curative option, 
especially in patients with squamous-cell carcinoma. In our multivariate analysis 
hospital of diagnosis also influenced the proportion of patient offered definitive 
chemoradiation, suggesting that there is a significant difference of knowledge of the 
palliative and curative possibilities of definitive chemoradiation.
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Limitations
A strength of the present study is that the ECR collects data on comorbidity and 
that we could correct for most factors that could influence decision-making in the 
multivariable analysis.  This study also has its limitations. We excluded patients 
with distant metastasis (M1). Furthermore we excluded all T4 tumors, since it was 
not possible to identify T4 tumors which might still be eligible for surgery  with or 
without neo-adjuvant treatment.  How accurate clinical staging was is unknown. At 
least endoscopy, CT scan and an ultrasound of the cervical region was performed 
in all patients. Since EUS was not performed in all patients, a relatively high number 
of missing T (n=387) and N stages (n=125) were identified. However, in determining 
resectability of esophageal cancer, an EUS is not accurate32. The use of PET/CT as the 
first staging procedure with reserving EUS for cases with uncertainty about positive 
lymph nodes or tumor depth is sufficient.
In conclusion, hospital of diagnosis plays a significant role on the probability to 
receive potentially curative treatment and overall survival in patients with resectable 
esophageal cancer in the southern part of the Netherlands. All patients diagnosed 
with esophageal cancer should be discussed within a regional multidisciplinary expert 
panel.
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Hospital of diagnosis influences the 
probability of receiving curative treatment 
for esophageal cancer
Authors:  
Margreet van Putten 1; Marijn Koëter MD2; Hanneke W.M. van Laarhoven MD, PhD3; 
Valery E.P.P. Lemmens PhD1,4; P.D. Siersema MD, PhD5;  
Maarten C.C.M. Hulshof MD, PhD6; Rob H.A. Verhoeven PhD1;  
Grard A.P. Nieuwenhuijzen MD, PhD2
Affiliation: 
1  Department of Research,  
Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands.
2  Department of Surgery,  
Catharina Hospital Eindhoven, The Netherlands.
3  Department of Medical Oncology,  
Academic Medical Center of Amsterdam, The Netherlands
4  Department of Public Health,  
Erasmus MC - University Medical Centre Rotterdam, The Netherlands
5  Department of Gastroenterology and Hepatology,  
Radboud University Medical Center, Nijmegen, The Netherlands
6  Department of Radiotherapy,  
Academic Medical Center of Amsterdam, The Netherlands
5Abstract
Background: Although Esophageal Cancer (EC) surgery is centralized in the Netherlands, 
the disease is often diagnosed in hospitals which do not perform this procedure. To 
study the influence of hospital of diagnosis on the probability of receiving curative 
treatment and its impact on survival among patients with esophageal cancer.
Material and method: Patients with potentially curable esophageal or gastro-
esophageal junction tumors diagnosed between 2005 and 2013 who were potentially 
curable (cT1-3,X, any N, M0,X) were selected from the Netherlands Cancer Registry. 
Multilevel logistic regression was performed to examine the probability to undergo 
curative treatment (resection with or without neoadjuvant treatment, definitive 
chemoradiotherapy or local tumor excision) according to hospital of diagnosis. Effects 
of variation in probability of undergoing curative treatment among these hospitals on 
survival were investigated by Cox regression.
Results: All 13,017 patients with potentially curable EC, diagnosed in 91 hospitals, were 
included. The proportion of patients receiving curative treatment ranged from 37% 
to 83% and from 45% to 86% in the periods 2005-2009 and 2010-2013, respectively, 
depending on hospital of diagnosis. After adjustment for patient- and hospital-related 
characteristics these proportions ranged from 41% to 77% and from 50% to 82%, 
respectively (both P<0.001). Multivariable survival analyses showed that patients 
diagnosed in hospitals with a low probability of undergoing curative treatment had a 
worse overall survival (HR=1.13 95%CI 1.06-1.20;HR=1.15; 95%CI 1.07-1.24).
Conclusion: The variation in probability of undergoing potentially curative treatment 
for EC between hospitals of diagnosis and its impact on survival indicates that 
treatment decision-making in EC may be improved.
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5Introduction
Esophageal cancer is the eighth most common cancer and the sixth leading cause 
of cancer-related mortality worldwide1. The incidence of esophageal cancer in the 
Western world has risen over the past four decades and is still rising but at a slower 
rate than previously observed2,3. Although survival rates have improved during the 
past decade, they still remain poor with a 5-year relative survival ranging from 19%-
25% for patients with M0 esophageal cancer and a 2-year relative survival of 9% for 
M1 esophageal cancer4,5.
Esophagectomy with neo-adjuvant chemoradiotherapy is the most commonly used 
curative treatment modality for patients with locally advanced esophageal cancer6,7. 
Other curative treatment options include definitive chemoradiotherapy (dCRT) for 
non-metastasized patients with unresectable tumors or patients who are too frail 
to undergo surgery8-10, whereas endoscopic mucosal resection (EMR) is indicated for 
early stage esophageal cancer (T1a-lesions)11,12. For esophageal cancer patients with 
distant metastasis at diagnosis (40%), treatment with curative intent is no longer an 
option12. Similarly, curative treatment should be withheld when patients are too frail, 
have severe comorbidities or a reduced performance status13.
Previous nationwide studies have shown that the probability of undergoing curative 
treatment for gastric or pancreatic cancer is associated with hospital of diagnosis14,15. 
Referring physicians may have several reasons to consider the patient to be unsuitable 
for surgery and withhold possible curative options. Furthermore, a regional Dutch 
study showed that among potentially curable esophageal cancer patients the 
percentage of patients undergoing surgical treatment varied between 33% and 67% 
according to hospital of diagnosis16. These results were however based on data from 
eleven general hospitals in the South of the Netherlands, with only two of them being 
centers for esophageal cancer surgery. 
Both surgical treatment of esophageal cancer and endoscopic mucosal resection 
for early cancer are nowadays centralized, but the initial decision which treatment 
modality to perform, including the decision whether or not to refer patients for a 
curative treatment option is made in all Dutch hospitals. Therefore, it is important 
to evaluate the impact of hospital of diagnosis on the referral pattern for curative 
treatment and ultimately survival. The aim of this study was to examine the influence 
of the hospital of diagnosis on the probability to undergo a curative treatment option 
for esophageal cancer in the Netherlands. Furthermore, the association between the 
variation in curative treatment probability among hospitals of diagnosis and overall 
survival was assessed. 
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Methods
Netherlands cancer registry
Data were obtained from the Netherlands Cancer Registry (NCR). This registry serves 
the total Dutch population of 16.9 million inhabitants. The NCR is based on notification 
of all newly diagnosed malignancies in the Netherlands by the national automated 
pathological archive (PALGA). Additional sources are the national registry of hospital 
discharge, hematology departments, radiotherapy institutions and diagnosis therapy 
combinations (specific codes for reimbursement purposes). Specially trained data 
managers of the NCR routinely extracted information on diagnosis, tumor stage 
and treatment from the medical records. Information on vital status was obtained 
through an annual linkage with the Municipal Administrative Database, in which all 
deceased and emigrated persons in the Netherlands are registered.
Topography and morphology were coded according to the International Classification 
of Diseases for Oncology (ICD-O-3)17, in which subsite distribution is divided as: 
proximal (C15.0, C15.3), mid (C15.4), distal (C15.5), overlapping or not otherwise 
specified (C15.8, C15.9) and gastro-esophageal junction (GEJ) (C16.0). Tumor staging 
was performed according to the International Union Against Cancer (UICC) TNM 
classification that was valid at the time of diagnosis. Patients diagnosed between 2005 
and 2009 were staged according to TNM-6 and patients diagnosed between 2010 
and 2013 were staged according to TNM-718,19. Patients with GEJ cancer diagnosed 
between 2005 and 2009 were staged according to the TNM-6 classification for gastric 
and after 2010 according to the TNM-7 classification for esophageal cancer. Clinical 
tumor stage was assessed for the inclusion of patients and used in the multilevel 
logistic regression analyses. For survival analyses, the pathologic reports of the 
resection specimen were assessed, or, if not available, clinical tumor stage was noted. 
Patients with a potentially curable esophageal and GEJ cancer (cT1-3,X, any N, M0,X) 
were eligible for this study (Figure 1). Patients were considered to be potentially curable 
in this study if they had no clinically distant metastasis (cM0 and cM1a according 
to TNM-6 and cM0 according to TNM-7) and no tumor infiltrating into surrounding 
organs (no cT4 according to TNM-6 and no cT4A or cT4b according to TNM-7). For the 
analyses, patients with a cM1a tumor according to TNM-6 were categorized as having 
cN+ as most patients with a cM1a tumor had a distal tumor with coeliac lymph nodes 
which can be considered as having cN+ according to TNM-7.  Furthermore, patients 
with unknown clinical distant metastases (cMX) were included. It should be noted 
that as of 2010 coding regulations to register a cM0 or cM1 status into the NCR were 
less strict than prior to 2010, and therefore as of 2010 relatively more patients were 
registered with a cM0 rather than a cMX into the NCR. To account for this, we decided 
to include all patients with cMX.
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Curative treatment
Curative treatment was defined as surgical resection, dCRT or a local tumor excision 
in potentially curable patients with cT1-3,X, any N, M0,X disease. A surgical resection 
could be combined with or without (neo)adjuvant therapy. dCRT was defined as 
undergoing chemotherapy combined with radiotherapy without a surgical resection. 
A local tumor excision was defined as having a local tumor excision or an EMR. 
Hospital of diagnosis  
As the focus of this study was the decision-making process, the hospital of diagnosis 
was investigated rather than the hospital of resection. Hospital of diagnosis was 
defined as the hospital of histological confirmation for patients with a histological 
confirmation of the tumor (98%). If patients only had a clinical diagnosis, the 
hospital of diagnosis was defined as the hospital of clinical diagnosis. Patients 
were excluded from the study if esophageal cancer was diagnosed abroad. 
In the Netherlands, patients are diagnosed with esophageal cancer in any of the 91 
hospitals, usually the one closest to the patient’s place of residence. If the hospital of 
diagnosis does not perform esophageal cancer surgery or EMR, patients should be 
referred to an expert center when these treatments are indicated. 
The experience of the hospital in performing esophageal cancer surgery was divided 
in two categories: Those that performed at least twenty resections per year and those 
with a lower annual volume, according to the year of diagnosis. For example, if a 
patient was diagnosed in 2011 in a hospital that performed twenty or more resections 
in 2011, the patient was included in the group of hospitals with an annual resection 
volume of at least twenty procedures. 
Outcome measures
Curative treatment probability and overall survival were the primary outcomes 
investigated in this study. The curative treatment probability was defined as the 
proportion of patients diagnosed in a hospital who eventually underwent surgical 
resection, dCRT or local tumor excision, regardless of the hospital in which those 
treatments were undertaken. Survival time was defined as time from diagnosis to 
death or until February 1st 2016 for patients who were still alive.
Statistical analysis
Multilevel logistic regression analyses were used to analyze the hierarchically 
structured data as patients were nested within hospitals. These analyses provide 
more accurate estimates when dealing with hierarchically structured data 
than traditional logistic regression analyses since it accounts for dependency 
of patients within hospitals20,21. The outcome variable was curative treatment 
probability. Multilevel logistic regression models were performed for the periods 
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2005-2009 and 2010-2013 as the entire study period included centralization of 
esophageal cancer surgery and two new treatment paradigms: the introduction 
of neoadjuvant chemoradiotherapy and the introduction of EMR. The multivariate 
multilevel regression models were generated, and patient-, tumor-, and hospital-
related variables were added. The effect of a variable on the likelihood of curative 
treatment was expressed as an odds ratio (OR) with 95% confidence intervals (CI). 
Each patient’s adjusted likelihood of undergoing curative treatment was given by 
the following formula: P = eL ⁄(1+eL ) where L is the calculated value from the logistic 
regression for that particular patient. The mean adjusted curative treatment 
probability for each hospital of diagnosis was obtained by calculating the mean 
adjusted curative treatment probability of all patients diagnosed within a hospital 
adjusted for differences in patient- and tumor characteristics between hospitals. 
Differences between probabilities for hospitals were tested for statistical significance 
by means of ANOVA with Bonferroni correction. Information on co-morbidity and 
socioeconomic status was not routinely collected by the NCR but only in a sub-
cohort, i.e. the Eindhoven Cancer Registry, which is also part of the NCR. Therefore, a 
similar analysis was performed in the group of patients within the Eindhoven Cancer 
Registry to examine the influence of co-morbidity and socio-economic status on the 
probabilities to undergo curative treatment depending on the hospital of diagnosis. 
Multivariable Cox regression analyses were performed to investigate the impact of 
the variation in curative treatment probability among the hospitals of diagnosis on 
the overall survival of the patients, after adjustment for patient-, tumor- and hospital-
related characteristics. The hospitals of diagnosis, including the patients, were 
clustered into three groups with a similar number of patients according to the adjusted 
probability to undergo curative treatment within a hospital. Two multivariable cox 
regression analyses were performed to investigate the prognostic impact of the 
variation separately for the periods 2005-2009 and 2010-2013. Calculation of the 
curative treatment probabilities of the hospitals in the entire study period would 
not provide an accurate estimate and so hospitals, and thus patients, could be 
categorized erroneous. Results from survival analyses using Cox regression analyses 
were reported as hazard ratios (HRs) and 95% CI. All analyses were conducted using 
SAS version 9.4 (SAS Institute, Cary, North Caroline, USA) and reported P values of 
<0.050 were considered statistically significant. 
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Results
Patients
Between January 2005 and December 2013, 21,621 patients were diagnosed with 
esophageal or GEJ cancer. Exclusion of patients (Figure 1) resulted ultimately in a 
study population of 13,017 patients with potentially curable esophageal or GEJ cancer 
(cT1-3,X, any N, M0,X). General characteristics of the patients are shown in table 1. 
The median age was 69 (IQR 61-78) years and the majority (73%) of the patients were 
male. 
Curative treatment
The curative treatment rate was 57% (N=3950) in the period 2005-2009, of which 44% 
underwent surgery, 9% received dCRT and 4% underwent a local tumor excision. 
In the period 2011-2013, the curative treatment rate was higher; 68% (N=4162), of 
which 46% undergoing surgery, 16% received dCRT and 6% underwent a local tumor 
excision (Table 1). 
Patients were diagnosed with esophageal cancer in 91 hospitals. Twenty of these 
hospitals performed at least twenty esophageal resections in 2013, whereas in 2005 
only two hospitals had a volume of twenty or more resections. The hospitals which 
performed in 2013 at least twenty resections comprised both academic and teaching 
hospitals. Surgery was not performed in 33 hospitals in 2005, which increased to 66 
hospitals in 2013. Furthermore, 42% of the patients (N=224) diagnosed in 2005 and 
who underwent a resection was referred to another hospital for surgery, whereas 
67% of the patients (N=464) diagnosed in 2013 and who underwent a resection were 
referred to another hospital for surgery in 2013. 
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Netherlands Cancer Registry 2005-2013
Diagnosis of esophageal cancer
N = 21,621
Preliminary patient selection
(cT1-3,X, any N, M0,X)
N = 13,224
Patient with potentially curable esophageal
cancer (cT1-3,X,any N, M0,X)
N = 13,017
Excluded according to tumour stage N = 8379 *
•  Distant metastasis (cM1//M1b) N = 7260 **
•  Tumours invading adjacent structures (cT4/T4A/T4B)
 N = 1816 ***
Excluded for other reasons N= 207 *
•  Lymphoma, melanoma, carcinoid tumours and GIST
   tumours N = 152
•  Unknown hospital of diagnosis or diagnosis in a
   hospital aboard N = 31
•  Treatment unknown N=24
Figure 1: Study flowchart 
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*  The sum of the excluded patients per exclusion criteria is larger than the total number of excluded patients  
because some patients met two exclusion criteria.
**   cM1B according to TNM-6 and cM1 according to TNM-7.  
Patients with a cM1A tumor were categorized as having a cN+ tumor.
***  cT4 according to TNM-6 and cT4A and cT4B according to TNM-7.
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Number of 
patients
%* Surgical 
treatment 
rate (%)**
dCRT rate 
(%)**
Local tu-
mor-excision 
(%)**
Curative 
treatment 
rate (%)**
P *** 
All patients 13017 100% 45% 12% 5% 62%
Gender <0.001
   Male 9486 73% 48% 12% 5% 66%
   Female 3531 27% 37% 12% 4% 53%
Age (years.) <0.001
   < 60 2820 22% 66% 12% 5% 83%
   60-74 5751 44% 56% 14% 5% 76%
   ≥ 75 4446 34% 17% 9% 5% 31%
Interval of diagnosis <0.001
   2005-2009 6915 53% 44% 9% 4% 57%
   2010-2013 6102 47% 46% 16% 6% 68%
Tumor location <0.001
   Proximal 659 5% 9% 42% 2% 53%
   Mid 1608 12% 34% 18% 4% 55%
   Distal 7639 59% 48% 11% 6% 66%
   GEJ 2550 20% 55% 5% 2% 62%
   Overlapping, unknown 561 4% 28% 14% 5% 47%
Morphology <0.001
   Squamous cell carcinoma 3185 24% 32% 23% 2% 57%
   Adenocarcinoma 9211 71% 52% 8% 6% 66%
   Other 621 5% 15% 13% 2% 31%
cT classification <0.001
   T1 844 6% 37% 5% 36% 78%
   T2 2378 18% 59% 14% <1% 73%
   T3 5243 40% 61% 17% <1% 79%
   TX 4552 35% 21% 7% 7% 35%
cN classification <0.001
   N0 4492 35% 52% 11% 8% 71%
   N+ 6165 47% 51% 17% <1% 68%
   NX 2360 18% 15% 3% 13% 31%
cM classification <0.001
   M0 11550 89% 49% 13% 5% 67%
   MX 1467 11% 16% 5% 8% 28%
Number of esophageal cancer 
resections in hospital of diagnosis 
<0.001
   <20 10520 81% 45% 12% 4% 61%
   ≥20 2497 19% 45% 14% 11% 70%
Table 1. Characteristics and differences in curative treatment among patients with potentially 
curable esophageal cancer (cT1-3,X,any N, M0,X), diagnosed between 2005 and 2013 in the 
Netherlands (N=13,017)
dCRT= definitive chemoradiotherapy, *column percentage **row percentage. *** X 2 test based on curative 
treatment rate. GEJ= gastro-esophageal junction
Hospital of diagnosis and probability of curative treatment
The unadjusted percentage of patients who underwent a curative treatment differed 
significantly between hospitals of diagnosis in the period 2005-2009, varying from 
37% to 83% (Figure 2a; P <0.001), and in the period 2010-2013 from 45% to 86% (Figure 
2b; p<0.001). In the most recent period, the proportion of patients who underwent 
surgery varied from 21% to 71%, while the percentage of patients receiving dCRT or 
local tumor resection varied from 0% to 38% and 0% to 31%, respectively. 
Multivariate multilevel analysis confirmed the effect of hospital of diagnosis on the 
probability to undergo curative treatment. After adjustment for patient-, tumor- 
and hospital- related factors, curative treatment rates ranged from 41% to 77% in 
the period 2005-2009 and from 50% to 82% in the period 2010-2013 depending 
on the hospital of diagnosis (both P <0.001; Figure 3a and 3b). Subgroup analysis 
of patients within the Eindhoven Cancer Registry showed that, after adjustment for 
comorbidity and socio-economic status, the mean probability to undergo curative 
treatment per hospital of diagnosis only changed by 0.1% to 1.5% compared 
with results from analyses without comorbidity and socio-economic status. 
Additional analyses based on outcomes of the multilevel analyses showed that patients 
diagnosed in nine hospitals had a significant higher probability to undergo curative 
treatment than the average probability of all hospitals in the period 2010-2013, while 
patients diagnosed in six other hospitals had a significant lower probability than the 
average probability of all hospitals (Supplementary figure 1). 
Results of the multivariate multilevel analysis showed that being diagnosed in a 
hospital that performed twenty or more resections per year was associated with a 
higher probability of undergoing curative treatment compared to being diagnosed in 
hospitals with less than twenty resections in the earlier period (OR 1.54; 95%CI 1.19-
1.98) (Table 2). However, in the recent period this association was no longer found. In 
figure 3a and 3b, hospitals which performed 20 or more resections in 2009 and 2013 
respectively, were highlighted. 
5
86  |  Chapter 5  |  Part I
Figure 2. Observed variation in the proportion of patients with potentially curable esophageal 
cancer (cT1-3,X,any N, M0,X) who underwent a curative treatment (resection, definitive 
chemoradiotherapy or local tumor excision).  
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Period 2005-2009 (N=6915, P<0.01). Each bar represents one hospital.
Period 2010-2013 (N=6102, P<0.01). Each bar represents one hospital.
Figure 2A.
Figure 2B.
Figure 3. Case-mix adjusted variation in the proportion of patients with potentially curable 
esophageal cancer (cT1-3,X,any N, M0,X) who underwent a curative treatment (resection, 
definitive chemoradiotherapy or local tumor excision) after adjustment for gender, age, cT 
classification, cN classification, tumor location, morphology, period of diagnosis and number of 
esophageal resections in the hospital of diagnosis. 
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Period 2005-2009 (N=6915, P<0.01). Each bar represents one hospital and hospitals which performed 20 or more resections in 
2009 and 2013. 
*Patients who underwent a surgical resection or local tumor excision were combined as the multilevel logistic model provided 
inaccurate results as the number of patients who underwent a local tumor excision per hospital of diagnosis was too small.
Period 2010-2013 (N=6102, P<0.01). Each bar represents one hospital and hospitals which performed 20 or more resections in 2009 
and 2013. 
*Patients who underwent a surgical resection or local tumor excision were combined as the multilevel logistic model provided 
inaccurate results as the number of patients who underwent a local tumor excision per hospital of diagnosis was too small.
Figure 3A.
Figure 3B.
Supplementary Figure 1. Case-mix adjusted variation in the proportion of patients with 
potentially curable esophageal cancer (cT1-3,X,any N, M0,X) who underwent a curative 
treatment (resection, definitive chemoradiotherapy or local tumor excision) in the period 2010-
2013 on a log scale with an odds ratio for every hospital of diagnosis presented as a dot with 
95% confidence interval. The 1-line represents the average probability of all hospitals. Patients 
diagnosed in hospitals with an odds ratio less than 1 had a lower likelihood to undergo curative 
treatment. Adjustment was made for gender, age, cT classification, cN classification, tumor 
location, morphology, period of diagnosis and number of esophageal resections in the hospital 
of diagnosis (N=6102). 
Hospital of diagnosis and overall survival
Multivariable Cox regression analyses showed that patients diagnosed in 
hospitals with a lower probability of undergoing curative treatment had a worse 
overall survival than those diagnosed in hospitals with a higher probability. 
In the recent time period patients diagnosed in hospitals with a probability to 
undergo curative treatment ranging from 72% to 82% had a significant favorable 
overall survival compared to patients diagnosed in hospitals with a lower 
probability ranging from 50% to 64% (HR=1.15 95%CI 1.07-1.24; Table 3). A similar 
association was also found in the earlier time period (HR=1.13 95%CI 1.06-1.20). 
Furthermore, the same multivariable cox regression analyses demonstrated that 
patients diagnosed in high-volume surgery hospitals had a favorable survival 
compared to patients diagnosed in low-volume surgery hospitals (HR=0.90 95%CI 
0.83-0.98). However, this association was not found in the recent time period (HR=0.99 
95%CI 0.93-1.08).
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Period 2005-2009 N=6915 Period 2010-2013 N=6102
Curative treatment Curative treatment
Yes No OR* 95%CI Yes No OR* 95%CI
Gender
   Male 3043 1965 1.0 3210 1268 1.0
   Female 907 1000 0.87 0.75-0.99 952 672 0.80 0.68-0.94
Age (yrs.)
   < 60 1250 324 1.0 1097 149 1.0
   60- 74 2075 835 0.64 0.57-0.78 2303 538 0.62 0.50-0.76
   ≥ 75 625 1806 0.10 0.08-0.12 762 1253 0.10 0.08-0.13
cT classification
   T1 301 109 1.05 0.77-1.42 356 78 1.43 1.04-1.97
   T2 802 318 1.0 936 322 1.0
   T3 1855 638 1.17 0.97-1.41 2266 484 1.57 1.30-1.89
   TX 992 1900 0.28 0.23-0.33 604 1056 0.29 0.24-0.35
cN classification
   N0 1583 710 1.0 1606 593 1.0
   N+ 1934 1192 0.38 0.33-0.45 2253 786 0.64 0.55-0.76
   NX 433 1063 0.31 0.26-0.37 303 561 0.38 0.30-0.47
Tumor location
   Proximal 169 183 0.98 0.73-1.30 179 128 0.73 0.53-0.99
   Mid 414 423 0.91 0.74-1.11 476 295 0.89 0.70-1.12
   Distal 2389 1612 1.0 2638 1000 1.0
   GEJ 870 565 1.47 1.25-1.73 716 399 0.67 0.56-0.80
   Overlapping, unknown 108 182 0.62 0.45-0.85 153 118 0.65 0.47-0.89
Morphology
   Squamous cell 882 788 0.67 0.56-0.79 944 571 0.57 0.47-0.70
   Adenocarcinoma 2972 1897 1.0 3123 1219 1.0
   Other 96 280 0.34 0.25-0.46 95 150 0.37 0.26-0.53
Number of esophageal cancer resec-
tions in hospital of diagnosis 
   <20 resections 3334 2671 1.0. 3031 1484 1.0
   ≥20 resections 616 294 1.54 1.19-1.98 1131 456 1.08 0.82-1.42
Table 2. Multivariate multilevel logistic regression analyses to examine predictors of curative 
treatment in patients diagnosed with potentially curable esophageal cancer in the Netherlands. 
*  Adjusted for all variables listed in table 2 and hospital of diagnosis by using multilevel analysis.  
GEJ= gastro-esophageal junction
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Table 3. Multivariable Cox proportional hazards analyses of overall survival for patients with potentially 
curable esophageal cancer in the Netherlands for two separated periods of diagnosis.
a  OS= overall survival.
*   Adjusted for gender, age, tumors stage, tumors location, morphology, tumor differentiation and number of esophageal 
cancer resections in hospital of diagnosis.
**   Patients were divided in three groups with a similar number of patients according to the adjusted probability to undergo 
curative treatment of the hospital in which they were diagnosed. 
N
um
ber of patients
Crude 
2-year O
S a
U
nivariable H
R a
95%
C
I
M
ultivariable 
H
R a *
95%
 C
I
2005-2009 (n=6915)
Curative treatment probability **
   41%-53% 2261 32% 1.28 1.20-1.36 1.13 1.06-1.20
   54%-59% 2128 33% 1.18 1.11-1.26 1.10 1.03-1.17
   60%-77% 2526 42% 1.0 1.0
2010-2013 (n=6102)
Curative treatment probability **
   50%-64% 2308 40% 1.26 1.18-1.36 1.15 1.07-1.24
   65%-71% 1711 47% 1.13 1.04-1.22 1.05 0.96-1.14
   72%-82% 2083 50% 1.0 1.0 5
Part I  |  Chapter 5  |  91
Discussion
In this population-based nationwide study the proportion of esophageal cancer 
patients who underwent curative treatment (surgery, dCRT or local tumor excision) 
varied between 37% and 83% in the period 2005-2009 and between 45% and 86% in 
the period 2010-2013. Multivariate multilevel regression analysis confirmed the effect 
of hospital of diagnosis on the likelihood to undergo curative treatment. Patients with 
esophageal cancer who had been diagnosed in hospitals with a low probability to 
undergo curative treatment had a worse overall survival than those diagnosed in 
hospitals with a high probability.
Hospital variation and treatment probability
Our results show that the differences between hospitals in the proportion of patients 
that underwent dCRT were larger than the differences in the proportion of patients 
that underwent surgery. An explanation may be that dCRT has only recently been 
introduced. Therefore, increased awareness of the possibilities of chemoradiation 
combined with favorable results reported by previous studies might have played a 
role in the implementation of dCRT as a potential curative option22,23. Furthermore, 
this variation might also be explained by the fact that the indications for dCRT are less 
well defined compared to the indications for surgery.
In previous studies it has been suggested that co-morbidity and socioeconomic status 
play a role in the probability of undergoing curative treatment13, 24. However, subgroup 
analysis of patients diagnosed in the Eindhoven Cancer Registry, in which co-morbidity 
is registered, revealed only small changes in the probability of curative treatment after 
adjustment for co-morbidity and socio-economic status. These findings suggest that 
co-morbidity and socio-economic status only minimally contributed to the observed 
variation in curative treatment probability between the hospitals of diagnosis. 
Centralization, specialization and MDT meetings
In the Netherlands, esophageal cancer surgery is currently performed in high volume 
hospitals. Since 2006, a yearly minimum of ten esophageal resections per hospital 
was enforced by the Dutch Health Care Inspectorate, which was increased to a yearly 
minimum of twenty esophageal resections per hospital in 2011. Centralization of surgical 
treatment for esophageal cancer patients has shown to improve long-term outcome in 
the Netherlands24-27. Results from the present study showed that the number of patient 
that are referred by the hospital of diagnosis for surgery increased during the study 
period which is likely related to the centralization of surgical treatment for esophageal 
cancer patients. These changes due to centralization emphasize the important 
role of the hospital of diagnosis on the likelihood to undergo a curative treatment. 
The probability to undergo curative treatment may be influenced by various factors, 
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such as type of hospital and its facilities, e.g. the availability of radiotherapy, endoscopy, 
regional agreements, and treatment protocols that are used. In general, all hospitals in 
the Netherlands have at least an endoscopy unit and radiology department, including 
CT scan for optimal staging. The probability of receiving curative treatment may also 
be affected by the available specialization of the hospital and medical specialists. 
Two previous studies have reported that patients treated by medical specialists with 
higher caseload were more likely to undergo surgery or other treatments compared 
to patients treated by medical specialists with a limited caseload28,29. Higher-volume 
medical specialists also used a wider range of diagnostic investigations, which was 
not only explained by a better access to these facilities28. Possibly, patients with 
potentially curable disease managed by low-volume medical specialists regarded 
incurable, could be regarded still curable by a more experienced physician because 
this physician may be more aware of the curative treatment possibilities29. The 
present study also shows that patients diagnosed in high-volume surgery hospitals 
had a greater likelihood of undergoing surgery and a better overall survival than 
those diagnosed in low-volume surgery hospitals. However, these associations were 
only found in the earlier period in which centralization of surgery was initiated. 
All esophageal cancer patients should be discussed in a multidisciplinary team (MDT) 
meeting for a consensus-based treatment decision in the Netherlands. Regional 
expert MDT meetings have been shown to alter initial treatment plans frequently 
in patients with esophageal, gastric, colorectal and breast cancer30-34. However, 
no information is available as to whether a medical specialist with experience in 
curative treatment of esophageal cancer is always present in this MDT. Regional MDT 
meetings become even more important when treatment decisions are complex as in 
esophageal cancer and it might be hypothesized that the presence of experienced 
specialists in these MDT meetings might explain differences between hospitals in the 
proportion of patients undergoing curative treatment. 
Survival 
The variation in the probability of curative treatment among hospitals of diagnosis 
was found to be associated with survival in both time periods. A similar study 
performed by the same lead author among patients with gastric cancer has also 
found that variation in the likelihood to undergo surgery was associated with 
survival.15 However, this study has only found an association in the more recent time 
period. An explanation for the differences in findings of these studies could be that 
centralization of gastric cancer surgery has only been implemented since 2012, which 
is six years later than the implementation of centralization of esophageal cancer 
surgery. Centralization of surgery could have led to a decrease in the number of 
medical specialists with experience in curative treatment options for esophageal and 
gastric cancer patients in hospitals of diagnosis which have no longer a program for 
these curative treatment options. This negative consequence of centralization may 
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have influenced the selection of patients who are eligible for curative treatment and 
subsequently the referral and survival of these patients among hospitals of diagnosis.
Strengths and limitations
This study has some limitations. First, some factors influencing treatment, such as 
performance status of the patient and information about MDT meetings decisions, 
were not registered and could therefore not be included in the analyses. Second, 
possible incompleteness of registration of local tumor excision in the earlier period 
could have led to more variation in curative treatment probability between hospitals 
in the earlier period compared to the recent period. Third, information about the 
intention of the chemoradiotherapy was not available. However, as only potentially 
curable esophageal cancer patients were included it was assumed that these patients 
underwent chemoradiotherapy with curative intention.  
Finally, patients with distant metastasis (cM1) and cT4 tumors were excluded from 
the study. However, the accuracy of the diagnostic and staging methods used is 
unknown. Because endoscopic ultrasonography is not always performed in patients 
with esophageal cancer, clinical stage was unknown in a relatively high percentage 
of patients (Table 1). Nevertheless, the variation in cT, cN status and cM status 
between hospitals was much smaller than the inter-hospital variation in curative 
treatment probabilities and is therefore unlikely to have influenced the results 
substantially. Moreover, clinical decision-making in esophageal cancer treatment is 
more often based on cN and cM rather than on cT status 35 and it is assumed that 
most of the patients with a cMX prior to 2010 had in fact a cM0 as the percentage 
of patients with a cM0 increased after 2010 when fewer diagnostic procedures were 
required to register a cM0 or cM1 according to the coding regulations of the NCR. 
This study has also several strengths, such as its population-based design resulting 
in a large and representative study population. This nationwide study enabled the 
evaluation of the influence of the hospital of diagnosis on the probability to undergo 
curative treatment and its impact on survival among patients with esophageal cancer.
Conclusions
This study revealed a large variation in the probability to undergo curative 
treatment for esophageal cancer depending on the hospitals of diagnosis, which 
also affected the survival of these patients. Regional expert MDT meetings with 
involvement of experienced specialists in this field should be initiated for all 
patients with esophageal cancer. The decisions made by these panels may improve 
the selection of patients with esophageal cancer who are eligible for a curative 
treatment option leading to an overall improvement of survival on the long term. 
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6Abstract
Background: Resectable gastro-esophageal junction (GEJ) tumors are treated either 
with an esophageal-cardia resection or with gastrectomy. The difference in outcome 
between these two treatment modalities is unknown. Therefore, the aim of this study 
was to evaluate population-based treatment strategies for patients with resectable 
adenocarcinomas of the GEJ and to compare the oncological outcomes. 
Methods: Patients with potentially resectable GEJ tumors diagnosed between 2005 
and 2012 were selected from the nationwide, population-based Netherlands Cancer 
Registry. Differences between patients were compared using the chi-square test. 
Survival curves were generated using the Kaplan-Meier method. Overall multivariate 
survival was assessed with Cox regression analyses.
Results: Patients treated with esophagectomy (n=939) were significantly younger than 
patients treated with gastrectomy (n=257, 64 vs. 66 years, p<0.001). No differences 
were noted regarding lymph node yield, lymph node ratio and radicality. Patients 
treated with an esophagectomy or gastrectomy exhibited comparable overall 5-year 
survival rates (36% vs. 33%, respectively, p=0.250). Multivariate analysis showed 
that patients receiving perioperative treatment and gastrectomy exhibited similar 
overall survival rates compared to patients receiving perioperative treatment and 
esophagectomy (hazards ratio [HR]: 1.0, 95% confidence interval [CI] 0.7-1.3, p=0.923). 
However, patients receiving esophagectomy alone (HR: 1.4, 95% CI 1.1-1.6, p=0.002) 
or gastrectomy alone (HR: 1.8, 95% CI 1.4-2.4, p<0.001) exhibited a significantly worse 
overall survival.
Conclusions: The chosen type of surgery (esophagectomy or gastrectomy) did 
not influence the overall survival in our cohort of patients with GEJ tumors. The 
administration of perioperative chemo (radio) therapy improved survival regardless 
of the surgical approach.  
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Introduction
The incidence of esophageal cancer has increased over the past two decades, 
particularly in developed countries, making it the eighth most common cancer 
worldwide1-3. In the Western world, this increased incidence is attributed to an 
increased incidence of adenocarcinomas, especially of the gastro-esophageal junction 
(GEJ) in white males4. According to the Siewert classification, an adenocarcinoma of 
the gastro-esophageal junction is a tumor which has its epicentre within 5 cm of the 
anatomic GEJ5. The anatomic GEJ is defined as the proximal end of the gastric folds. 
According to the 7th edition of the TNM staging system6, a tumor with the epicentre 
within 5 cm of the GEJ that extends into the esophagus is classified and staged as an 
esophageal carcinoma, whereas a tumor with an epicentre within 5 cm of the GEJ 
without extension in the esophagus is classified and staged as a gastric carcinoma.
Patients with resectable GEJ tumors are either treated via an esophageal resection 
followed by a reconstruction with a gastric pull-up or by a gastrectomy followed by 
Roux-en-Y reconstruction. The difference in outcome between these two treatment 
modalities is unknown. To date, the literature does not provide conclusive evidence 
regarding the optimal treatment strategy in patients with GEJ tumors7. No randomized 
study has evaluated the optimal treatment strategy for GEJ tumors. This type of study 
appears to be difficult due to clinical tumor characteristics, such as the extension in 
the esophagus, that influence the decision whether to perform an esophagectomy or 
a gastrectomy.
Therefore, the aim of this study was to evaluate population-based patterns of care in 
treatment strategies for patients with resectable adenocarcinomas of the GEJ and to 
compare oncological outcomes. 
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Patients and Methods
Data
Nationwide population-based data from the Netherlands Cancer Registry (NCR) were 
used. The NCR collects data on all patients with newly diagnosed cancer in all Dutch 
hospitals. Patient, treatment and tumor characteristics are routinely extracted from 
the medical records by specially trained registrars of the cancer registry within 9 
months after diagnosis. The topography and morphology of the tumors were coded 
according to the International Classification of Diseases for Oncology (ICD-O-3)8. All 
patients diagnosed with a cancer of the GEJ (C16.0) between 2005 and 2012 were 
extracted from the NCR.  The registry does not provide the Siewert classification, 
however we defined a GEJ tumor as a tumor with its epicentre within 5cm of the GEJ. 
For this study, only adenocarcinomas (M8140–M8384) were selected for analysis. 
Patients diagnosed from 2005 to 2009 were staged according to TNM-6, whereas 
patients diagnosed from 2010-2012 were staged according to TNM-79;10. Tumor stage 
recorded by the NCR was defined by histopathological examination of the resected 
specimen. Clinical tumor stage was primarily determined by computed tomography 
(CT) scanning and endoscopic ultrasound (EUS) if available. Survival status was 
obtained from the nationwide population registries network, a nationwide population-
based registry that collects information on all deceased Dutch citizens. Institutional 
Review Board approval was obtained from the NCR. 
 
Patients
Between January 2005 and December 2012, 4050 patients were diagnosed with an 
adenocarcinoma of the GEJ in the Netherlands. Patients with metastatic disease 
(n=1620) or unknown/missing M-status (n=307) were excluded. Furthermore, 149 
patients with tumors infiltrating surrounding organs (T4) were excluded given that 
it was uncertain whether these patients were eligible for curative resection. Finally, 
patients with unknown treatment (n=7) or unknown type of surgical treatment (n=10) 
were also excluded. This resulted in 1957 patients with a resectable and potentially 
curable adenocarcinoma of the GEJ (T1-3, N0-3, M0). Of these patients, 1196 (61.1%) 
received surgical treatment, and these patients were analysed in this study to compare 
the different types of neoadjuvant and surgical treatment.
6
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Statistical analysis
Differences in patient and tumor characteristics were compared using the Pearson’s 
Chi-square test for nominal data. For differences in continuous variables, the Mann-
Whitney U test or the independent T-test were used. Survival curves were obtained 
using the Kaplan-Meier method, and differences between groups were assessed via 
the log-rank test. To evaluate independent prognostic factors for survival, uni- and 
multivariate analyses and Cox regression analyses were performed. All analyses 
were performed using Statistical Package for Social Sciences version 19.0 (SPSS Inc., 
Chicago, IL, USA). All reported p-values less than 0.05 were considered statistically 
significant. 
Results
Patients
A total of 1196 patients with resectable and potentially curable adenocarcinoma of 
the GEJ treated with a surgical resection were evaluated. Mean age was 64.4 years 
(SD 10.4) (Table 1). The majority of the patients were male (80%). Most patients 
were clinically diagnosed with a T3 tumor (n=520, 43%) and N+ disease (n=624, 
52%). Neoadjuvant therapy was administered in 651 patients (54%) prior to surgery, 
including perioperative chemotherapy in 385 patients (32%) and neoadjuvant 
chemoradiation in 266 patients (22%). Esophagectomy was performed in 939 patients 
(79%), and gastrectomy in the remaining 257 patients (21%). 
Esophagectomy vs. gastrectomy
Patients who underwent an esophagectomy were significantly younger than 
patients treated with gastrectomy (64 vs. 66 years, respectively, p<0.001, 
Table 1). Furthermore, patients treated with esophagectomy exhibited higher 
clinical T-stages (T3: 45.9% vs. T3: 34.6%) with more clinically positive lymph 
nodes (55.6% vs. 39.7%) compared with patients treated with gastrectomy. 
Perioperative chemotherapy was administered in 30% of the patients treated with 
esophagectomy compared with 40% of the patients treated with gastrectomy 
(p=0.002). More patients treated with esophagectomy were treated with neoadjuvant 
chemoradiation compared with gastrectomy (25% vs. 11%, respectively) (p<0.001). 
No significant differences were observed with respect to lymph node yield, total 
number of positive lymph nodes, lymph node ratio and the radicality of the resection 
between the two types of surgical approaches (Table 2). 
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All patients
(n=1196)
Esophagectomy
(n=939, 78.5%)
Gastrectomy
(n=257, 21.5%) p-value
Mean age (years, SD) 64.4 (SD 10.4) 63.9 (SD 10.1) 66.4 (SD 11.4) <0.001 
Gender
  Male
  Female
954 (79.8%)
242 (20.2%)
761 (81.0%)
178 (19.0%)
193 (75.1%)
64 (24.9%) 0.036
cT stage
  T1
  T2
  T3
  Tx (unknown/missing)
33 (2.8%)
308 (25.8%)
520 (43.5%)
335 (28.0%)
23 (2.4%)
254 (27.1%)
431 (45.9%)
231 (24.6%)
10 (3.9%)
54 (21.0%)
89 (34.6%)
104 (40.5%) <0.001
cN-stage
  N0
  N+
  Nx (unknown/missing)
445 (37.2%)
624 (52.2%)
127 (10.6%)
325 (34.6%)
522(55.6%)
92 (9.8%)
120 (46.7%)
102 (39.7%)
35 (13.6%) <0.001
Perioperative therapy
  None
  Chemotherapy
  Chemoradiation
545 (45.6%)
385 (32.2%)
266 (22.2%)
419 (44.6%)
282 (30.0%)
238 (25.3%)
126 (49.0%)
103 (40.1%)
28 (10.9%) <0.001
Table 1. Baseline patient characteristics for patients treated with esophagectomy or 
gastrectomy. 
Table 2. Histopathological characteristics. 
Esophagectomy
(n=939, 78.5%)
Gastrectomy
(n=257, 21.5%) p-value
Tumor differentiation
  Well
  Moderate
  Poor
   Unknown
26 (2.8%)
223 (23.7%)
403 (42.9%)
287 (30.6%)
12 (4.7%)
59 (23.0%)
117(45.5%)
69 (26.8%) 0.308
Tumor stagea
  I
  II
  III
  IV
198 (21.5%)
246 (26.7%)
447 (48.6%)
29 (3.2%)
68 (27.5%)
63 (25.5%)
103 (41.7%)
13(5.3%) 0.056
Lymph node yield (SD)b 16.0 (SD 9.1) 15.8 (SD 9.3) 0.813 
Positive lymph nodes (SD)c 3.31 (SD 4.6) 3.23 (SD 5.6) 0.132 
Lymph node ratio 0.37 0.37 0.951 
R-statusd
  R0
  R1/2 
786 (86.7%)
121 (13.3%)
209 (83.6%)
41 (16.4%) 0.217
a Exclusion of unknown (n=29) 
b Exclusion of unknown (n=23) 
c Exclusion of unknown (n=19) 
d Exclusion of unknown (n=39)
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Survival
Patients treated with an esophagectomy or gastrectomy exhibited comparable overall 
5-year survival rates (36% vs. 33%, respectively, p=0.250, Figure 1). Additionally, no 
significant difference was observed between esophagectomy and gastrectomy in 
patients who were treated with perioperative therapy (41% vs. 41%, respectively, 
p=0.787). However, the overall 5-year survival in the group receiving surgery combined 
with perioperative therapy was significantly higher compared with esophagectomy 
alone (31%) or gastrectomy alone (26%, p<0.001), (Figure 2). No significant difference 
in 5-year overall survival was noted in patients treated with chemotherapy or 
chemoradiation (43% vs. 39%, p=0.323).
Figure 1. Overall survival of patients with a resectable adenocarcinoma of the GEJ treated with 
an esophagectomy or gastrectomy. 
Numbers at risk 0 1 2 3 4 5 6 7 8
Esophagectomy 939 760 477 312 209 149 97 59 30
Gastrectomy 257 188 130 90 60 45 32 17 9
Multivariate analyses showed that patients greater than 70 years of age, male gender, 
high tumor stage and R1-resection were significantly associated with a worse overall 
survival. Good tumor differentiation and tumor stages I and II were significantly 
associated with a better overall survival. Regarding the treatment strategy, patients 
receiving perioperative treatment and gastrectomy exhibited similar overall survival 
compared with patients receiving perioperative treatment and esophagectomy 
(hazard ratio [HR]: 1.0, 95% confidence interval [CI] 0.8-1.3, p=0.923). However, 
patients receiving an esophagectomy (HR: 1.4, 95% CI 1.1-1.6, p=0.002) or gastrectomy 
alone (HR: 1.8, 95% CI 1.4-2.4, p<0.001) exhibited a significantly worse overall survival 
(Table 3). 
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Figure 2. Overall survival of patients with a resectable adenocarcinoma of the GEJ treated with 
surgery alone or surgery with chemotherapy or chemoradiation (CRT)
Numbers at risk 0 1 2 3 4 5 6 7 8
Esophagectomy with chemo or CRT 520 456 264 156 88 51 25 8 3
Gastrectomy with chemo or CRT 131 107 75 49 32 23 13 4 2
Esophagectomy 416 303 212 155 121 98 72 51 27
Gastrectomy 124 80 54 40 27 21 17 12 7
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Table 3. Multivariable Cox regression analysis on overall survival. 
Univariable Multivariable
Number of patients
(n=1196)
HR 95% CI p-value HR 95% CI p-value
Age
  <70
  ≥70
781
415
1.0
1.4 1.2-1.6 <0.001
1.0
1.4 1.2-1.6 <0.001
Gender
  Male
  Female
954
242
1.0
0.8 0.7-1.0 0.051
1.0
0.7 0.6-0.9 0.001
Treatment
  Esophagectomy with chemo or CRT
  Gastrectomy with chemo or CRT
  Esophagectomy alone
  Gastrectomy alone
  Other
520
131
416
124
5
1.0
1.0
1.5
1.8
1.5
0.8-1.4
1.3-1.8
1.4-2.2
0.5-4.5
0.756
<0.001
<0.001
0.522
1.0
1.0
1.4
1.8
1.8
0.8-1.3
1.1-1.6
1.4-2.4
0.6-5.8
0.923
0.002
<0.001
0.327
Tumor differentiation
  Good
  Moderate
  Poor
  Unknown 
38
282
519
356
0.5
0.8
1.0
0.6
0.3-0.9
0.6-0.9
0.5-0.7
0.011
0.004
<0.001
0.6
0.9
1.0
0.7
0.4-1.0
0.7-1.0
0.6-0.9
0.042
0.108
0.002
Tumor stage (pathologic)
  I
  II
  III
  IV
  Unknown 
266
309
550
42
29
0.3
0.7
1.0
2.2
0.3
0.3-0.4
0.6-0.8
1.5-3.0
0.2-0.6
<0.001
<0.001
<0.001
<0.001
0.3
0.7
1.0
2.0
0.4
0.3-0.4
0.6-0.8
1.4-2.9
0.2-0.8
<0.001
<0.001
<0.001
0.013
Radicality
  R0
  R1/2
  Unknown
995
162
39
1.0
2.5
1.8
2.1-3.0
1.2-2.6
<0.001
0.002
1.0
1.8
1.5
1.5-2.2
1.0-2.2
<0.001
0.031
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Discussion
This large nationwide, population-based study showed that patients with a 
resectable GEJ tumor in the Netherlands and were treated with surgery received an 
esophagectomy in 79% and gastrectomy 21% of the cases. Similar surgical outcomes 
were noted between the two types of resection with respect to lymph node yield, 
lymph node ratio and radicality. No survival difference was observed between patients 
treated with esophagectomy or gastrectomy regardless of neoadjuvant treatment. 
However, perioperative chemotherapy and neoadjuvant chemoradiation were most 
crucial for oncological outcome. 
Tumor location is important in choosing the most optimal surgical approach. In 
particular, extension of the tumor in the esophagus influences the decision whether 
to perform an esophagectomy or gastrectomy. Previous studies have reported 
difficulties in determining the exact localization and extent of the tumor. Additionally, 
in the evaluation of the nodal status, a discrepancy between preoperative findings 
and postoperative histopathological outcome is observed11. These findings may 
impede decision making related to the treatment approach. This study showed that 
the majority of patients with GEJ tumors in the Netherlands are treated according 
to the guidelines for esophageal cancer. The definition of GEJ tumors was based on 
the clinical definition as recorded in medical files, which may vary between hospitals, 
but reflects everyday clinical practise. Therefore, it is difficult to differentiate which 
tumor-related factors were used to determine whether the tumor was treated via 
esophagectomy or gastrectomy.
In this study, no survival difference was noted between patients treated with 
esophagectomy or gastrectomy regardless of the use of neoadjuvant treatment. 
However, the baseline characteristics in clinical tumor stage between the 
esophagectomy and gastrectomy group differed with a higher cT-stage and more cN+ 
disease observed in patients receiving an esophagectomy. Although we corrected for 
tumor staging in our multivariable survival analysis, the high number of unknown T 
and N stages potentially influenced the results. 
This study revealed no differences between esophagectomy and gastrectomy 
regarding lymph node yield, lymph node ratio and radicality of the resection. These 
findings are consistent with previous studies and demonstrate no benefit for an 
esophagectomy or gastrectomy for these parameters12-14. A radical resection (R0) in 
the current study was performed in 84% of patients treated with esophagectomy and 
in 81% treated with gastrectomy. In the literature, R0 resection rates ranges from 
72 to 93% for esophagectomy and from 62 to 93% for gastrectomy7. Several studies 
demonstrated that a wide proximal resection margin (>3.8 to 6 cm) was associated 
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with an improved survival12;13. Theoretically, this margin width is difficult to achieve 
with a gastrectomy and more easily obtained with an esophagectomy. Also, it would 
be expected that an esophagectomy would result in more extensive lymph node 
dissection because it includes an additional mediastinal lymphadenectomy. However, 
in this study, a significant difference in the lymph node yield, the number of positive 
lymph nodes or the lymph node ratio was not established. Additionally, with regard to 
overall survival, we did not observe a difference between the two surgical strategies 
as previously reported in the literature13;15-18. This observation was independent 
of perioperative treatment. A recent study showed an unadjusted survival benefit 
for patients receiving an esophagectomy. However, this benefit disappeared after 
adjusted survival analysis19. These findings indicate that the type of surgery chosen 
based on clinical factors in GEJ cancer does not influence oncological outcomes. 
A possible explanation could be the fact that the sites with the most affected 
lymph nodes in GEJ tumors are paracardial and near the lesser curvature17;18;20. 
A full lymphadenectomy of these stations is generally being performed in both 
esophagectomy and gastrectomy. Nevertheless, a full lymphadenectomy of upper 
mediastinal nodes (of which involvement is present in 11% of type II GEJ tumors17) 
can only be achieved via a transthoracic esophagectomy. In our study, patients with 
clinically positive lymph nodes received an esophagectomy more often, indicating 
that an esophagectomy is more often chosen when mediastinal lymph node positivity 
was expected. Furthermore, this might have influenced pathologic staging since it 
might lead to stage migration. This study showed more stage III tumors in the 
esophagectomy group, however this difference was not significant. Nevertheless, a 
recent study demonstrated that the number of resected nodes was not associated 
with survival after neoadjuvant chemoradiation, which questions the importance of 
the extent of the lymphadenectomy in case of neoadjuvant chemoradiation followed 
by an esophagectomy21.  
Neoadjuvant chemoradiation and perioperative chemotherapy are beneficial in 
the treatment of both esophageal and GEJ tumors, respectively, based on the 
CROSS-trial22 and the MAGIC-trial23. Based upon multivariate analysis in this study, 
perioperative treatment of GEJ tumors via chemotherapy or chemoradiation prior to 
surgery significantly improved overall survival, whereas the type of surgery did not. 
This result is consistent with a recent study of the NSQIP/SEER data. In these data, the 
type of resection did not significantly influence survival compared with multimodality 
treatment, which improved survival19. However, data on chemotherapy were lacking, 
and radiation was used as a surrogate for multimodality treatment. There is no 
conclusive evidence in the literature on which perioperative treatment (chemotherapy 
or chemoradiation) regime should be used in the treatment of GEJ tumors. The CROSS 
trial22 and the MAGIC trial23 both included GEJ tumors. A meta-analysis24 revealed a 
survival benefit of neoadjuvant chemoradiotherapy or chemotherapy compared 
with surgery alone in both esophageal and GEJ carcinoma patients. In our study, 
no difference in 5-year survival was noted between perioperative chemotherapy 
and chemoradiation. A clear advantage for chemotherapy or chemoradiation in GEJ 
tumors has not been established in the literature to date. An early, closed phase III 
trial by Stahl et al.25 revealed a non-significant survival advantage for preoperative 
chemoradiotherapy compared with preoperative chemotherapy in adenocarcinomas 
of the esophago-gastric junction. A randomised phase II trial by Burmeister et 
al.26 revealed no survival difference; however, chemoradiotherapy resulted in a 
significantly increased pathological response and R0 resection rate and thus appeared 
to advantageous for bulky GEJ tumors. An Irish trial is currently recruiting patients with 
esophageal and GEJ tumors to compare the MAGIC regimen with the CROSS regimen. 
This study might provide more insight into the optimal preoperative strategy.
Given that oncological findings appear to be similar, patient-related outcomes with 
respect to morbidity, mortality, hospital stay and quality of life are even more important 
in decision making regarding the optimal surgical treatment strategy. Unfortunately, 
we did not have insight into these factors. A recent study reported adjusted 30-day 
mortality rates for esophagectomy and gastrectomy in the Netherlands of 4.6% and 
6.9%, respectively27. Several additional studies addressed mortality and morbidity rates 
and found no difference in mortality between esophagectomy and gastrectomy13;16;17. 
According to the literature, the morbidity rates of both surgical strategies appear to 
be comparable, with a morbidity rate ranging from 33 to 77% after esophagectomy 
and from 11 to 67% after gastrectomy15-17. Only one of these studies revealed 
increased morbidity after esophagectomy. Two studies demonstrated that quality 
of life after surgery was more severely affected by esophagectomy compared with 
gastrectomy28;29; however, these studies involved a relatively small study population. 
Our study has strengths and limitations. The definition of GEJ tumors was 
based on various clinical definitions as recorded in the medical files, and these 
definitions may vary between hospitals. We excluded all T4 tumors given that it 
was impossible to identify T4 tumors that were potentially eligible for surgery with 
or without neoadjuvant treatment. Given that a CT scan but not always a EUS was 
performed in each patient, we observed a relatively large number of unknown or 
missing T stages (n=355), and this limitation potentially influenced our results. 
Another limitation of this study was that the NCR does not provide data on whether 
or not the patients received the whole course of perioperative chemotherapy or 
neoadjuvant chemoradiation. According to the Dutch guidelines patients treated 
with an esophageal scheme were advised to receive neoadjuvant chemoradiation 
followed by esophagectomy and patients treated with a gastric scheme should 
receive perioperative chemotherapy. Unfortunately, in the NCR database it is not 
registered whether or not the patients received the whole course of perioperative 
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treatment (CRT or chemotherapy). Despite the fact that some patients may not 
fully completed the perioperative treatment, this study still revealed an important 
influence of perioperative treatment. Therefore the observed phenomenon might 
even underestimate the effect of a ideally fully  completed perioperative scheme. 
In this study only 54% of the patients received perioperative chemotherapy or 
neoadjuvant chemoradiation, this is probably due to the fact that our study has started 
in 2005 and the randomized trials like the Magic and CROSS trials were still ongoing. As a 
consequence, the use of perioperative chemotherapy or neoadjuvant chemoradiation 
increased from 31% in the period 2005-2008 to 78% in the period 2009-2012. 
The strengths of this study are its large number of patients and its 
observational nature with no patient selection; therefore, it represents the 
entire population and provides an overview of everyday clinical practise. 
 
In conclusion, this nationwide cohort study revealed no difference in surgical 
outcomes in patients with a resectable GEJ tumor treated with esophagectomy or 
gastrectomy with respect to lymph node yield, lymph node ratio, radicality and overall 
survival. Perioperative treatment with chemotherapy or chemoradiation rather than 
the surgical approach appears to be most critical for overall survival.
6
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7Abstract
Background: Patients with resectable esophageal cancer are treated with neoadjuvant 
chemoradiotherapy (nCRT) followed by surgery within 3 to 8 weeks. In practice, 
surgery is often delayed for various reasons. The aim of this study was to evaluate 
whether delaying surgery beyond 8 weeks has an effect on postoperative morbidity, 
long-term survival, and pathologic response in patients treated for esophageal ADC.
Methods: Patients who underwent nCRT followed by surgery, for cT1-3, N0-3, M0 ADC 
between 2001 and 2014 were retrospectively included from a prospectively obtained 
database. Patients with a time from the end of nCRT to surgery (TTS) ≤ 8 weeks were 
compared with patients with a TTS > 8 weeks.
Results: Of 190 patients, 65 had a TTS ≤ 8 weeks, and 125 had a TTS > 8 weeks. 
Patient characteristics were comparable for both groups, but patients with TTS > 8 
weeks exhibited higher ASA scores (p = 0.013) and more comorbidities (p = 0.007). 
Multivariate analysis revealed that TTS did not significantly influence postoperative 
morbidity, pathologic complete response rates, and five-year survival rates (42% in 
patients with TTS ≤ 8 weeks and 37% in patients with TTS > 8 weeks).
Conclusions: Delaying surgery beyond 8 weeks after nCRT did not significantly 
influence postoperative morbidity, pathologic response, and survival in patients with 
non-metastatic ADC. Therefore, it appears reasonable to postpone surgery beyond 8 
weeks in patients who have not yet recovered from nCRT. However, if the patient is fit 
for surgery, postponing surgery does not have any additional advantages.
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Introduction
Neoadjuvant chemoradiotherapy (nCRT) followed by radical surgery improves overall 
survival and locoregional control in patients with non-metastatic locally advanced 
esophageal cancer1-3. Postoperative morbidity rates after esophagectomy vary 
between 26% and 66.7%4-6. Several factors influence postoperative morbidity rates, 
such as patient characteristics (age, smoking, and the presence of comorbidities) and 
surgical approach. Postoperative morbidity is also influenced by nCRT7;8. According to 
clinical guidelines, surgery is performed 3 to 8 weeks after completion of nCRT; this 
guideline is typically followed in randomised controlled trials9-11. This period allows 
acute inflammation to resolve following nCRT, patients to recuperate from neo-
adjuvant treatment, and patients to be fit for surgery.  In practice, however, surgery 
is often postponed beyond this timeframe due to the toxicity of nCRT and the patient 
condition. Time to surgery (TTS) may further depend on logistical reasons12-14 and the 
patient’s personal preference.
Delaying surgery may affect postoperative outcome given that nCRT is associated 
with inflammation and fibrosis in the surgical field15. Furthermore, radiation-induced 
fibrosis or radionecrosis could complicate surgery and postoperative recovery16. 
Finally, postponing surgery after nCRT may influence oncological outcome. On the 
one hand, a longer wait time could result in more tumor regression; however, this 
waiting period may lead to the progression of (systemic) disease15;17;18. In rectal cancer, 
postponing surgery beyond 8 weeks is associated with higher rates of pathologic 
complete response (pCR)19-21. Additionally, postoperative morbidity, mortality, and 
overall survival were not significantly influenced by the interval between nCRT and 
surgery19-22.
Several studies suggest that patients with esophageal squamous cell carcinoma 
(SCC) benefit more from nCRT than patients with adenocarcinoma (ADC). In the 
Chemoradiotherapy for Esophageal Cancer Followed by Surgery Study (CROSS) trial, 
patients with SCC exhibited an increased pCR rate and better survival compared with 
patients with ADC3. Given its lower response rate, increasing TTS in ADC patients may 
have less of an influence on tumor regression compared with SCC patients. Little is 
known about the optimal timing of surgery after nCRT in ADC. Retrospective studies 
have shown conflicting results about whether or not delaying surgery is beneficial 
with respect to pathological response17;18;23-27. These studies, however, mainly 
focused on SSC of the esophagus, whereas most tumors in the Western population 
currently are ADC.  Kim et al.18 performed a retrospective study in ADC patients, in 
which delaying surgery did not affect pathologic response. However, a recent study 
in SCC and ADC patients by Shapiro et al.25 indicated that increasing TTS  improved 
pathologic response with a trend towards more postoperative complications. Others 
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however showed that delaying surgery beyond 8 weeks was not associated with more 
postoperative complications17;18;24-26.
The aim of this study was to evaluate the influence of the time period between nCRT 
and surgery on the postoperative course, pathological response, and long-term 
survival in patients with ADC.
Methods
A database of all patients with esophageal cancer treated at the Catharina Hospital in 
Eindhoven in the Netherlands was obtained and retrospectively analysed for patients 
treated between 1 January, 2001 and 1 May, 2014. All data concerning diagnosis, 
treatment, and follow-up were recorded.  In all patients, the standard work-up included 
a clinical examination, endoscopy with biopsies, endoscopic ultrasonography (EUS), 
ultrasonography or computer tomography (CT) of the cervical region, CT of the chest 
and abdomen, and a whole body positron emission tomography fused with CT (PET-
CT. Follow-up data were updated every 6 months based on outpatient-clinic reports.
Patients were recruited into this study if they were diagnosed with cT1-3, N0-3, 
M0 (TNM 7th edition) ADC and underwent nCRT followed by an esophagectomy. 
Neoadjuvant therapy consisted of 23 fractions of 180 cGy three-dimensional (3D) 
conformal radiotherapy, which was administered 5 days a week, combined with 5 
weekly intravenous administrations of paclitaxel (50 mg/m2) and carboplatin (AUC 2). 
Because of inclusion in a phase II trial28, patients treated between 2001 and 2004 were 
treated with a different regimen which consisted of paclitaxel 175mg/m2 intravenously 
and carboplatin AUC 5 intravenously on day 1 and day 22 and continuous infusion 
of 5-FU 200mg/m2 on day 1 through day 42. The surgical approach was changed in 
this period from an open transhiatal or transthoracic approach to a laparoscopic 
transhiatal, and recently, to a completely, minimally invasive thoracolaparoscopic 
approach.    The exclusion criteria were SCC and a tumor located in the proximal 
esophagus. Furthermore, we excluded patients who underwent salvage surgery, 
which was defined as an esophagectomy for tumor recurrence after initial 
chemoradiotherapy (dCRT).
7
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Patients were divided into two groups based on the time to surgery (TTS) after 
completion of neoadjuvant chemoradiotherapy. One group consisted of patients with 
a TTS ≤ 8 weeks; the other group with a TTS > 8 weeks. We compared both groups for 
perioperative course, postoperative mortality, long-term survival, pCR (ypT0N0), and 
Mandard tumor regression grade to evaluate the response of the tumor to nCRT29. 
Postoperative mortality was defined as death within 30 days or during the hospital 
stay.
Univariable analysis was performed by means of χ2. Survival was defined as the time 
between surgery and death or the date of last follow-up. In March 2015, the survival 
status of the patients was recorded. Survival analysis was performed using the 
Kaplan-Meier method, and comparisons were analysed using the log-rank test.  For 
multivariable analysis, we used binary logistic regression and Cox’ regression analysis 
to determine independent predictors for perioperative complications and survival. 
TTS (≤ 8 weeks and  > 8 weeks) was used as a dichotomous variable for perioperative 
course and survival. For analysis of pathologic response, TTS was considered as a 
continuous variable. The following variables were also included in multivariable 
analysis: age, sex, number of comorbidities, American Society of Anesthesiologists 
classification, need for tube feeding, weight loss, tumor location, and surgical 
approach. Analyses were performed using Statistical Package for Social Sciences 
version 21.0 (SPSS Inc., Chicago, IL, USA). A p-value less than 0.05 was considered 
significant.
Results
In a period between 1 January, 2001 and 1 May, 2014, 387 patients were treated 
for resectable esophageal carcinoma at our center of which 190 patients met the 
inclusion criteria and were further analysed. Sixty-five patients had a TTS ≤ 8 weeks, 
and 125 patients had a TTS > 8 weeks. The distribution of the time intervals between 
the completion of nCRT and esophagectomy is presented in Figure 1. The median 
duration of the interval between completion of nCRT and surgery within the patients 
with a TTS ≤ 8 weeks was 50 days and 70 days for patients with a TTS > 8 weeks. The 
groups did not significantly differ in age, sex, clinical T-stadium, tumor location, weight 
loss at diagnosis, and need for enteral tube feeding after nCRT. Patients with a TTS 
> 8 weeks exhibited significantly more co-morbidities and a higher ASA classification 
(Table 1).
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A transthoracic approach was performed in 30.8% of patients with a TTS ≤ 8 weeks and 
in 43.2% of patients with a TTS > 8 weeks (p = 0.096).  A R0 resection was performed 
in 61 patients (93.8%) with a TTS ≤ 8 weeks and in 115 patients (92.0%) with a TTS > 
8 weeks. Operative outcomes, such as duration of surgery, blood loss, and need for 
intra-operative blood transfusion, were comparable between both groups (Table 2). 
The mean duration of surgery did not differ between patients with a TTS ≤ 8 weeks 
and patients with a TTS > 8 weeks. The median hospital stay was similar between both 
groups: 11 (range 7 to 82) days in patients with a TTS ≤ 8 weeks and 12 (range 6 to 89) 
days in patients with TTS > 8 weeks (p = 0.459). Five patients with a TTS ≤ 8 weeks and 
19 patients with a TTS > 8 weeks were readmitted within 30 days after discharge from 
the hospital (p = 0.139). A total of 33 patients were readmitted to the ICU, of which 26 
patients had a TTS > 8 weeks (p = 0.083).
Figure 1. Distribution of the timing (in weeks) of esophagectomy after completion of nCRT. 
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TTS ≤ 8 weeks
N = 65 (%)
TTS > 8 weeks
N = 125 (%)
Overall
N = 190 (%)
p- Value
Sex
  Female
  Male
11 (16.9)
54 (83.1)
10 (8.0)
115 (92.0)
21 (11.1)
169 (88.9) 0.063
Age
  ≤ 65 year
  > 65 year
42 (64.6)
23 (35.4)
66 (52.8)
59 (47.2)
108 (56.8)
82 (43.2) 0.119
Comorbidity
  0
  1
  ≥ 2
24 (36.9)
25 (38.5)
16 (24.6)
26 (20.8)
41 (32.8)
58 (46.4)
50 (26.3)
66 (34.7)
74 (38.9) 0.007
ASA score
  I
  II
  III
18 (28.1)
43 (67.2)
3 (4.7)
18 (14.5)
86 (69.4)
20 (16.1)
36 (19.1)
129 (68.6)
23 (12.2) 0.013
Tumor location
  Mid- thoracic esophagus
  Distal thoracic esophagus
  GE-junction
2 (3.1)
48 (73.8)
15 (23.1)
6 (4.9)
83 (68.0)
33 (27.0)
8 (4.3)
131 (70.1)
48 (25.7) 0.670
cT stage
  cT1
  cT2
  cT3
1 (2.0)
2 (4.0)
47 (94.0)
0 (0.0)
10 (9.0)
101 (91.0)
1 (0.6)
12 (7.5)
148 (91.9) 0.181
cN stage
  cN0
  cN1
  cN2
  cN3
14 (29.8)
28 (59.6)
5 (10.6)
0 (0.0)
30 (27.0)
53 (47.7)
24 (21.6)
2 (1.8)
44 (27.8)
81 (51.3)
29 (18.4)
2 (1.3) 0.374
Weight loss at diagnosis
  0%
  ≤ 10%
  > 10%
25 (39.7)
25 (39.7)
13 (20.6)
41 (33.6)
61 (50.0)
20 (16.4)
66 (35.7)
86 (46.5)
33 (17.8) 0.407
Enteral tube feeding 
during/after nCRT 11 (17.5) 32 (25.8) 43 (23.0) 0.200
Table 1. Demographic and tumor characteristics depending on the time to surgery after 
completion of nCRT 
Table 2. Surgical data for each group 
TTS ≤ 8 weeks
N = 65 (%)
TTS > 8 weeks
N = 125 (%)
Overall
N = 190 (%)
p-Value
Esophagectomy approach
  Transhiatal approach
  Transthoracic approach
45 (69.2)
20 (30.8)
71 (56.8)
54 (43.2)
116 (61.1)
74 (38.9) 0.096
Level of anastomosis
  Cervical
  Intrathoracic
55 (84.6)
10 (15.4)
85 (68.0)
40 (32.0)
140 (73.7)
50 (26.3) 0.014
Duration of surgery > 4 hours 14 (21.5) 37 (29.6) 51 (26.8) 0.234
Perioperative complications 3 (4.6) 13 (10.4 ) 16 (8.4 ) 0.173
Blood transfusion during surgery 2 (3.1) 8 (6.4) 10 (5.3) 0.499
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The overall complication rate, regardless of the severity of the complication, was 
64.6% in patients with a TTS ≤ 8 weeks and 70.4% of patients with a TTS > 8 weeks 
(p = 0.416). As presented in Table 3, no significant differences were observed in 
postoperative mortality, anastomotic complications, pulmonary complications, and 
major complications (Clavien-Dindo score of 3B or greater)30. Multivariable analysis 
revealed that TTS did not significantly influence the occurrence of postoperative 
complications. Age was the only significant predictor of overall complication rate 
(odds ratio (OR) 1.056, 95% confidence interval (CI) [1.007-1.106], p = 0.023) and, in 
particular, pulmonary complications (age ≤ 65 years vs. age > 65 years: OR 0.462, 95% 
CI [0.240-0.891], p = 0.021). An independent predictor of anastomotic leakage was 
tumor location (mid-thoracic esophageal tumor vs. distal tumor OR 12.871, 95% CI 
[1.402-118.157], p = 0.024). The Clavien-Dindo grade 3B or greater complication rate 
was 16.9% in patients with a TTS ≤ 8 weeks and 29.6% in patients with TTS ≥ 8 weeks 
(p = 0.056) Multivariable analysis revealed that TTS did not influence the occurrence 
of these major complications. Thirty patients required surgery due to complications 
(7 relaparotomies, 11 rethoracoscopies, 4 rethoracotomies, and 8 drainages of the 
cervical wound). Seven patients (10.8%) had a TTS ≤ 8 weeks, and 23 (18.4%) patients 
had a TTS > 8 weeks (p = 0.171). Multivariable analysis revealed that TTS did not 
significantly influence the occurrence of interventions or reoperations. Compared 
with the transthoracic approach, the transhiatal approach was a significant predictor 
of fewer interventions (OR 0.421, 95% CI [0.200-0.890]) and reoperations (OR 0.243, 
95% CI [0.104-0.569]).
 
Fifty patients (26%) exhibited a pCR. The distribution of TTS is presented in Table 
4. Logistic regression analysis showed that TTS did not significantly influence the 
occurrence of pCR. Furthermore, TTS did not significantly influence the magnitude 
of the response to nCRT since a good response (Mandard score of TRG 1, 2, or 3) was 
observed in 55.7% of patients with a TTS ≤ 8 weeks and in 46.3% of patients with a TTS 
> 8 weeks) (OR 1.015, 95% CI [0.999-1.03 1], p = 0.065).
 
The five-year overall survival rate did not significantly differ between the groups TTS ≤ 8 
weeks (42%) and TTS > 8 weeks (37%, p = 0.430) (Figure 2). Multivariate Cox regression 
analysis revealed that TTS did not influence survival (HR 0.806, 95% CI [0.508-1.254], 
p = 0.339). Locoregional or distant recurrence occurred in 73 patients; 28 patients 
(43.1%) had a TTS ≤ 8 weeks, and 45 patients (36.0%) had a TTS > 8 weeks. TTS did 
not significantly influence recurrence rate (OR 1.345, 95% CI [0.730-2.481]). Median 
disease-free survival did not significantly differ between the two groups with a median 
disease-free survival of 4.24 and 4.81 years, respectively (p = 0.495) (Figure 3).
Table 3. Postoperative course 
Table 4. Pathologic outcome
* anastomotic complications are either anastomotic leakage or conduit necrosis. 
TTS ≤ 8 weeks
N = 65 (%)
TTS > 8 weeks
N = 125 (%)
Overall
N = 190 (%)
p-Value
Complications 42 (64.6) 88 (70.4) 130 (68.4) 0.416
Anastomotic complications * 13 (20.0) 37 (29.6) 50 (26.3) 0.154
Clavien –Dindo score
  < 3B
  ≥ 3B
56 (86.2)
9 (13.8)
95 (76.0)
30 (24.0)
151 (79.5)
39 (20.5) 0.100
Pulmonary adverse events
ARDS
Pneumonia
Empyema thoracis
24 (36.9)
3 (4.6)
16 (24.6)
3 (4.6)
61 (48.8)
6 (4.8)
42 (33.6)
12 (9.6)
85 (44.7)
9 (4.7)
58 (30.5)
15 (7.9)
0.118
1.000
0.202
0.227
Interventions 
Endoscopic
Radiologic
Reoperation 
11 (16.9)
2 (3.1)
3 (4.6)
8 (12.3)
37 (29.6)
16 (12.8)
4 (3.2)
26 (20.8)
48 (25.3)
18 (9.5)
7 (3.7)
34 (17.9)
0.056
0.030
0.692
0.147
Re-admission ≤ 30 days 5 (7.7) 19 (15.2) 24 (12.6) 0.139
Postoperative mortality 3 (4.8) 6 (4.8) 9 (4.8) 1.000
TTS ≤ 8 weeks
N = 65 (%)
TTS > 8 weeks
N = 125 (%)
Overall
N = 190 (%)
p-Value
Resection radicality
  R0
  R1
61 (93.8)
4 (6.2)
115 (92.0)
10 (8.0)
176 (92.6)
14 (7.4) 0.775
ypT-stadium
  ypT 0
  ypT 1
  ypT 2
  ypT 3
  ypT 4
19 (29.2)
9 (13.8)
15 (23.1)
21 (32.3)
1 (1.5)
28 (22.4)
29 (23.2)
23 (18.4)
45 (36.0)
0 (0)
47 (24.7)
38 (20.0)
38 (20.0)
66 (34.7)
1 (0.5) 0.250
ypN stadium
  ypN 0
  ypN 1
  ypN 2
  ypN3
42 (64.6)
18 (27.7)
5 (7.7)
0 (0)
74 (59.2)
29 (23.3)
16 (12.8)
6 (4.8)
116 (61.1)
47 (24.7)
21 (11.1)
6 (3.2) 0.215
Pathologic complete response
  pCR
  Non-pCR
19 (31.1)
42 (68.9)
31 (25.6)
90 (74.4)
50 (27.5)
132 (72.5) 0.430
Mandard score
  TRG 1&2 
  TRG 3,4&5
34 (55.7)
27 (44.3)
50 (46.3)
58 (53.7)
84 ( 49.7)
85 (50.3) 0.265
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Figure 2. Overall survival
Figure 3. Disease-free survival
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Discussion
In this study, we analysed the influence of delaying surgery beyond 8 weeks after 
completion of nCRT on postoperative morbidity, pathologic response, and overall 
survival in patients diagnosed with cT1-3, N0-3, M0 ADC of the esophagus. Because 
ADC is one of the major afflictions in the Western world and given the reduced 
response rate of ADC to nCRT compared with SCC, we excluded SCC patients and 
exclusively focused on ADC patients. Overall, our findings suggested that delaying 
surgery did not significantly influence these factors in ADC patients.
A recently published randomised controlled trial31 comparing neoadjuvant 
chemotherapy followed by surgery with nCRT followed by surgery revealed that 
patients treated with chemoradiotherapy suffered significantly from more severe 
complications. Consistent with this finding, we observed that postoperative morbidity 
in our study was relatively high. Although we observed a trend towards more 
postoperative events in patients with an extended time interval beyond 8 weeks, 
postoperative morbidity was not significantly influenced by an increased TTS. This 
trend may be confounded by a selection bias because patients with a longer waiting 
period exhibited significantly more comorbidities. Additionally, the study included 
more ASA III patients and thus reflects the influence of different patient populations. 
This indicates that we favoured a longer interval based on the patient’s condition 
after completion of the neoadjuvant therapy. However, in our multivariable analysis, 
comorbidities and ASA III were not significant factors. Shapiro and colleagues25 made 
a similar observation wherein an increase in TTS was associated with a longer hospital 
stay and increased postoperative complications. They also concluded from their 
analysis that the Charlson comorbidity index, the Karnofsky performance status at 
the end of nCRT, and weight loss were potential delay-related confounders.  
Our findings regarding postoperative complications are consistent with previous 
studies of SCC patients17;18;23-26. However, a study conducted by Wang et al.27, in which 
a large population of patients diagnosed with SCC was studied, demonstrated that 
delaying surgery after nCRT was associated with positive surgical margins and surgical 
mortality. This observation may be explained by findings from this current study, 
namely advanced pathological stages were more frequently observed in patients with 
a time to surgery over 60 days. Delaying surgery after nCRT should not be compared 
with salvage esophagectomy after definitive CRT (dCRT). A systematic review32 
revealed that postoperative mortality and morbidity are both significantly increased 
in patients who were treated with dCRT followed by salvage esophagectomy, rather 
than nCRT followed by a planned esophagectomy. Possible explanations for these 
differences are the patient’s condition (dCRT is often chosen due to the patient’s poor 
performance status) and the higher dose of radiotherapy, which can induce more 
fibrosis16 and lead to higher postoperative morbidity.
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A pCR was observed in 26.3% of the patients. This finding was consistent with pCR 
rates for ADC, as described in previous studies33. Surprisingly, a non-significant 
decrease in pCR rate was observed when the TTS increased. Although not significant, 
this study also revealed more patients with a good response (TRG 1-3) in patients 
with TTS ≤ 8 weeks. We hypothesize that the clinical condition of patients with a 
poor response may be worse, which is a valid reason to postpone surgery beyond 8 
weeks. However, this needs to be further studied. Data on the influence of delaying 
TTS on pathologic response rate are conflicting. Some studies revealed no influence 
on pathologic response17;18;23;26, whereas others indicated that delaying surgery after 
nCRT significantly increased the probability of pCR. An increased interval between 
nCRT and surgery revealed a significantly increased pCR rate in a study conducted 
by Shaikh and colleagues24. However, this study was performed on a relatively small 
sample size (n = 88), which led to smaller groups for each timeframe.  Patients in the 
study performed by Shapiro and colleagues25 were treated according to the CROSS 
protocol3, which was also used for most patients in our study. Despite using the same 
neoadjuvant treatment regimen, their study showed that increasing TTS significantly 
increased the occurrence of pCR. However, in contrast to our study, only a minority of 
the patients in their study had a TTS beyond 8 weeks, both ADC (77%) and SCC (23%) 
were included, and tumor histology was not included in their multivariable analysis.
The five-year survival rate in our study was similar for both groups, which is consistent 
with previous studies demonstrating that delaying surgery beyond the currently 
accepted timeframe does not have a negative influence on overall survival17;18;26. 
Ruol et al.23 demonstrated that overall survival increased when TTS was prolonged 
from 6 weeks to the maximal 13 weeks in a subgroup of patients who underwent R0 
resection. This finding may be because only patients with SCC were included in the 
study.  In our study, in which a radical resection was achieved in greater than 90% 
of the cases, we could not confirm that increasing the interval between nCRT and 
surgery affected the overall survival. Overall survival, however, is not equivalent to 
the quality of life (QoL). Although studies demonstrated that nCRT has a temporary 
negative effect on QoL, one study revealed that QoL was not impaired by nCRT34. 
Given that our patients were not subjected to health-related QoL questionnaires, we 
were not informed on the course of the QoL in our study. 
This study has some limitations that should be taken into consideration. Although 
all data obtained from this study were collected prospectively and the survival data 
were updated in a timely manner, it is still a retrospective cohort study and was 
not randomised. The arbitrary period of 8 weeks was used as a cut-off point based 
on previous retrospective studies addressing the same issue15;18. A different cut-
off point may change the outcomes. Another limitation could be the selection bias 
given that surgery was delayed because of the patient’s condition in the majority 
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of cases, demonstrating that decisions were made based on the clinical condition 
and not on randomised clinical trial regulations. Although the results were adjusted 
in the multivariable analysis for comorbidities and ASA classification, the lack of 
randomisation could still influence our results. Furthermore, we were not informed 
on the histological response when a patient with an extended interval was treated 
earlier given that histopathological verification only occurred at the time of surgery. 
There are many reasons for delaying surgery after nCRT such as logistical and patient 
related factors like poor physical status, malnutrition or medical conditions like the 
complications and toxicity of nCRT. Since this study suggest that delaying surgery has 
no significant effect on postoperative outcome, for some patients delaying surgery 
after nCRT seems a safe option to improve patients general status or for logistic 
reasons.  
To draw firmer conclusions, prospective randomised trials are necessary. Recently, 
a prospective single arm feasibility trial named PreSANO35 was initiated. This study 
addressed the issue of TTS after nCRT and its effect on clinical and pathologic 
response. This study could form the basis for a randomised trial to compare planned 
surgery after nCRT and with surgery as needed, which postpones surgery in patients 
with a reliable pCR.
In conclusion, our findings suggest that delaying surgery beyond 8 weeks does 
not affect pathologic response nor does it have a significantly negative impact on 
postoperative morbidity or overall survival. Our results suggest that it is safe to 
postpone surgery beyond 8 weeks for patients experiencing serious toxicity following 
nCRT. On the other hand, it appeared that if the patient is fit for surgery, postponing 
surgery does not have any additional advantages. Definitive conclusions from a 
randomised trial are needed to define the optimal TTS and to determine whether a 
longer TTS is beneficial for patients. 
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8Abstract
Background: Neoadjuvant chemoradiation might increase anastomotic leakage and 
stenosis in patients with esophageal cancer treated with neoadjuvant chemoradiation 
and esophagectomy. The aim of this study was to determine the influence of radiation 
dose on the incidence of leakage and stenosis. 
Methods: Fifty-three patients with esophageal cancer received neoadjuvant 
chemoradiation (23 x 1.8 Gy) (combined with Paclitaxel and Carboplatin) followed by 
a transhiatal esophagectomy between 2009 and 2011. On planning CT, the future 
anastomotic region was determined and the mean radiation dose, V20, V25, V30, 
V35 and V40 were calculated. Logistic regression analysis was conducted to examine 
determinants of anastomotic leakage and stenosis.  
Results: Anastomotic leaks occurred in 13 of 53 patients (25.5%) and anastomotic 
stenosis occurred in 24 of 53 patients (45.3%). Median follow-up was 20 months. 
Logistic regression analysis showed that mean dose, V20-V40, age, co-morbidity, 
method of anastomosis, operating time and interval between last radiotherapy 
treatment and surgery were not predictors of anastomotic leakage and stenosis. 
Conclusions: A radiation dose of 23 x 1.8 Gy on the future anastomotic region has 
no influence on the occurrence of anastomotic leakage and stenosis in patients with 
esophageal cancer treated with neoadjuvant chemoradiation followed by transhiatal 
esophagectomy.
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Introduction
Esophageal cancer is the eighth most commonly diagnosed type of cancer worldwide 
and it is the sixth leading cause of cancer deaths1. The incidence of esophageal 
carcinoma in the Netherlands, especially adenocarcinoma, has rapidly risen from 
1731 new cases in 2000 to 2499 in 20102. According to the current Dutch guidelines, 
the preferred curative treatment for non-metastatic disease is neoadjuvant 
chemoradiation followed by transhiatal or transthoracic esophagectomy3. Patients 
with an irresectable tumor, or patients who are too vulnerable for surgery are often 
proposed for definitive chemoradiation which show encouraging results4;5 
Surgical treatment has an acceptable mortality in high volume centres, but high 
rates of post-operative morbidity have still been described6-9. However, pulmonary 
complications and anastomotic complications like leakage and stenosis are still 
common7-9. The incidence of anastomotic leakage reported in the literature ranges 
from 5.7% to 41%6-16. Incidence rates of anastomotic stenosis are even higher ranging 
from 21.8% to 44%6;10-12. 
Factors like co-morbidity, nutrition status, anastomotic location, anastomotic 
technique and blood loss during surgery are hypothesised to be related to the 
development of anastomotic leakage and stenosis10;17. 
Neoadjuvant chemoradiation might also play a role in developing anastomotic 
complications. Studies comparing neoadjuvant chemoradiation followed by surgery 
with surgery alone showed conflicting results with respect to the risk of anastomotic 
leakage and stenosis due to the neoadjuvant treatment8;11;15;16;18. However, these 
studies incorporated heterogeneous patient groups, radiation fields and anastomotic 
locations. A recent study showed that in patients receiving neoadjuvant chemoradiation 
median radiation dose to the gastric fundus was an independent predictor for early 
anastomotic complications in patients with an Ivor-Lewis esophagectomy19. However 
in an intrathoracic anastomosis the region below the gastric fundus rather than the 
gastric fundus itself is used for the anastomosis because a shorter gastric conduit is 
needed when compared with a cervical anastomosis, raising the question of whether 
or not other factors are responsible for the observed difference. When compared 
with an Ivor-Lewis esophagectomy, in patients receiving a transhiatal resection 
and a cervical anastomosis, a larger part of the irradiated gastric fundus is used for 
the anastomosis. Hence, the aim of our study was to determine the influence of 
radiation dose on the incidence of anastomotic complications (leakage and stenosis) 
in a more homogeneous patient group with distal esophageal or gastro-esophageal 
junction cancer undergoing neoadjuvant chemoradiation followed by a transhiatal 
esophagectomy and cervical anastomosis. In all of these patients the fundus of the 
stomach was irradiated to a varying degree.
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Methods
Study population
Between 2009 and 2011 we included 53 consecutive patients with distal esophageal 
cancer (C15.5) or gastro-esophageal junction cancer (C16.0), who received neoadjuvant 
chemoradiation followed by an open or laparoscopic transhiatal esophagectomy with 
a left cervical anastomosis. Median follow-up duration was 20 months (range 0.2-25). 
All patients had histologically proven adenocarcinoma or squamous cell carcinoma 
with no evidence of distant metastases (cT1-3, N0-3, M0; TNM 7)20. Cancer staging 
included clinical examination, esophago-gastroscopy with biopsies, endoscopic 
ultrasonography (EUS), external ultrasonography of the cervical region, computed 
tomography (CT) of the chest and abdomen and a positron emission tomography 
fused with CT (PET- CT). This research is reviewed by the local medical ethics committee 
but the Dutch Medical Research (Human Subjects) Act is not applicable to this study.
Surgery
Surgical treatment consisted of a laparoscopic or open transhiatal esophagectomy 
with gastric tube interponate18. A left cervical anastomosis was performed (at 
surgeon’s preference) end-to-end with hand-sewn continuous or interrupted sutures 
or side-to-side with a stapling device (Collard anastomosis21).  
Neoadjuvant chemoradiation regimen
The neoadjuvant regimen consisted of Three-Dimensional Conformal Radiotherapy 
(3D-CRT) to a total dose of 41.4 Gy (23 fractions of 1.8Gy, 5 fractions a week) combined 
with Paclitaxel (50mg/m2) and Carboplatin (AUC=2) administered by intravenous 
infusion on days 1, 8, 15, 22 and 29. The Gross Tumor Volume (GTV) included all visible 
tumor and pathologically enlarged lymph nodes (determined by CT, PET-CT or EUS). 
The Clinical Target Volume (CTV) was defined by the GTV (node and tumor) plus the 
area of regional lymph nodes up to at least 3 cm in cranial and caudal extension 
of the esophagus from the tumor GTV. To ensure adequate margins around the 
macroscopic tumor, a minimum CTV-GTV margin of 0.5 cm was required. For distal 
tumors, the caudal margin should follow the wall of esophagus and cardia. The 
margin in the direction of the wall of the cardia was limited to 2 cm. The Planning 
Target Volume (PTV) consisted of the CTV plus a margin of 1 cm in all directions (Figure 
1). These margins were chosen as these are the margins we use in clinical practice. We 
realise that these margins should preferably be patient specific and dependent on, 
for example, the individual tumor motion. Because of these margins, the fundus in all 
patients with distal or junction tumors was irradiated to a varying degree. 
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Figure 1. Example pictures of dose distribution.
Blue: GTV, Green: CTV, Red: PTV
Calculation of RT dose to the anastomotic region of interest
The future anastomotic region was retrospectively determined on the preoperative 
planning CT using the Philips Pinnacle treatment planning system version 9.0. CT slice 
thickness and separation were 3 mm. The most proximal part of the stomach was 
determined. From that point, a 5 cm distal (coronal plane) vertical line was drawn. On 
the transversal plane the distal margin at 7 cm was drawn. We used a 2 cm margin 
from the lesser curvature and a 2 cm margin from the most proximal part of the 
stomach (Figure 2). These margins are determined after consultation of the operating 
surgeon. The future anastomotic region in all patients was determined by the first 
author.
From this future anastomotic region we calculated the following parameters: volume, 
mean dose, V20, V25, V30, V35 and V40 (percentage irradiated volume receiving more 
than respectively 20, 25, 30, 35 and 40 Gy). In order to quantify the effect of a larger 
CTV-PTV margin on the parameters we repeated the analysis with an expansion of 
0.5cm in all directions (anastomotic region volume + 0.5cm)
Classification of leakage and stenosis
Anastomotic leakage was defined as any clinical evidence of leakage of salivary fluid in 
the cervical region, gastric conduit necrosis or evidence of anastomotic leakage on CT 
or with esophago-gastroscopy (CTCAE grade 1-5)22. Anastomotic stenosis was defined 
as dysphagia for which one or more endoscopic dilatation(s) of the anastomosis was 
needed. 
Statistical analysis
Differences in patient, tumor and dose characteristics between patients with 
or without anastomotic leakage or anastomotic stenosis were compared using 
the Mann-Whitney U test and the chi-square test. Univariable and multivariable 
logistic regression analyses were conducted to evaluate the potential risk factors 
for developing anastomotic leakage or stenosis. All analyses were performed using 
Statistical Package for Social Sciences version 19.0 (SPSS Inc., Chicago, IL, USA). All 
reported p-values below 0.05 were considered statistically significant.
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Figure 2. Example of a planning CT in which the future anastomotic region is drawn
Results
All 53 patients completed the neoadjuvant chemoradiation regimen followed by 
transhiatal esophagectomy after a therapy free interval of 4-18 weeks, with a median 
of 9 weeks. The mean irradiation dose to the anastomotic region was 30.3Gy [range 
6-42], with a mean volume of 48.2 cm3 [range 21-92]. Postoperatively, 13 of 53 patients 
(25.5%) developed an anastomotic leak and six patients (11.3%) needed a surgical re-
intervention; of these, 4 patients (7.5%) required re-intervention because of severe 
anastomotic problems. Two patients needed thoracic drainage for thoracic empyema. 
In three patients, drainage of a cervical abscess was performed. One patient needed 
re-intervention for an abdominal dehiscence. Two patients (3.8%) died in hospital: 
one patient died because of Acute Respiratory Distress Syndrome and another of 
myocardial infarction. To date, 15 patients (28.3%) have died during follow-up, with 
median follow-up duration of 20 months. Of these patients, 10 died because of cancer 
recurrence, 3 patients died from a non-disease-related cause and 2 patients had an 
unknown cause of dead. 
Patients with an anastomotic leakage were hospitalised significantly longer than 
patients without anastomotic leakage (22 vs. 13 days, p=0.001). Between the groups 
with or without anastomotic leakage no significant differences in age, gender, 
BMI, co-morbidity, ASA classification, histology, type of operation, duration of the 
procedure, method of anastomosis, anastomotic region volume, mean dose and time 
between the end of the neoadjuvant treatment and surgery were observed (table 
1). Comparable results on leakage rate were observed using the anastomotic region 
volume + 0.5 cm.  In Figure 3 we depicted the percentage of patients with and without 
leakage as a function of DVH parameters. 
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Table 1. Characteristics of patients with or without anastomotic leakage, treated with neo-
adjuvant chemoradiation followed by transhiatal esophagectomy. 
Anastomotic leakage
Yes (n=13) No (n=40) p-value
Mean age 62.4 [41-77] 63.8 [41-82] 0.83
Gender:
   Male (n=49)
   Female (n=4)
13 (27%)
0 (0%)
36 (73%)
4 (100%) 0.56
BMI 27.5 [21-41] 26.4 [19-35] 0.65
Co-morbidity:
   0 (n=13)
   1 (n=18)
   2 or more (n=22)
3 (23%) 
4 (22%)
6 (27%)
10 (77%)
14 (78%)
16 (73%) 0.93
ASA classification:
   I (n=8)
   II (n=41)
   III (n=4)
3 (38%)
9 (22%)
1 (25%)
5 (63%)
32 (78%)
3 (75%) 0.65
Histologic type:
   Adenocarcinoma (n=49)
   Squamous cell carcinoma (n=4)
12 (24%)
1 (25%)
37 (76%)
3 (75%) 0.98
Mean volume (cm3) 53.1 [33-71] 46.6 [21-92] 0.10
Mean dose (Gy) 26.4 [6-41] 31.6 [15-42] 0.16
V20 71.2% 88.3% 0.54
V25 53.8% 66.2% 0.27
V30 45.4% 57.3% 0.24
V35 39.1% 50.3% 0.24
V40 26.2% 36.5% 0.32
OR time (min) 172 [118-329] 187 [134-292] 0.09
Resection type: 
   Open (n=21)
   Laparoscopic (n=32)
7 (33%)
6 (19%)
14 (67%)
26 (81%) 0.23
Method of anastomosis:
   End-to-end continuous (n=33)
   End-to-end interrupted (n=11)
   Side-to -side stapler (n=9)
6 (18%)
4 (36%) 
3 (33%) 
27 (82%) 
7 (64%) 
6 (67%) 0.38
Interval last RT– surgery (days) 70 [40-127] 69 [31-121] 0.87
Hospital stay (days) 22 [13-71] 13 [6-35] 0.001
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Clinically, anastomotic stenosis occurred in 24 of 53 patients (45.3%). Between 
the groups with or without anastomotic stenosis, no significant differences in age, 
gender, BMI, co-morbidity, ASA classification, histology, type of operation, operating 
time, method of anastomosis, anastomotic region volume, mean dose and time 
between the end of the neoadjuvant treatment and surgery were observed (table 
2). Comparable results on stenosis rate were observed using the anastomotic region 
volume +0.5 cm. In Figure 4 we depicted the percentage of patients with and without 
stenosis as a function of DVH parameters.
Figure 3. Percentage of patients with and without leakage as a function of DVH 
parameters. Error bars represent 1 SD.
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Table 2. Characteristics of patients with or without anastomotic stenosis, treated 
with neo-adjuvant chemoradiation followed by transhiatal esophagectomy.
Anastomotic stenosis
Yes (n=24) No (n=29) p-value
Mean age 61.3 [41-78] 65.4 [48-82] 0.30
Gender:
   Male (n=49)
   Female (n=4) 
21 (43%)
3 (75%)
28 (57%)
1 (25%) 0.32
BMI 26.6 [19-41] 26.7 [21-35] 0.68
Co-morbidity:
   0 (n=13)
   1 (n=18) 
   2 or more (n=22)
9 (69%)
8 (44%)
7 (32%)
4 (31%)
10 (56%)
15 (68%) 0.10
ASA classification:
   I (n=8)
   II (n=41)
   III (n=4)
4 (50%)
19 (46%)
1 (25%)
4 (50%)
22 (54%)
3 (75%) 0.69
Histologic type:
   Adenocarcinoma (n=49)
   Squamous cell carcinoma (n=4)
22 (45%)
2 (50%)
27 (55%)
2 (50%) 0.84
Volume (cm3) 48.3 [29-81] 48.1 [21-92] 0.92
Mean dose (Gy) 31.2 [6-42] 29.6 [8-42] 0.38
V20 84.9% 83.4% 0.27
V25 68.8% 58.5% 0.24
V30 59.5% 50.1% 0.30
V35 52.9% 43.1% 0.28
V40 40.1% 28.8% 0.14
OR time (min) 184 [118-329] 182 [138-292] 0.75
Resection type: 
   Open (n=21)
   Laparoscopic (n=32)
11 (52%)
13 (41%)
10 (48%)
19 (59%) 0.40
Method of anastomosis:
   End-to-end continuous (n=33)
   End-to-end interrupted (n=11)
   Side-to -side stapler (n=9)
15 (45%)
7 (64%)
2 (22%)
18 (55%)
4 (36%)
7 (78%) 0.18
Interval last RT– surgery (days) 65 [37-118] 73 [31-127] 0.31
Hospital stay (days) 14 [6-35] 16 [6-71] 0.63
Anastomotic leakage (n=13) 7 (54%) 6 (46%) 0.48
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Figure 4. Percentage of patients with and without stenosis as a function of DVH 
parameters. Error bars represent 1 SD.
Univariable logistic regression analysis showed that mean radiation dose was a 
borderline significant predictor for anastomotic leakage. In addition univariable 
analysis also showed that patients with a high V20 percentage were less likely to 
develop anastomotic leakage. However, multivariable analysis showed that V20 
percentage and mean dose to the proposed area of the anastomosis were not 
significant predictors for anastomotic leakage anymore. Again, all other factors 
like age, BMI, co-morbidity (including cardiovascular and pulmonary co-morbidity 
separately), histology, ASA classification, type of resection, operating time, method of 
anastomosis, mean dose, V25-V40 and interval between the end of the neoadjuvant 
treatment and surgery were not significant predictors for anastomotic leakage in our 
univariable analysis and were therefore not analysed in the multivariable analysis 
(table 3). Furthermore, the same analyses for the anastomotic region volume + 0.5 cm 
had no influence on the results.  
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Table 3. Predictors of anastomotic leakage in patients with distal esophageal or esophago-
gastric junction cancer treated with neoadjuvant chemoradiation followed by transhiatal 
esophagectomy.
Univariable analysis Multivariable analysis
OR 95% CI p-value OR 95% CI p-value
Age 0.99 0.93-1.05 0.63
BMI 1.07 0.91-1.24 0.42
Co-morbidity:
   0
   1
   2 or more
0.80
0.76
ref
0.16-3.94
0.18-3.26
0.78
0.71
Cardiovascular co-morbidity:
   No
   Yes
1.29
ref
0.37-4.53 0.69
Pulmonary co-morbidity:
   No
   Yes
ref
1.7 0.36-8.04 0.50
ASA classification:
   I
   II
   III
2.13
ref
1.19
0.43-10.68
0.11-12.82
0.36
0.89
Histology:
   Adenocarcinoma 
   Squamous cell carcinoma
ref 
0.98 0.10-10.83 0.98
Mean Dose 1.00 1.00-1.00 0.07 1.00 1.00-1.00 0.67
V20 0.97 0.96-1.00 0.03 0.96 0.90-1.02 0.21
V25 0.99 0.97-1.01 0.23
V30 0.99 0.98-1.01 0.25
V35 0.99 0.97-1.01 0.28
V40 0.99 0.97-1.01 0.32
OR time 0.99 0.97-1.01 0.25
Resection type:
   Open
   Laparoscopic 
2.17
ref
0.61-7.71 0.23
Method of anastomosis:
   EE continuous
   EE interrupted
   Side-to -side stapler
ref 
2.57
2.25
0.57-11.69
0.44-11.65
0.22
0.33
Interval last RT- surgery 1.00 0.83-1.20 0.99
Univariable analysis showed that age and interval between the end of the 
neoadjuvant treatment and surgery were borderline significant. Anastomotic stenosis 
developed significantly more often in patients without comorbidity compared with 
patients with >=1 comorbidity. However, multivariable analysis showed that factors 
such as age, co-morbidity and interval between radiotherapy dose and surgery 
were not significant predictors for anastomotic stenosis. All other factors like BMI, 
cardiovascular and pulmonary co-morbidity, histology, ASA classification, type 
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of operation, operating time, method of anastomosis, mean dose, and V20-V40 
were not significant predictors for anastomotic stenosis in our univariable analysis 
and were therefore not analysed in the multivariable analysis (table 4). Again, the 
same analyses for the ROI + 0.5 cm had no influence on the results observed in our 
analysis.                                                                                                                                                                                                                             
Univariable analysis Multivariable analysis
OR 95% CI p-value OR 95% CI p-value
Age 0.96 0.90-1.01 0.14 0.99 0.92-1.06 0.66
BMI 0.99 0.87-1.14 0.92
Co-morbidity:
   0
   1
   2 or more
4.82
1.71
ref
1.10-21.19
0.77-6.24
0.04
0.41
3.17
1.39
0.54-18.82
0.34-5.67
0.20
0.64
Cardiovascular co-morbidity:
   No
   Yes
2.73
ref
0.89-8.33 0.78
Pulmonary co-morbidity:
   No
   Yes
ref
0.96 0.23-4.06 0.96
ASA classification:
   I
   II
   III
1.16
ref
0.39
0.25-5.72
0.04-4.03
0.85
0.43
Histology:
   Adenocarcinoma 
   Squamous cell carcinoma
ref 
1.23 0.16-9.43 0.84
Mean dose 1.00 1.00-1.00 0.50
V20 1.00 0.98-1.03 0.81
V25 1.01 0.99-1.03 0.24
V30 1.01 0.99-1.03 0.28
V35 1.01 0.99-1.03 0.27
V40 1.01 0.99-1.03 0.21
OR time 1.00 0.99-1.01 0.87
Resection type:
   Open
   Laparoscopic 
1.61
ref
0.53-4.88 0.40
Method of anastomosis:
   EE continuous
   EE interrupted
   Side-to -side stapler
ref
2.10
0.34
0.51-8.57
0.06-1.90
0.30
0.22
Interval last RT- surgery 0.88 0.74-1.04 0.14 0.92 0.77-1.11 0.39
Anastomotic leakage 1.58 0.45-5.55 0.48
Table 4. Predictors of anastomotic stenosis in patients with distal esophageal or esophago-
gastric junction cancer treated with neoadjuvant chemoradiation followed by transhiatal 
esophagectomy. 
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Discussion 
In this study we determined the influence of radiation dose in the future anastomotic 
region on developing anastomotic leakage and stenosis in patients with distal 
esophageal or esophago-gastric junction cancer (cT1-3, N0-3, M0) treated with 
neoadjuvant chemoradiation followed by transhiatal esophagectomy with gastric tube 
reconstruction and a left cervical anastomosis. Overall, 25.5% of patients developed 
anastomotic leakage and 45.3% developed anastomotic stenosis. Our study identified 
no significant predictors of anastomotic leakage and stenosis. In contrast with a recent 
study19, radiation dose did not have a significant influence on developing anastomotic 
leakage and stenosis. 
This study shows that variations in mean dose and V20 until V40 had no significant 
influence on developing anastomotic leakage. However, a recent study demonstrated 
that the mean radiation dose on the gastric fundus dose was an independent 
predictor for early anastomotic complications like leakage19. The recent study had 
a different neoadjuvant treatment regime (36 Gy in 20 fractions combined with 
5-FU and cisplatin) and a different surgical procedure (Ivor-Lewis) compared with 
the current study. Although the authors did not describe their surgical procedure 
in detail, the region below the gastric fundus at the level of the watershed of the 
gastroepiploic vessels is most commonly used for the intra-thoracic anastomosis in 
the Ivor-Lewis procedure. In a cervical anastomosis, the gastric tube should be longer 
and the anastomosis reconstructed from the fundus region of the stomach. Hence, 
the radiation dose on the future anastomotic region could even be less than the dose 
suggested by the authors and other factors could potentially be more responsible for 
the observed effects than the irradiation on the gastric fundus itself.  Therefore, it is 
even more remarkable that we did not observe a negative effect of irradiation to the 
fundus on anastomotic complications in our series. Furthermore, the authors did not 
have a clear definition of anastomotic leakage; in addition, their description of the 
determined anastomotic region was not clear and not reproducible.  
In our study, variations in mean dose and V20-V40 showed no significant influence on 
developing anastomotic stenosis. This is in concordance with a study in which it was 
demonstrated that neoadjuvant chemoradiation was not a predictor for the incidence 
of benign anastomotic strictures. However, this study did show that neoadjuvant 
chemoradiation was an independent predictor for patients with refractory strictures 
(requiring >10 dilatations)18. Furthermore, a recent study showed a higher mean 
radiation dose in patients with anastomotic stenosis19. 
Comorbidity in our study did not have an influence on the development of anastomotic 
leakage or stenosis. This is in concordance with another study showing that major 
co-morbidity is not an independent predictor for early anastomotic complications like 
leakage19. Another study confirmed these results and showed that diabetes, chronic 
obstructive pulmonary disease and coronary artery disease had no influence on 
developing anastomotic leakage8. 
Anastomotic leakage rates vary between studies, with leakage rates between 5.7 and 
41%6-16. This might be the result of the various definitions of anastomotic leakage. 
Some studies define leakage as clinical or radiological evidence of leakage. However, 
other definitions include only clinical leakage or anastomotic leakage requiring re-
intervention. In this study, anastomotic leakage was defined as every evidence 
of leakage (including all clinical and radiologic evidence of leakage), explaining the 
relatively high rate of anastomotic leakage (25.5%) in our study compared with 
others6-15. As summarised in table 5, randomized controlled trials that have compared 
neo-adjuvant chemoradiation with subsequent surgery versus surgery alone show 
different results with regard to the incidence of anastomotic leakage and the influence 
of chemoradiation on leakage rate. The incidence of leakage rates in those RCTs ranged 
from 3% to 30%. The influence of neo-adjuvant chemoradiation on leakage rate is 
often not statistically tested. Furthermore, the differences in leakage rate between 
patients receiving neo-adjuvant chemoradiation with surgery vs. surgery alone are 
small. When comparing our leakage rate  with the rate reported in a recent Dutch 
multicentre randomized trial studying the role of  neo-adjuvant chemoradiation with 
the same regime as our study,  our leakage rate appears to be comparable16. 
The influence of (chemo)radiation on anastomotic leakage has also been studied in 
other solid tumors like rectal cancer.  A large randomized and a large retrospective 
study showed that neo-adjuvant chemoradiation did not influence anastomotic 
leakage rates following Total Mesorectal Excision in patients with rectal cancer23;24. 
Another large Dutch Multicentre RCT showed no difference in anastomotic leakage 
rates between patients who received short course neoadjuvant radiotherapy followed 
by surgery compared to surgery alone. However, they did observe significantly more 
post-operative wound complications in the radiotherapy group25. 
Anastomotic stenosis occurred in 45.3% of the patients; however, other studies have 
shown a lower incidence (21.8-41.7%)6;11;12;18. As shown in table 5, anastomotic stenosis 
is often not registered in randomized controlled trials. Only two studies mention 
anastomotic stenosis, and show no significant differences between chemoradiation 
with subsequent surgery vs. surgery alone. The incidence of anastomotic stenosis 
in this study is relatively high; however, it is in concordance with a study in which 
the incidence of anastomotic stricture was 44% in patients with an end-to-end 
anastomosis10.  
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Anastomotic leakage was not a predictor for anastomotic stenosis in our study. This 
is not supported by other studies in which anastomotic leakage was found to be an 
independent predictor for anastomotic stenosis11;12;18. This difference might be a 
result of the relatively small number of patients and the relatively high anastomotic 
leakage rate identified in the current study. 
Other factors besides chemoradiation that might influence anastomotic problems 
are, according to the literature, type of resection (transthoracic vs. transhiatal) and 
location of anastomosis (thoracic vs. cervical)6;10;17. In the studied RCTs, both types 
of surgery have been often used and anastomotic location was mostly cervical or 
not mentioned at all (Table 5). Based on these heterogeneous RCTs, it is difficult to 
determine factors that influence anastomotic leakage and stenosis. Therefore, we 
investigated a homogenous patient population with the same type of resection and a 
strictly defined cervical anastomotic location.
This study is unique, but also has some limitations. The study population is relatively 
small; however, the group used here is more homogenous than others with respect to 
the uniform treatment and type of anastomosis. Furthermore, the determination of 
the future anastomotic region, despite the consultation with the consulting surgeon, 
may be prone to a certain degree of subjective variability. However, since we have 
uniformly determined the anastomotic region within a pre-defined distance from the 
most proximal part of the stomach, we believe that the comparison between groups 
is accurate enough to draw firm conclusions from the results.
Furthermore, we were not able to compensate breathing-induced organ motion. This 
could have influenced the calculated dose to the region of interest. However because 
the PTV consisted of the CTV plus a margin of 1 cm in all directions we do not think 
this will have a significant influence on our results. As in other studies looking at the 
correlation between radiation induced morbidity and  anastomotic complications, the 
influence of day-to-day treatment variations on the dose to the region could not be 
quantified as we do not have CBCT imaging data of these patients, which is a clear 
limitation. Realising this, it is even more striking that we did not observe a correlation 
between dose and morbidity, as including day-to-day variations will only blur the dose 
distributions we want to correlate with morbidity even more.  In this study we did 
not measure esophagitis grade after chemoradiation. Recent study in lung cancer 
patients showed association between higher V50 and esophagitis26. The number 
of patients with esophagitis in our study will be comparable with recent published 
results from the CROSS II trial with the same chemoradiation regimen. They observed 
that 19% of the patients developed esophagitis16. 
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In conclusion, this study demonstrates that radiation dose on the future anastomotic 
region did not have a significant influence on the occurrence of anastomotic leakage 
and stenosis in patients with esophageal cancer treated with this commonly used 
regimen of neoadjuvant chemoradiation followed by transhiatal esophagectomy and 
left cervical anastomosis. Although with a relative small study population, our study is 
important for clinical practice since it suggests that radiation to the future anastomotic 
region within a regimen of neo-adjuvant chemoradiation with a moderate total dose 
has no apparent negative effect of anastomotic complications.
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9Abstract 
Background: The influence of the extent and dose of radiation on complications 
was investigated in patients with esophageal cancer treated with neoadjuvant 
chemoradiation and subsequent esophagectomy with gastric tube reconstruction 
with a cervical anastomosis.
Methods: Between 2005 and 2012, 364 consecutive patients with esophageal cancer 
treated with neoadjuvant chemoradiation (41.4 Gy combined with chemotherapy) 
followed by esophagectomy were included. The future anastomotic region in the 
fundus was determined and the mean dose, V20-V40, upper planning target volume 
(PTV) border in relation to mediastinal length expressed as the mediastinal ratio were 
calculated. 
Results: Anastomotic leakage (AL) occurred in 22% and anastomotic stenosis (AS) in 
41%. Logistic regression analysis revealed no influence of age, comorbidity, mean 
fundus dose, V20-V40, or the mediastinal ratio on the incidence of AL or AS. In 28% 
of the patients severe complications (Clavien-Dindo score of ≥ IIIB) occurred. The 
presence of multiple co-morbidities (HR 2.4 [CI 1.3-4.5], p=0.006) and a mediastinal 
ratio of  0.5-1.0 (HR 1.9 [CI 1.0-3.5], p=0.036) were both independent predictors of 
severe complications. 
Conclusions: With a mean radiation dose of 24.2 Gy to the future anastomotic region 
of the gastric fundus, the radiation dose was not associated with the incidence of 
anastomotic leakage or anastomotic stenosis. The incidence of severe complications 
was associated with a high superior mediastinal PTV border. 
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Introduction 
The incidence of esophageal cancer in the Netherlands has increased in the past 
two decades, especially that of adenocarcinomas1. The preferred treatment for non-
metastatic esophageal cancer in the Netherlands is neoadjuvant chemoradiation 
followed by transhiatal or transthoracic esophagectomy2. Survival in the Netherlands 
has improved over the past ten years due to multiple factors; however, the introduction 
of neoadjuvant therapy is regarded as one of the most important factors3. 
Esophageal surgery still has high morbidity rates with anastomotic complications, 
such as leakage, stenosis, and pulmonary complications. Several factors, such as co-
morbidity presence, nutritional status, anastomotic location, anastomotic technique, 
and atherosclerotic vascular condition, are hypothesized to influence anastomotic 
leakage and stenosis4-6. Neoadjuvant chemoradiation may also serve as a factor in 
the development and severity of anastomotic complications. A recent study revealed 
that the median radiation dose to the gastric fundus was a predictor of anastomotic 
leakage in patients treated with an Ivor-Lewis esophagectomy and intra-thoracic 
anastomosis7. However, another study showed no influence of radiation dose to 
the future anastomotic region on the occurrence of anastomotic leakage in patients 
treated with transhiatal esophagectomy and cervical anastomosis8. 
Two meta-analyses revealed no difference in mortality and postoperative morbidity 
in patients treated with neoadjuvant chemoradiation and surgery compared with 
surgery alone9;10. However, neoadjuvant chemoradiation may influence postoperative 
pulmonary complications11;12. Recently, it was shown in a small series that neoadjuvant 
chemoradiation did not affect the incidence of postoperative complications, but the 
severity of postoperative complications was significantly affected13.   
Thus, the aim of our study was to determine, in a large series, the influence of the 
extent and dose of radiation to the fundus of the stomach and mediastinum on the 
development and severity of anastomotic complications in patients with esophageal 
cancer treated with neoadjuvant chemoradiation followed by esophagectomy with 
cervical anastomosis. 9
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Methods
Study population 
Between 2005 and 2012, 364 consecutive patients diagnosed in the Catharina 
Hospital Eindhoven (n=113) and the Academic Medical Centre Amsterdam (n=251) 
with esophageal cancer who received neoadjuvant chemoradiation followed by 
an esophagectomy with cervical anastomosis were included. All patients had a 
histologically proven tumor with no evidence of irresectability or distant metastases 
(cT1-4, N0-3, M0; TNM 714). Cancer staging included clinical examination, esophago-
gastroscopy with biopsies, external ultrasonography (or computed tomography (CT)) 
of the cervical region, CT of the chest and abdomen, and endoscopic ultrasound 
when appropriate. Information on medical history and co-morbidity was based on a 
modified list of the Charlson co-morbidity index15. This research was reviewed by the 
local medical ethics committee.
Surgery
Surgical treatment consisted of an open or minimally invasive transhiatal or 
transthoracic esophagectomy with a gastric tube reconstruction and cervical 
anastomosis. Reconstructions with an intrathoracic anastomosis were excluded. The 
type of surgical treatment was chosen at the surgeon’s discretion. 
Neoadjuvant chemoradiation regimen 
The neoadjuvant regimen consisted of three-dimensional conformal radiotherapy 
(3D-CRT) with a total dose of 41.4 Gy (23 fractions of 1.8 Gy, 5 fractions a week) 
combined with chemotherapy. The most commonly used chemotherapy scheme 
was paclitaxel (50 mg/m2) and carboplatin (area under the curve [AUC]=2) 
administered by intravenous infusion on days 1, 8, 15, 22, and 29. A minority 
of the patients received other chemotherapy schemes in ongoing clinical trials. 
The gross tumor volume (GTV) included the primary tumor and pathologically enlarged 
lymph nodes. The clinical target volume (CTV) was defined as the GTV (nodes and 
tumor) plus the area of regional lymph nodes up to at least 3 cm from the GTV in the 
cranial and caudal extension of the esophagus. For distal and gastro-esophageal (GE) 
junction tumors, the lymph node area along the left gastric artery (lesser curvature) 
was always included in the CTV. A minimum GTV-CTV esophageal margin of 0.5 cm 
was prescribed in the transverse direction. For distal tumors, the caudal margin 
followed the wall of the esophagus and cardia. The margin in the direction of the wall 
of the cardia was limited to 2 cm. The planning target volume (PTV) consisted of the 
CTV plus a margin of 1 cm in all directions. The set up accuracy was standard verified 
by Cone beam CT scan imaging on day 1,2 and 3 of radiation treatment and thereafter 
once weekly, with an off-line correction protocol. If set up corrections were necessary, 
this was always followed by 3 days of extra cone beam CT verifications.
9
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Calculation of RT dose to the anastomotic region of interest
The future anastomotic region was retrospectively determined on the preoperative 
planning CT using the Philips Pinnacle treatment planning system version 9.2 or the 
Nucletron Oncentra External Beam planning system version 4.5. The CT slice thickness 
and separation were 3 and 2.5 mm, respectively. The most proximal part of the stomach 
was determined. From that point, a 5-cm distal (coronal plane) vertical line was drawn. 
On the transverse plane, the distal margin at 7 cm was drawn. We used a 2-cm margin 
from the lesser curvature and a 2-cm margin from the most proximal part of the 
stomach (Figure 1). These margins were determined after surgical consultation. The 
future anastomotic region in all patients was determined by the first and second author. 
From this future anastomotic region, we calculated the following parameters: volume, 
mean dose, V20, V25, V30, V35, and V40 (percentage of irradiated volume of the 
fundus receiving equal or more than 20, 25, 30, 35, and 40 Gy, respectively). Since 
a leakage of a cervical anastomosis often has a mediastinal manifestation, radiation 
to the mediastinal field may have an impact on the incidence and severity of the 
sequelae of a cervical leakage. In order to determine the upper PTV border in relation 
to the mediastinal field we introduced the mediastinal ratio as a relative ratio which 
is not dependent on the absolute dimensions of the patient. The mediastinal ratio is 
calculated as the distance between the diaphragm and upper border of the PTV (PTV-
top) divided by the distance between the diaphragm and the manubrium-sternal joint 
(sternal angle) which corresponds with the level of the carina. We divided our patients 
in three groups: a group with a mediastinal ratio of < 0.5 (diafragm to halfway of the 
carina), a group with a mediastinal ratio of 0.5-1.0 (halfway of the carina to the carina) 
and a group with a mediastinal ratio ≥ 1.0 (above the carina).
Classification of complications
Anastomotic leakage was defined as any clinical evidence of leakage of salivary fluid 
in the cervical region, gastric conduit necrosis, or evidence of anastomotic leakage on 
CT or with esophago-gastroscopy (Common Terminology Criteria for Adverse Events 
(CTCAE) grade 1-5)16. Anastomotic stenosis was defined as dysphagia for which one 
or more endoscopic dilatation(s) were needed. Complications were scored using the 
Clavien-Dindo classification. A severe complication was defined as any complication 
with a Clavien-Dindo classification of IIIB or higher at admission17. 
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Figure 1. Schematic representation of the region of interest representing the future 
anastomotic region (A). Example of a planning CT on which the future anastomotic 
region is drawn according to these rules (B).
Figure 1A.
Figure 1B.
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Statistical analysis
Univariate and multivariate logistic regression analysis were performed to determine 
predictors (age, gender, body mass index (BMI), co-morbidity, histology, location, 
mean dose, V20-40, mediastinal ratio, and type of surgery) of developing anastomotic 
leakage or stenosis and a complicated postoperative course with Clavien-Dindo 
IIIB complications or higher. In the multivariate analysis, we included factors with 
a p-value below 0.1 in the univariate analysis. All analyses were performed using 
Statistical Package for Social Sciences version 22.0 (SPSS Inc., Chicago, IL, USA). 
Reported p-values less than 0.05 were considered statistically significant. 
Results
Patient characteristics
The mean age of the study population was 64 years (SD 8.9), and 80% of the individuals 
were male. Most tumors were adenocarcinomas (76%) located distally in the 
esophagus. Transthoracic esophagectomy was performed in 62.1% of the patients, 
and transhiatal esophagectomy was performed in 37.9% of the patients. A minimally 
invasive resection was performed in 51.6% of the cases. The mean radiation dose to 
the anastomotic region was 24.2 Gy (SD 11.8). Mean mediastinal ratio was 0.6 (SD 0.2). 
The postoperative in-hospital mortality rate was 4.7% (Table 1), and the median 
follow-up duration for this study was 23 months (range 1-121).
Anastomotic leakage 
Anastomotic leakage (CTCAE grade 1-5) occurred in 78 (22%) of 351 patients. The 
univariate logistic regression analysis revealed no significant influence of age, gender, 
co-morbidity, BMI, tumor location, or surgery type on postoperative anastomotic 
leakage. Furthermore, the mean dose, V20-V40 and mediastinal ratio revealed no 
significant influence on anastomotic leakage. Univariate analysis revealed that 
squamous cell carcinoma was a significant predictor of anastomotic leakage (hazard 
ratio (HR) 2.3 [confidence interval (CI) 1.3-4.0], p=0.005). Since histology was the only 
significant predictor and no other variables had a p-value below 0.1 a multivariate 
analysis was therefore not performed (Table 2). 
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Age (years) 63.6 (SD 8.9)
Gender
  Male
  Female
290 (79.7%)
74 (20.3%)
cT stage
  T1
  T2
  T3
  T4
  Tx
2 (0.5%)
48 (13.2%)
292 (80.2%)
10 (2.7%)
12 (3.3%)
cN stage
  N0
  N1
  N2
  N3
  Nx
76 (20.9%)
172 (47.3%)
90 (24.7%)
7 (1.9%)
19 (5.2%)
BMI 25.7 (SD 4.2)
Co-morbidity
  0
  1
  2 or more
108 (29.7%)
141 (38.7%)
115 (31.6%)
Tumor location
  Mid
  Distal
  GEJ
46 (12.6%)
238 (65.4%)
80 (22%)
Histology
  Adenocarcinoma
  Squamous cell
  Other/unknown
276 (75.8%)
75 (20.6%)
13 (3.6%)
Type of surgery
  Open transthoracic 
  Open transhiatal 
  Laparoscopic transhiatal
  Hybrid (thoracoscopy/laparotomy) 
  Complete minimally invasive
86 (23.6%)
90 (24.7%)
48 (13.2%)
27 (7.4%)
113 (31.0%)
Mean fundus dose 24.2 Gy (SD 11.8)
Mean mediastinal ratio 0.6 (SD 0.2)
In-hospital mortality 4.7%
Median length of admission (days) 13.0 (SD 19.8)
Table 1. Characteristics of patients diagnosed with esophageal carcinoma and 
treated with neoadjuvant chemoradiation followed by esophagectomy with gastric 
tube reconstruction with a left cervical anastomosis (n=364). 
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Univariate analysis
OR 95% CI p-value
Age
  <70 (n=274)
  ≥70 (n=77)
1.0
0.8 0.4-1.5 0.513
Gender
  Male (n=280)
  Female (n=71)
1.0
1.5 0.8-2.7 0.179
BMI 1.0 0.9-1.1 0.975
Co-morbidity
0 (n=104)
1 (n=135)
2 or more (n=112)
1.0
0.9
1.4
0.5-1.7
0.7-2.6
0.717
0.334
Histology
Adenocarcinoma (n=261)
Squamous cell carcinoma (n=74)
Other (n=13)
1.0
2.3
0.8
1.3-4.0
0.2-3.6
0.005
0.745
Tumor location
  Mid (n=46)
  Distal (n=231)
  GEJ (n=74)
1.8
1.0
0.8
0.9-3.5
0.4-1.5
0.112
0.452
Mean dose 1.0 1.0-1.0 0.133
V20 per 10%* 1.0 0.9-1.0 0.437
V25 per 10%* 1.0 0.9-1.1 0.692
V30 per 10%* 1.0 0.9-1.1 0.501
V35 per 10%* 1.0 0.9-1.1 0.574
V40 per 10%* 1.0 0.9-1.1 0.669
Mediastinal ratio#
  <0.5 (n=107)
  0.5-1.0 (n=213)
  ≥1.0 (n=28)
1.0
1.4
1.9
0.8-2.6
0.7-4.8
0.242
0.207
Type of surgery
  Transthoracic (n=83)
  Transhiatal (n=86)
  Laparoscopic transhiatal (n=48)
  Thoracoscopic/laparotomy (n=27)
  Thoracoscopic/laparoscopic (n=107)
0.8
0.9
1.1
0.9
1.0
0.4-1.7
0.4-1.7
0.5-2.4
0.3-2.6
0.635
0.686
0.825
0.900
Table 2. Univariate logistic regression analysis of anastomotic leakage (n=351). 
*Odds ratios displayed in steps of 10%. 
# Exclusion of 3 missings.
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Anastomotic stenosis
Anastomotic stenosis requiring one or more dilatation(s) was observed in 149 
patients (41%). The univariate logistic regression analysis indicated that age, gender, 
BMI, co-morbidity, histology, tumor location, mean dose, V20-V40, type of surgery, 
and anastomotic leakage were not significantly associated with the development 
of anastomotic stenosis. Multivariate analysis revealed that only patients with a 
mediastinal ratio of 0.5-1.0 were less likely to develop anastomotic stenosis (HR 0.6 
[CI 0.4-1.0], p=0.036) (Table 3).
Clavien-Dindo ≥ IIIB and mortality
A total of 102 patients (28%) had severe complications with a Clavien-Dindo 
classification ≥ IIIB. Univariate analysis revealed that age, gender, BMI, tumor location, 
V20-V40, and resection type had no significant influence on the incidence of a 
complicated course with complications Clavien-Dindo ≥ IIIB. The presence of multiple 
co-morbidities, squamous cell histology, mean dose, and mediastinal ratio 0.5-1.0 or 
≥1.0 had a significant influence on the incidence of complications with Clavien-Dindo ≥ 
IIIB. Multivariate analysis revealed that the presence of multiple co-morbidities (HR 2.4 
[CI 1.3-4.5], p=0.006) and a mediastinal ratio 0.5-1.0 (HR 1.9 [CI 1.0-3.5], p=0.036) were 
independent predictors of complications with Clavien-Dindo ≥ IIIB (Table 4). Similar 
results were obtained when using the median of 0.6 as a cut-off point in the analysis. 
No significant difference were observed on postoperative in-hospital mortality 
between patients with mediastinal ratio < 0.5 vs. mediastinal ratio 0.5-1.0 vs. 
mediastinal ratio ≥ 1.0 (3.5% vs. 5.5% vs. 3.6%, p=0.692).
Table 3. Univariate and multivariate logistic regression analysis of  
anastomotic stenosis (n=361).
Univariate analysis Multivariate analysis
OR 95% CI p-value OR 95% CI p-value
Age
  <70 (n=282)
  ≥70 (n=79)
1.0
1.1 0.7-1.8 0.719
Gender:
   Male (n=289)
   Female (n=72)
1.0
1.1 0.7-1.9 0.646
BMI 1.0 1.0-1.1 0.575
Co-morbidity
   0 (n=107)
   1 (n=139)
   2 or more (n=115)
1.0
0.7
0.7
0.4-1.1
0.4-1.2
0.107
0.251
Histological type
   Adenocarcinoma (n=275)
   Squamous cell carcinoma (n=73)
  Other (n=13)
1.0
1.4
0.7
0.8-2.3
0.2-2.2
0.222
0.509
Tumor location
  Mid (n=44)
  Distal (n=238)
  GEJ (n=79)
1.2
1.0
1.6
0.6-2.4
0.9-2.6
0.537
0.082
1.5
1.0
1.0
0.7-3.1
0.6-1.8
0.260
0.964
Mean dose 1.0 1.0-1.0 0.987
V20 per 10%* 1.0 1.0-1.0 0.701
V25 per 10%* 1.0 1.0-1.1 0.615
V30 per 10%* 1.0 1.0-1.1 0.628
V35 per 10%* 1.0 0.9-1.1 0.775
V40 per 10%* 1.0 0.9-1.1 0.580
Mediastinal ratio#
  <0.5 (n=112)
  0.5-1.0 (n=218)
  ≥1.0 (n=28)
1.0
0.5
0.6
0.3-0.8
0.3-1.4
0.005
0.239
1.0
0.6
0.7
0.4-1.0
0.2-1.7
0.036
0.381
Type of surgery
  Transthoracic (n=84)
  Transhiatal (n=89)
  Laparoscopic transhiatal (n=48)
  Thoracoscopic/laparotomy (n=27)
  Thoracoscopic/laparoscopic (n=113)
0.7
1.5
1.9
0.9
1.0
0.4- 1.3
0.8-2.6
0.9-3.7
0.4-2.2
0.248
0.182
0.076
0.855
0.7
1.3
1.7
0.9
1.0
0.4-1.3
0.7-2.4
0.8-3.5
0.4-2.2
0.243
0.419
0.163
0.829
Anastomotic leakage
  No (n=272)
  Yes (n=76)
  Unknown (n=13)
1.0
1.4
0.7
0.9-2.4
0.2-2.3
0.162
0.522
* Odds ratios displayed in steps of 10%. 
# Exclusion of 3 missings. 
9
Part II  |  Chapter 9  |  163
Univariate analysis Multivariate analysis
OR 95% CI p-value OR 95% CI p-value
Age
  <70 (n=285)
  ≥70 (n=79)
1.0
0.8 0.5-1.5 0.545
Gender
   Male (n=290)
   Female (n=74)
1.0
1.5 0.9-2.6 0.129
BMI 1.0 0.9-1.0 0.577
Co-morbidity
   0 (n=108)
   1 (n=141)
   2 or more (n=115)
1.0
1.3
2.1
0.7-2.4
1.2-3.9
0.367
0.013
1.0
1.3
2.4
0.7-2.5
1.3-4.5
0.353
0.006
Histological type
   Adenocarcinoma (n=276)
   Squamous cell carcinoma (n=75)
  Other (n=13)
1.0
1.9
1.9
1.1-3.3
0.6-6.0
0.017
0.270
1.0
1.3
2.0
0.6-2.6
0.6-6.5
0.500
0.255
Tumor location
  Mid (n=46)
  Distal (n=238)
  GEJ (n=80)
1.8
1.0
0.7
1.0-3.5
0.4-1.3
0.068
0.255
1.3
1.0
0.9
0.6-3.1
0.5-1.7
0.484
0.732
Mean dose 1.0 1.0-1.0 0.026 1.0 1.0-1.0 0.674
V20 per 10% 1.0 0.9-1.0 0.104
V25 per 10% 0.9 0.9-1.0 0.115
V30 per 10% 0.9 0.9-1.0 0.078 0.9 0.6-1.5 0.919
V35 per 10% 0.9 0.9-1.0 0.097 1.1 0.7-1.8 0.602
V40 per 10% 0.9 0.9-1.0 0.118
Mediastinal ratio#
  <0.5 (n=114)
  0.5-1.0 (n=219)
  ≥1.0 (n=28)
1.0
2.0
3.3
1.2-3.5
1.4-8.1
0.012
0.008
1.0
1.9
2.2
1.0-3.5
0.8-6.1
0.036
0.143
Type of resection
  Transthoracic (n=86)
  Transhiatal (n=90)
  Laparoscopic transhiatal (n=48)
  Thoracoscopic/laparotomy (n=27)
  Thoracoscopic/laparoscopic (n=113)
0.9
0.8
0.6
1.4
1.0
0.5-1.7
0.6-1.6
0.3-1.4
0.6-3.3
0.737
0.592
0.231
0.486
Table 4. Univariate and multivariate logistic regression analysis of a postoperative 
complicated course with a Clavien-Dindo classification of IIIB or higher (n=364). 
* Odds ratios displayed in steps of 10%. 
# Exclusion of 3 missings. 9
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Discussion
In this study, the influence of the radiation dose to the future anastomotic region on 
the incidence of anastomotic complications and on the severity of these complications 
was determined in patients curatively treated for esophageal cancer. This study 
showed no significant influence of radiation dose to the future anastomotic region 
of the gastric fundus on the incidence of anastomotic leakage and stenosis with a 
radiation dose up to 41.4 Gy. However, an association was demonstrated between 
severe complications (≥ Clavien-Dindo IIIB) and the upper PTV border in relation to the 
mediastinal length, which implies that a higher mediastinal PTV border in combination 
with esophagectomy with gastric tube reconstruction and cervical anastomosis may 
increase the probability of severe complications. 
An anastomotic leakage of 22% is comparable to rates in other studies with cervical 
anastomoses, including the prospective CROSS trial, in which a leakage rate of 26% 
was described18. The finding that the mean radiation dose and V20-V40 to the future 
anastomotic region of the gastric fundus were not correlated with anastomotic 
leakage is consistent with the results of our previous study with a smaller 
study population8. Furthermore, the CROSS trial patients receiving neoadjuvant 
chemoradiation had a non-significantly lower incidence of anastomotic leakage 
than the patients receiving esophagectomy alone (22% vs. 30%, respectively)18. 
A large series from a European multicenter study and two meta-analyses also 
demonstrated no significant difference in the anastomotic leakage rate between 
patients receiving neoadjuvant chemoradiation and surgery vs. surgery alone9;10;19. 
However, other studies have shown that the radiation dose to the gastric fundus was 
an independent predictor of anastomotic complications in patients undergoing intra-
thoracic anastomosis7. This study included 54 patients with only 7 early anastomotic 
events. In contrast, a more recent study from the same group with a larger patient 
number did not reveal a dose-effect relationship with postoperative complications20. 
In our study we did not find a correlation between radiation dose to the gastric 
fundus and anastomotic complications with the use of 3-D conformal techniques. 
This is somewhat in contrast to a study of Wang et al.21 who showed that a reduced 
dose to the normal tissues by using sophisticated techniques like Intensity-Modulated 
Radiotherapy (IMRT) or Proton Beam Therapy (PBT) reduced both pulmonary and 
gastro-intestinal complications compared to 3D Conformal Radiation Therapy 
(3D-CRT). An explanation for this different outcome might be the higher radiation 
dose that was used in their study (50.4Gy compared to 41.4Gy in current study) and a 
low median dose to the fundus in our study. Furthermore, a different chemotherapy 
scheme was used (cisplatinum/5-FU compared to carboplatin/paclitaxel in current 
study) which might have influenced the toxicity after neoadjuvant chemoradiation22. 
Our study revealed that squamous cell carcinoma was a significant predictor 
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of anastomotic leakage. This finding is probably caused by the more proximal 
anatomical location of squamous cell tumors. This was also found in a large meta-
analysis. A subgroup analysis of patients with a squamous cell carcinoma treated with 
neoadjuvant chemoradiation had a higher risk of postoperative mortality, treatment-
related mortality and pulmonary complications compared to surgery alone. 
However, in patients with an adenocarcinoma there was no difference in mortality or 
postoperative complications10. 
A rate of anastomotic stenosis requiring dilatation(s) of 41% is consistent with a large 
study of patients undergoing esophagectomy with cervical anastomosis in which 
42% of the patients developed a cervical stricture requiring dilatation(s)23. This study 
showed no influence of the mean radiation dose and V20-V40 on the development of 
anastomotic stenosis, which is consistent with two earlier studies23;24. However, the 
latter studies suggested that neoadjuvant chemoradiation appears to be associated 
with refractory strictures, requiring more than 10 dilations23. 
 To date, the literature has reported conflicting results regarding whether neoadjuvant 
chemoradiation influences the severity of postoperative complications. A recent 
Swedish study also did not report an increase in postoperative complications by nCRT, 
but suggested a relationship between radiation dose to the future anastomotic site 
and the severity of postoperative complications25. In the current study, we observed 
an association with incidence of severe complications (≥ Clavien-Dindo IIIB) with the 
cranial PTV border in relation to the mediastinal length. This finding may imply that 
a higher mediastinal PTV border in combination with esophagectomy and cervical 
anastomosis increases the probability of severe complications. However, a proximal 
tumor location was a predictor of anastomotic leakage and not nCRT in a French 
study19, and this result was also suggested by a meta-analysis9 .Proximal tumor location 
is directly related to a more cranial extent of the PTV. Thus, whether the location 
of the superior PTV border or the proximal tumor location itself accounts for the 
increased severity remains unknown. Nevertheless, randomized studies comparing 
nCRT and esophagectomy with esophagectomy alone describe no differences in 
the overall incidence and severity of complications and morbidity between the two 
groups18;19;26-28. Furthermore, the suggested association between the superior border 
of the mediastinal PTV, as expressed as the mediastinal ratio, and the increased 
incidence of a complicated course with complications of a Clavien-Dindo score of ≥ 
IIIB should be interpreted with care, since the results were borderline significant and 
we did not observed an association between the mediastinal ratio and the incidence 
of anastomotic leakage. Since no significant differences in mortality between the 
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two groups were observed, the fear for postoperative complications should be 
weighed against the 14% absolute 5 year overall survival advantage of neoadjuvant 
chemoradiation observed in the CROSS trial29. Irradiation to the remained cervical 
esophagus was unfortunately not registered in the database. This might be an 
important factor and should be addressed in further research in the future. 
This study is limited by its retrospective nature; however, we included a large study 
population from two high-volume esophageal surgery centers in the Netherlands. 
The determination of the future anastomotic region after consultation of the 
surgeon may of course have a certain degree of inaccuracy. However, our method 
has been performed meticulously and is reproducible, in contrast with other studies. 
A minor statistical limitation in our study is the relative small group of 
patients with a mediastinal ratio of ≥1.0, however our chosen cut-off points 
are anatomically understandable and furthermore similar results were 
obtained when using the median of 0.6 as a cut-off point in the analysis. 
 
In conclusion, this study demonstrates that with a mean radiation dose of 24.2 Gy to the 
future anastomotic region of the gastric fundus, the radiation dose was not associated 
with the incidence of anastomotic leakage or anastomotic stenosis in patients treated 
with nCRT followed by esophagectomy with gastric tube reconstruction with a cervical 
anastomosis. The incidence of severe complications was associated with the a high 
superior mediastinal PTV border without knowing whether the location of the superior 
PTV border or the proximal tumor location itself accounts for the increased severity. 
However, the possible increase in severe complications should be weighed against 
the potential survival benefit of a high upper mediastinal PTV border.
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CHAPTER 10 
Summary and future perspectives 
Summary 
In this thesis, patterns of care and the influence of neoadjuvant treatment on 
perioperative morbidity and oncological outcome in patients with esophageal cancer 
were investigated. 
Part I. Patterns and determinants of care in patients with 
esophageal cancer
In the current literature most studies focus on results of patients treated in individual 
centres or on specific treatments strategies and not on the whole group of patients 
diagnosed with esophageal cancer. Therefore, the aim of chapter two was to 
determine, in a population-based setting, which factors influenced overall survival 
and whether these factors play a role in the decision to propose potentially curative 
treatment to patients with resectable esophageal cancer. Between 2003 and 2010, 
849 patients with potentially resectable esophageal cancer were selected from the 
Eindhoven Cancer Registry. Forty-five percent of the patients underwent potentially 
curative surgery. Treatment modalities including surgery with or without neoadjuvant 
chemoradiation and definitive chemoradiation alone as well as the stage of disease 
were independent predictors of a better overall survival in patients with potentially 
resectable esophageal cancer. Although age and socioeconomic status had no 
significant influence on overall survival, a higher age and low socioeconomic status 
negatively influenced the probability to receive potentially curative treatment in 
patients with potentially resectable esophageal cancer. 
Surgical treatment of esophageal cancer is a complex procedure with high 
postoperative morbidity, especially in elderly patients with multiple co-morbidities. 
This might be an argument to withhold these patients from surgical treatment 
and propose alternative strategies like definitive chemoradiation. Most treatment 
strategies and guidelines are based on clinical trials in which elderly patients are 
often excluded. Therefore, the aim of chapter three was to describe treatment 
patterns and its impact on overall survival in elderly patients (75 years and older) with 
potentially curable esophageal cancer in the Netherlands.  Between 2003 and 2013, 
4501 elderly patients with potentially curable esophageal cancer were selected from 
the nationwide population-based Netherlands Cancer registry. In this period, there 
was an increase in treatment with curative intent, with a consistent use of surgical 
treatment with or without neoadjuvant treatment and a significant increase in the use 
of definitive chemoradiation among elderly patients. The increase in administration 
of definitive chemoradiation was most prominent in elderly patients with a squamous 
cell carcinoma. Multivariable Cox regression analysis showed no difference in overall 
survival between patients who received surgery with neoadjuvant chemo(radio)
therapy, surgery alone or definitive chemoradiation among elderly patients with a 
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squamous cell carcinoma. However, elderly patients with an adenocarcinoma that 
underwent surgery with neoadjuvant chemo(radio)therapy had a better overall survival 
compared to patients who underwent surgery alone or definitive chemoradiation.
Due to a process of centralization, treatment of esophageal cancer in the Netherlands 
is now largely performed in regional referral centres. In these centres, patients are 
discussed at multidisciplinary team (MDT) meetings and managed according to the 
national guidelines and latest evidence. Concentration of esophageal cancer care is 
associated with improved overall survival. However, most patients with esophageal 
cancer are diagnosed in non-referral centres and might not be discussed within 
MDT meetings with proficient knowledge of all aspects of diagnosis and treatment 
of esophageal cancer. In these hospitals of diagnosis however, the decision is made 
whether or not a patient is referred to an expert centre for further treatment. The aim 
of both chapter four and chapter five was to assess the relationship between hospital 
of diagnosis and referral for a curative treatment. Secondly, the referral pattern 
and its influence on overall survival in patients with resectable esophageal cancer 
was explored. In chapter four, 849 patients with potentially resectable esophageal 
cancer were selected from the Eindhoven Cancer registry between 2003 and 2010. 
In this registry, co-morbidity has been registered systematically and therefore 
multivariate regression analysis could be performed which included adjustments 
for co-morbidity. A difference in the proportion of patients referred for surgery was 
observed, ranging from 33% to 67% between hospitals of diagnosis. Furthermore, 
a large variation between the referring hospitals was observed in patients that 
underwent definitive chemoradiation (8% to 25%). Patients diagnosed in the majority 
of hospitals were less likely to receive treatment with a curative intent (surgery or 
definitive chemoradiation) compared to being diagnosed in the reference centre 
with the highest probability to receive this treatment. Furthermore, multivariable 
survival analysis showed that hospital of diagnosis also  affected overall survival. 
In chapter five, these results could be confirmed on a nationwide level. Patients 
with potentially curable esophageal cancer (n=13017) diagnosed in 91 hospitals 
between 2005 and 2013, were selected from the nationwide Netherlands cancer 
registry. The proportion of patients receiving curative treatment ranged from 37% 
to 83% and from 45% to 86% in the periods 2005-2009 and 2010-2013, respectively, 
depending on hospital of diagnosis. After adjustment for patient- and hospital-
related characteristics these proportions ranged from 41% to 77% and from 50% to 
82%, respectively. Multivariable survival analyses showed that patients diagnosed 
in hospitals with a low probability of undergoing curative treatment had a worse 
overall survival compared to those diagnosed in hospitals with a high probability. 
These two studies revealed a large variation in the probability to undergo curative 
treatment for esophageal cancer depending on the hospitals of diagnosis, which also 
affected the survival of these patients. Regional expert MDT meetings with involvement 
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of experienced specialists in this field should thus be initiated for all patients with 
esophageal cancer. The decisions made by these expert panels may improve the 
selection of patients with esophageal cancer who are eligible for a curative treatment 
option leading to an overall improvement of survival on the long term.
Part II. The influence of neoadjuvant treatment on morbidity 
and oncological outcome in esophageal surgery
In the literature there is no conclusive evidence which perioperative regime 
(chemotherapy or chemoradiation) and which surgical resection (esophagectomy 
or gastrectomy) should be used in treatment of GEJ tumors since there are no 
specific trials performed in GEJ tumors and the two cornerstone perioperative trials 
(MAGIC and CROSS) both included GEJ tumors. Therefore, chapter six evaluates in a 
population-based setting, the patterns of care in treatment strategies for patients with 
resectable adenocarcinomas of the GEJ and to compare oncological outcomes. From 
the nationwide population-based Netherlands Cancer Registry 1196 patients with 
potentially resectable GEJ tumors diagnosed between 2005 and 2012 who received 
surgical treatment were selected. Seventy-nine percent of the patients received 
an esophagectomy and 21% were treated with a gastrectomy. Similar oncological 
outcomes were noted between the two types of resection with respect to lymph node 
yield, lymph node ratio and radicality. No survival difference was observed between 
patients treated with an esophagectomy or a gastrectomy regardless of neoadjuvant 
treatment. However, perioperative chemotherapy or neoadjuvant chemoradiation 
were strongly correlated with oncological outcome. Therefore, any perioperative 
treatment with chemotherapy or chemoradiation rather than the surgical approach 
appeared to be most critical factor for overall survival.
Surgery after completion of neoadjuvant chemoradiation is routinely performed 
within 2 to 8 weeks following guidelines based on randomised controlled trials. In 
practice however, surgery is often postponed due to several factors like toxicity of 
neoadjuvant chemoradiation, comorbidity, poor physical status or logistical problems. 
It is unclear whether or not postponing surgery after completion of neoadjuvant 
chemoradiation influences postoperative outcomes. Therefore, chapter seven 
evaluates the influence of the time period between neoadjuvant chemoradiation and 
surgery on the postoperative course, pathological response, and long-term survival in 
patients with esophageal adenocarcinoma. Between 2001 and 2014, 190 patients with 
esophageal adenocarcinoma were treated with neoadjuvant chemoradiation followed 
by esophagectomy. Of these patients 125 received surgery more than 8 weeks after 
completion of neoadjuvant chemoradiation. Multivariable analysis revealed that 
time to surgery did not significantly influence postoperative morbidity, pathologic 
complete response rates and five-year overall survival. These results suggest that it is 
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safe to postpone surgery beyond 8 weeks if needed. On the other hand, postponing 
surgery beyond 8 weeks does also not have any additional advantages. 
The preferred treatment for non-metastatic esophageal cancer in the Netherlands 
is neoadjuvant chemoradiation followed by a transhiatal or transthoracic 
esophagectomy. Esophageal surgery has high postoperative morbidity rates and 
anastomotic complications such as leakage and stenosis. Neoadjuvant chemoradiation 
might be a factor influencing postoperative anastomotic complications. Therefore, 
the aim of chapter eight and nine was to determine the influence of radiation dose 
to the fundus of the stomach on the development of anastomotic complications 
in patients treated with neoadjuvant chemoradiation followed by esophagectomy. 
In chapter eight, data were used from 53 patients with esophageal cancer in the 
Catharina Hospital Eindhoven who received neoadjuvant chemoradiation (41.4Gy 
combined with chemotherapy) followed by transhiatal esophagectomy with cervical 
anastomosis between 2009 and 2011. On planning CT, radiation dose on the future 
anastomotic region of the gastric fundus was determined. Anastomotic leakage 
occurred in 26% of the patients and anastomotic stenosis in 45%. Multivariable 
analysis revealed no influence of the radiation dose on the future anastomotic region 
on anastomotic leakage and stenosis. 
In chapter nine, 364 consecutive patients with esophageal cancer, diagnosed in two 
high-volume esophageal surgery centers (i.e. Catharina Hospital Eindhoven and the 
Academic Medical Centre Amsterdam), treated with neoadjuvant chemoradiation 
(41.4 Gy combined with chemotherapy) followed by an esophagectomy and cervical 
anastomosis were included. The future anastomotic region in the gastric fundus was 
determined and the mean dose and upper planning target volume (PTV) border in 
relation to mediastinal length expressed as the mediastinal ratio were calculated. 
Anastomotic leakage occurred in 22% and anastomotic stenosis in 41%. Mean dose of 
24.2 Gy to the future anastomotic region of the gastric fundus were not associated with 
the incidence of anastomotic leakage or anastomotic stenosis. In 28% of the patients, 
severe complications (Clavien-Dindo score of ≥ IIIB) occurred. An association was 
demonstrated between severe complications (≥ Clavien-Dindo IIIB) and the upper PTV 
border in relation to the mediastinal length, which implies that a higher mediastinal 
PTV border in combination with esophagectomy with gastric tube reconstruction and 
cervical anastomosis may increase the probability of severe complications. However, 
the possible increase in severe complications should be weighed against the potential 
survival benefit of a high upper mediastinal PTV border.
10
Part III  |  Chapter 10  |  177
Future perspectives
In the first part of this thesis patterns of care and treatment decisions are investigated 
in a population based setting. Since it represents the total patient population it 
provides an overview of everyday clinical practice. However, the translation to the 
individual patient in clinical setting is always a challenge. Determinants in decision 
making and patterns of care are of crucial importance especially by the introduction 
of concentration of care. This concentration of care has proven its effectiveness in 
terms of postoperative morbidity and a more tailored-made decision making in a 
multidisciplinary approach. However, it has also led to a new phenomenon, which is 
the importance of the hospital of diagnosis in this process, since this is the first chain 
in the decision making process. Furthermore, concentration of care could potentially 
lead to a decrease in treatment decisional capacities of the teams  in the less 
experienced hospitals of diagnosis. Hence, concentration of care could potentially lead 
to an unwanted “brain drain” of specific knowledge out of the hospitals of diagnosis. 
Therefore, we believe that regional tumor specific video MDT’s with treating physicians 
as well as tumor specific experts should be implemented. The initiative to organize 
these regional MDT’s should be coordinated by the expert centre. The Netherlands 
Comprehensive Cancer organization and regional Comprehensive Cancer Networks 
could coordinate this process on a national and regional level and the government 
and insurance companies could provide the technical infrastructure. 
As described in chapter four and five, hospital of diagnosis plays an important role 
in esophageal cancer treatment. Concentration of esophageal cancer is one of many 
cancer types which are concentrated in high volume centres in the Netherlands. 
Therefore, further research on the influence of hospital of diagnosis on other 
centralised cancer types such as gastric, pancreatic and hepatobilliary cancer should 
be performed in the near future. 
A limitation in this thesis is that we focussed on resectable esophageal cancer patients 
only. Unfortunately, most patients are treated in a palliative setting. Since there are 
many different options in palliative and supportive care it is important to discuss all 
patients in MDT meetings diagnosed with esophageal cancer. Furthermore, research 
should also focus on palliative and non surgical treatment decisions.
In this thesis we also focussed on the growing group of elderly patients. The overall 
western population is ageing and therefore the elderly patients constitute a large and 
increasing part of the overall population. However, elderly patients are very often 
excluded from randomised controlled trials. In this thesis we described patterns of 
care in the elderly patients and revealed no survival difference in elderly patients 
with squamous cell carcinoma receiving surgery or definitive chemoradiation. 
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Therefore, definitive chemoradiation appears to be a good alternative to surgery in 
elderly patients with squamous cell carcinoma, though in elderly patients with an 
adenocarcinoma surgery leads to a better overall survival compared to definitive 
chemoradiation. However, this survival advantage after surgery should be weighed 
against the postoperative morbidity and decrease in health-related quality of life. 
Since a randomised trial in only the elderly patients will be very difficult these results 
however advocate for inclusion of elderly in clinical trials. Furthermore, this is a warm 
plea for the SANO trial which will randomize direct surgery after neoadjuvant CRT and 
a watchful follow up strategy with only surgery when needed in case of recurrence of 
residual disease. 
In the literature there is an ongoing discussion on the optimal surgical treatment 
(esophagectomy or gastrectomy) and perioperative treatment (chemoradiation or 
chemotherapy) in patients with a resectable GEJ tumor. In this thesis we revealed 
in a population based setting that there was no survival difference between 
esophagectomy or gastrectomy, however perioperative chemotherapy and 
neoadjuvant chemoradiation were strongly correlated  with oncological outcome. 
The surgical decision making for optimal treatment is mainly based on tumor 
ingrowth into the esophagus and surgeons’ preference. Since we could not observe 
a difference in outcome regarding the surgical strategy, we should focus on the 
optimal perioperative treatment. In order to achieve conclusive evidence on optimal 
perioperative treatment, a randomised controlled trial is needed which will compare 
neoadjuvant chemoradiation and perioperative chemotherapy followed by surgery. 
Fortunately, an Irish trial is currently recruiting patients with esophageal and GEJ 
tumors to compare the MAGIC regimen with the CROSS regimen. This study might 
provide more insight into the optimal preoperative strategy.
Since the introduction of neoadjuvant chemoradiation there is discussion on the 
timing of subsequent surgery after neoadjuvant treatment and also on the influence 
of neoadjuvant chemoradiation on postoperative morbidity. Timing of surgery after 
neoadjuvant chemoradiation is a difficult subject to investigate since it is depending 
on many factors such as toxicity of neoadjuvant treatment, comorbidity, patient’s 
physical status and also logistical problems. Furthermore, also tumor characteristics 
like histology and classification play a role. A large population based study in which for 
all those confounding factors can be adjusted probably will lead the way in providing 
an optimal treatment timeframe. In addition, new biological tumor characteristics 
will be developed in order to further personalize the choice and timing of optimal 
treatment strategy.
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Furthermore, another very interesting patient group are those that have a 
pathologically complete response after neoadjuvant chemoradiation. Especially 
in the patients with a squamous cell carcinoma the complete response rate after 
neoadjuvant chemoradiation was 49% in the CROSS trial. It will be important to 
determine a safe and reliable surveillance in patients with a complete response which 
might eventually lead to a wait and see policy with only performing surgery when 
needed as will be investigated in the SANO trial.
In this thesis we investigated the influence of radiation dose to the gastric fundus 
and their influence of anastomotic complications. In both of our studies we found no 
relation between radiation dose and anastomotic complications. Therefore, we believe 
that the negative effects of radiation on postoperative anastomotic complications 
are overestimated in the current literature.  Other factors like the surgical approach 
comparing intrathoracic anastomosis versus cervical anastomosis might be  of more 
importance. Besides that, we should not underestimate the important survival benefit 
of neoadjuvant radiation therapy. We do believe however that further research on 
radiation dose to the part of the esophagus which is used for the anastomosis is 
necessary. Therefore, we advocate for new research which determines influence 
of radiation on complications after Ivor-Lewis esophagectomy with an intrathoracic 
anastomosis.  
In conclusion, every patient, independent of the hospital of diagnosis, deserves the 
optimal curative or palliative management in which factors like quality of life, age, 
fragility, neoadjuvant treatment and the probability of complications on oncological 
and surgical outcome are taken into account. Every patient should be discussed in 
obligatory tumor specific multidisciplinary board meetings. This can be achieved 
by a regional network of open access tumor specific video multidisciplinary board 
meetings which are organized by regional expert centres. This will reduce variation in 
care and will provide optimal patient tailored management.
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Nederlandse samenvatting
In dit proefschrift worden verschillende patronen van zorg en de invloed van 
neoadjuvante behandeling op morbiditeit en oncologische uitkomst onderzocht bij 
patiënten met een slokdarmcarcinoom. 
Deel I Besluitvorming in behandeling van het 
slokdarmcarcinoom. 
In de beschikbare wetenschappelijke literatuur wordt er met name aandacht besteed 
aan resultaten van behandelingen in een bepaald ziekenhuis. In deze literatuur wordt 
niet zozeer gekeken naar de gehele groep patiënten met een slokdarmcarcinoom 
in een populatie. Daarom was het doel van hoofdstuk twee om in een populatie 
onderzoek factoren te bepalen die van invloed zouden kunnen zijn op de overleving 
van patiënten met een slokdarmcarcinoom. Tevens was het doel om te onderzoeken 
of deze factoren een rol spelen in de besluitvorming voor het al dan niet krijgen van een 
curatieve behandeling. Tussen 2003 en 2010 werden 849 patiënten met een resectabel 
slokdarmcarcinoom geselecteerd uit de Eindhoven Kanker Registratie. Vijfenveertig 
procent van de patiënten kreeg een chirurgische behandeling. Behandelingen, 
zoals chirurgie en chemoradiatie, en tevens tumorstadium waren onafhankelijke 
voorspellers voor een betere overleving bij patiënten met een slokdarmcarcinoom. 
Hoewel leeftijd en sociaaleconomische status geen significante invloed hadden op 
de overleving, waren een hogere leeftijd en een lage sociaaleconomische status 
factoren die invloed hadden op het al dan niet krijgen van een curatieve behandeling 
bij patiënten met een resectabel slokdarmcarcinoom. 
Chirurgische behandeling van het slokdarmcarcinoom is een complexe behandeling 
waarbij vaak postoperatieve morbiditeit optreedt, met name bij patiënten op leeftijd 
met veel comorbiditeit. Dit zou een argument kunnen zijn om deze patiëntengroep 
een alternatief voor een chirurgische behandeling te bieden. De meeste 
behandelstrategieën en richtlijnen zijn echter gebaseerd op klinische studies waarbij 
patiënten op leeftijd vaak zijn uitgesloten van deelname. Het doel van hoofdstuk 
drie was daarom om de verschillende patronen in de geleverde zorg te beschrijven 
en tevens te onderzoeken welke invloed dit heeft op de overleving bij oudere 
patiënten (75+) met een, in principe, curatief te behandelen slokdarmcarcinoom in 
Nederland. Tussen 2003 en 2013 werden 4501 oudere patiënten met een dergelijk 
curatief te behandelen slokdarmcarcinoom geselecteerd uit een nationale database 
van de Nederlandse Kanker Registratie. Tussen 2003 en 2013 was er een toename in 
curatieve behandeling, waarbij het aandeel chirurgische behandeling al dan niet in 
combinatie met neoadjuvante therapie gelijk bleef, maar er een significante toename 
was in de toepassing van definitieve chemoradiatie bij de oudere patiëntengroep. Deze 
toename van definitieve chemoradiatie was met name te zien bij oudere patiënten 
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met een plaveiselcel carcinoom. Multivariabele analyse liet zien dat er geen verschil 
was in overleving bij oudere patiënten met een plaveiselcel carcinoom die werden 
behandeld met neoadjuvante chemo(radio)therapie gevolgd door chirurgie danwel 
met definitieve chemoradiatie. Echter, bij oudere patiënten met een adenocarcinoom 
was de overleving na neoadjuvante chemo(radio)therapie gevolgd door chirurgie 
significant beter dan na alleen chirurgie of definitieve chemoradiatie. 
Door de centralisatie van zorg in Nederland wordt de behandeling van het 
slokdarmcarcinoom nu met name uitgevoerd in regionale verwijscentra. In deze 
verwijscentra worden de patiënten besproken in multidisciplinaire teams en 
behandeld volgens de nationale richtlijnen en recente wetenschappelijk literatuur. 
Concentratie van zorg bij het slokdarmcarcinoom heeft geleid tot een verbetering 
in overleving.  Echter, de meeste patiënten met een slokdarmcarcinoom worden in 
Nederland niet gediagnosticeerd in een expertise centrum maar in een verwijzend 
ziekenhuis waar wellicht niet alle expertise op het gebied van slokdarmkanker 
aanwezig is. De beslissing om een patiënt al dan niet door te verwijzen naar een 
expertise centrum voor verdere behandeling wordt gemaakt in het ziekenhuis van 
diagnose. Derhalve was het doel van hoofdstuk vier en hoofdstuk vijf om bij 
patiënten met een resectabel slokdarmcarcinoom de relatie tussen het ziekenhuis 
van diagnose en de kans op een curatieve behandeling te onderzoeken. Daarnaast 
werd deze kans op een curatieve behandeling gerelateerd aan de kans op overleving. 
Voor hoofdstuk vier werden 849 patiënten met een potentieel resectabel 
slokdarmcarcinoom in de periode 2003 tot 2010 geselecteerd uit de Eindhoven 
Kanker Registratie. In deze registratie wordt comorbiditeit systematisch geregistreerd 
waardoor het mogelijk is om een multivariabele regressie analyse toe te passen 
waarbij wordt gecorrigeerd voor comorbiditeit. Het percentage patiënten dat een 
chirurgische resectie onderging varieerde tussen de 33 en 67%.  Tevens werd er een 
grote variatie gezien tussen de verwijzende ziekenhuizen met betrekking tot de kans op 
het krijgen van definitieve chemoradiatie (8% tot 25%). De patiënten gediagnosticeerd 
in een meerderheid van de ziekenhuizen hadden minder kans op het krijgen van 
een in opzet curatieve behandeling (chirurgie of definitieve chemoradiatie) dan 
patiënten die werden gediagnosticeerd in het verwijscentrum met de hoogste kans 
op een curatieve behandeling. Daarnaast liet de multivariabele overlevingsanalyse 
zien dat ziekenhuis van diagnose een duidelijk effect had op de overleving. 
 Voor hoofdstuk vijf werd een landelijke studie verricht en werden 13017 patiënten met 
een potentieel resectabel slokdarmcarcinoom, gediagnosticeerd in 91 ziekenhuizen 
tussen 2005 en 2013, geselecteerd uit de nationale Nederlandse Kanker Registratie. 
Afhankelijk van het ziekenhuis van diagnose, bleek het aantal patiënten dat een 
behandeling met een curatieve intentie kreeg te variëren van 37% tot 83% en van 
45% tot 86% in respectievelijk de perioden 2005-2009 en 2010-2013. Multivariabele 
overlevingsanalyse liet zien dat patiënten gediagnosticeerd in ziekenhuizen met een 
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lage kans op het ondergaan van een in opzet curatieve behandeling een slechtere 
overleving hadden dan patiënten welke werden gediagnosticeerd in een ziekenhuis 
met een hoge kans op het krijgen van een dergelijke curatieve behandeling. 
Beide studies lieten, afhankelijk van het ziekenhuis van diagnose, een grote 
variatie zien in de kans op het krijgen van een in opzet curatieve behandeling bij 
het slokdarmcarcinoom, welke tevens de overlevingskansen van deze patiënten 
beïnvloedde. Regionaal multidisciplinair (video-)overleg met betrokkenheid 
van slokdarmkanker experts zou een oplossing kunnen zijn voor alle patiënten 
gediagnosticeerd met een slokdarmcarcinoom. Dergelijke besluitvorming zou kunnen 
zorgen voor een betere selectie van patiënten die in aanmerking komen voor een 
curatieve behandeling welke zal leiden tot een verbetering in overleving op de lange 
termijn. 
Deel II De invloed van neoadjuvante behandeling op morbiditeit 
en oncologische uitkomst na slokdarmchirurgie
Patiënten, gediagnosticeerd met een slokdarm/maag overgangstumor 
(cardiacarcinoom), worden behandeld door middel van een slokdarmresectie 
gevolgd door een buismaagreconstructie of door een (totale) maagresectie met 
oesophagojejunostomie. De beschikbare wetenschappelijke literatuur geeft nog geen 
sluitend bewijs over de beste behandeling voor patiënten met een cardiacarcinoom. In 
hoofdstuk zes werd - door middel van een populatie onderzoek - de zorgpatronen en 
behandelstrategieën bij patiënten met een resectabel adenocarcinoom van de cardia 
onderzocht, en werden oncologische uitkomsten vergeleken. Voor dit onderzoek 
werden uit de Nederlandse Kanker Registratie  1196 patiënten geselecteerd met een 
in potentie resectabel cardiacarcinoom (gediagnosticeerd tussen 2005 en 2012) die 
werden behandeld met een chirurgische resectie. Negenenzeventig procent van de 
patiënten werd behandeld met een slokdarmresectie en 21% met een maagresectie. 
Tussen deze twee behandelingen werden gelijkwaardige chirurgische uitkomsten 
gezien wat betreft lymfeklieropbrengst, lymfeklier ratio and radicaliteit. Daarnaast 
werd er onafhankelijk van neoadjuvante behandeling geen verschil in overleving 
gezien tussen patiënten die werden behandeld met een slokdarmresectie danwel 
een maagresectie. Echter de perioperatieve chemotherapie en de neoadjuvante 
chemoradiatie waren beiden bepalend voor de oncologische uitkomst. Daaruit is 
gebleken dat perioperatieve behandeling met chemotherapie dan wel chemoradiatie 
een belangrijkere rol speelde in de overleving dan de chirurgische benadering. 
Een chirurgische resectie wordt routinematig uitgevoerd 2 tot 8 weken nadat de 
neoadjuvante chemoradiatie is afgerond, gebaseerd op richtlijnen al dan niet uit 
gerandomiseerd onderzoek. Echter in de praktijk wordt de chirurgische resectie vaak 
uitgesteld door verschillende factoren, zoals toxiciteit na neoadjuvante chemoradiatie, 
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comorbiditeit, slechte fysieke gesteldheid of door logistieke problemen. Het is 
onduidelijk of de lengte van de wachttijd tussen operatie en neoadjuvante behandeling 
invloed heeft op de postoperatieve uitkomst. In hoofdstuk zeven werd geëvalueerd 
of de wachttijd tussen de neoadjuvante chemoradiatie en de chirurgische resectie 
invloed heeft op het postoperatieve beloop, de pathologische respons en overleving 
op de lange termijn bij patiënten met een adenocarcinoom van de slokdarm. Tussen 
2001 en 2014 werden 190 patiënten met een adenocarcinoom van de slokdarm 
behandeld met neoadjuvante chemoradiatie gevolgd door een slokdarmresectie. Bij 
125 patiënten was de wachttijd tussen neoadjuvante behandeling en de chirurgische 
resectie meer dan 8 weken. Multivariabele analyse liet zien dat het tijdsinterval 
tot chirurgie geen significante invloed had op de postoperatieve morbiditeit, 
pathologische respons and 5-jaarsoverleving. Deze resultaten toonden aan dat 
- indien nodig - het veilig is om de chirurgische resectie meer dan 8 weken na het 
afronden van neoadjuvante chemoradiatie te verrichten. Echter het liet ook zien dat 
het uitstellen van de chirurgische resectie geen extra voordelen geeft. 
Bij de behandeling van patiënten in Nederland met een niet uitgezaaid 
slokdarmcarcinoom heeft neoadjuvante chemoradiatie gevolgd door transhiatale of 
transthoracale slokdarmresectie de voorkeur. Een slokdarm operatie heeft een hoge 
postoperatieve morbiditeit en tevens complicaties gerelateerd aan de anastomose 
zoals lekkage en stenose. Neoadjuvante chemoradiatie zou een rol kunnen spelen in het 
ontstaan van deze postoperatieve anastomose complicaties. Het doel van hoofdstuk 
acht en negen was derhalve om de invloed van dosis van de bestraling op de fundus van 
de maag op het ontstaan van anastomose gerelateerde complicaties te onderzoeken. 
Voor hoofdstuk acht werden 53 patiënten opgenomen in het onderzoek met 
een slokdarmcarcinoom die tussen 2009 en 2011 in het Catharina Ziekenhuis 
werden behandeld met neoadjuvante chemoradiatie (41.4 Gy gecombineerd met 
chemotherapie), gevolgd door een transhiatale slokdarmresectie met een cervicale 
anastomose. Op de planning CT, werd de radiatie dosis op de fundus van de maag - waar de 
toekomstige anastomose mee zou worden gemaakt - bepaald. Bij 25.5% van de patiënten 
ontstond een naadlekkage en bij 45.3% een naadstenose. Multivariabele analyse liet 
echter geen invloed van radiatie dosis zien op het ontstaan van naadlekkage en stenose. 
Voor hoofdstuk negen werden 364 patiënten met een slokdarmcarcinoom die 
zijn behandeld met neoadjuvante chemoradiatie (41.4Gy gecombineerd met 
chemotherapie) gevolgd door een slokdarmresectie met een cervicale naad in het 
onderzoek opgenomen. Deze patiënten zijn gediagnosticeerd in twee hoogvolume 
ziekenhuizen (het Catharina Ziekenhuis Eindhoven en het Academisch Medisch 
Centrum Amsterdam). De toekomstige anastomose regio van de maag fundus werd 
bepaald en daarnaast werd  de gemiddelde dosis, en de bovengrens mediastinale 
planning target volume (PTV) in relatie tot de mediastinale lengte uitgedrukt als 
mediastinaal ratio berekend. In deze groep ontstond bij 22% van de patiënten een 
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naadlekkage en bij 41% een naadstenose. Een gemiddelde dosis van 24.2 Gy op de 
toekomstige anastomose regio had ook in deze grotere en multi-institutionele studie 
geen invloed op de incidentie van naadlekkage of stenose. Bij 28% van de patiënten 
ontwikkelde zich een ernstige complicatie (Clavien Dindo 3B of hoger). Er werd wel 
een relatie gezien tussen het ontstaan van ernstige complicaties en de mediastinale 
PTV bovengrens in relatie met de mediastinale lengte. De geconstateerde relatie 
suggereerde dat een hogere mediastinale PTV bovengrens bij patiënten na 
slokdarmresectie met buismaagreconstructie en cervicale anastomose en hogere 
kans hadden op het ontwikkelen van ernstige postoperatieve complicaties. Deze 
mogelijk hogere kans op ernstige complicaties moet worden afgezet tegen de 
potentiële overlevingswinst van een hogere mediastinale PTV bovengrens. 
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